{"gname":"University of Geneva","grp_id":"26","rels":[{"rel_title":"Hybrid Video and Instance Segmentation for Surgical Scene Understanding in Robotic Mitral Valve Surgery","rel_doi":"10.64898\/2026.11.16.26367936","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.16.26367936","rel_abs":"Objective: Artificial intelligence-based surgical scene segmentation is fundamental to surgical scene understanding. However, the optimal segmentation strategy for robotic cardiac surgery remains unknown. We developed and evaluated a hybrid segmentation framework combining Mask R- CNN and Segment Anything Model 2 (SAM2) for surgical scene recognition during the entry phase of robotic mitral valve surgery. Methods: Intraoperative videos from ten robotic mitral valve operations performed at two institutions were analyzed. Seven anatomical structures and surgical object classes (ascending aorta, diaphragm, lung, pericardium, right atrium, robotic arms, and sutures) were manually annotated from 2172 image frames. We created three patient-level training, validation, and test splits after ruling out any split where an object class was completely missing from validation or test. Three segmentation approaches were compared: Mask R-CNN, Mask R-CNN-prompted SAM2 for all seven classes, and a hybrid late-fusion model combining SAM2 for anatomical structures and Mask R-CNN for robotic arms and sutures. Model performance was assessed using pixel accuracy, mean intersection over union (IoU), and Dice score. Results: Across the three patient-level splits, the hybrid late-fusion model achieved the highest average overall segmentation performance, with pixel accuracy of 0.79-0.91, mean IoU of 0.64-0.74, and mean Dice of 0.76-0.84. At the object level, late-fusion Dice scores across the three splits were 0.86-0.96 for aorta, 0.38-0.90 for diaphragm, 0.77-0.92 for lung, 0.48-0.77 for pericardium, 0.68- 0.90 for right atrium, 0.95-0.97 for robotic arms, and 0.66-0.76 for sutures. Mask R-CNN- prompted SAM2 outperformed Mask R-CNN for the aorta in all three splits and for the lung, pericardium, diaphragm, and right atrium in two of three splits, whereas Mask R-CNN was more reliable for sutures, including Dice scores of 0.76 vs 0.21 and 0.66 vs 0.53 in Splits 2 and 3. By combining prompted SAM2 for anatomy with Mask R-CNN for robotic arms and sutures, late fusion achieved the highest mean Dice in two of three splits (0.84 and 0.76) and the highest mean Dice averaged across all three splits; all-object SAM2 propagation performed slightly better in the remaining split (0.81 vs 0.80). Conclusions: A hybrid segmentation framework combining SAM2 and Mask R-CNN achieved the highest overall segmentation performance in two of three patient-level splits and performed comparably to the best-performing model in the remaining split. These findings suggest that object-specific hybrid segmentation strategies may improve surgical scene segmentation during robotic mitral valve surgery.","rel_num_authors":15,"rel_authors":[{"author_name":"Christina Waldron","author_inst":"Columbia University Irving Medical Center"},{"author_name":"Rohit Ravindra Gulve","author_inst":"Yale School of Medicine"},{"author_name":"Nikhil Bhasin","author_inst":"Yale University"},{"author_name":"Zaid Al-Shoha","author_inst":"Cornell University"},{"author_name":"Heidi Eren","author_inst":"Columbia University"},{"author_name":"Nashita Bhuiyan","author_inst":"New York University"},{"author_name":"Mina Zaky","author_inst":"Yale University School of Medicine"},{"author_name":"Danial Ahmad","author_inst":"Yale University - MEDSUR Cardiac-Adult Cardiac"},{"author_name":"Viswajit Kandula","author_inst":"Columbia University Vagelos College of Physicians and Surgeons"},{"author_name":"Sriharsha Talapaneni","author_inst":"Yale University - MEDSUR Cardiac-Adult Cardiac"},{"author_name":"Ebony Jernigan","author_inst":"Yale University - MEDSUR Surgical Education"},{"author_name":"Marc Pelletier","author_inst":"Yale University - MEDSUR Cardiac-Adult Cardiac"},{"author_name":"Nasir Rahim","author_inst":"Yale University - MEDSUR Cardiac-Adult Cardiac"},{"author_name":"Arnar Geirsson","author_inst":"Columbia University Irving Medical Center"},{"author_name":"Makoto Mori","author_inst":"Yale School of Medicine"}],"rel_date":"2026-11-18","rel_site":"medrxiv"},{"rel_title":"Hybrid Video and Instance Segmentation for Surgical Scene Understanding in Robotic Mitral Valve Surgery","rel_doi":"10.64898\/2026.11.16.26367936","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.16.26367936","rel_abs":"Objective: Artificial intelligence-based surgical scene segmentation is fundamental to surgical scene understanding. However, the optimal segmentation strategy for robotic cardiac surgery remains unknown. We developed and evaluated a hybrid segmentation framework combining Mask R- CNN and Segment Anything Model 2 (SAM2) for surgical scene recognition during the entry phase of robotic mitral valve surgery. Methods: Intraoperative videos from ten robotic mitral valve operations performed at two institutions were analyzed. Seven anatomical structures and surgical object classes (ascending aorta, diaphragm, lung, pericardium, right atrium, robotic arms, and sutures) were manually annotated from 2172 image frames. We created three patient-level training, validation, and test splits after ruling out any split where an object class was completely missing from validation or test. Three segmentation approaches were compared: Mask R-CNN, Mask R-CNN-prompted SAM2 for all seven classes, and a hybrid late-fusion model combining SAM2 for anatomical structures and Mask R-CNN for robotic arms and sutures. Model performance was assessed using pixel accuracy, mean intersection over union (IoU), and Dice score. Results: Across the three patient-level splits, the hybrid late-fusion model achieved the highest average overall segmentation performance, with pixel accuracy of 0.79-0.91, mean IoU of 0.64-0.74, and mean Dice of 0.76-0.84. At the object level, late-fusion Dice scores across the three splits were 0.86-0.96 for aorta, 0.38-0.90 for diaphragm, 0.77-0.92 for lung, 0.48-0.77 for pericardium, 0.68- 0.90 for right atrium, 0.95-0.97 for robotic arms, and 0.66-0.76 for sutures. Mask R-CNN- prompted SAM2 outperformed Mask R-CNN for the aorta in all three splits and for the lung, pericardium, diaphragm, and right atrium in two of three splits, whereas Mask R-CNN was more reliable for sutures, including Dice scores of 0.76 vs 0.21 and 0.66 vs 0.53 in Splits 2 and 3. By combining prompted SAM2 for anatomy with Mask R-CNN for robotic arms and sutures, late fusion achieved the highest mean Dice in two of three splits (0.84 and 0.76) and the highest mean Dice averaged across all three splits; all-object SAM2 propagation performed slightly better in the remaining split (0.81 vs 0.80). Conclusions: A hybrid segmentation framework combining SAM2 and Mask R-CNN achieved the highest overall segmentation performance in two of three patient-level splits and performed comparably to the best-performing model in the remaining split. These findings suggest that object-specific hybrid segmentation strategies may improve surgical scene segmentation during robotic mitral valve surgery.","rel_num_authors":15,"rel_authors":[{"author_name":"Christina Waldron","author_inst":"Columbia University Irving Medical Center"},{"author_name":"Rohit Ravindra Gulve","author_inst":"Yale School of Medicine"},{"author_name":"Nikhil Bhasin","author_inst":"Yale University"},{"author_name":"Zaid Al-Shoha","author_inst":"Cornell University"},{"author_name":"Heidi Eren","author_inst":"Columbia University"},{"author_name":"Nashita Bhuiyan","author_inst":"New York University"},{"author_name":"Mina Zaky","author_inst":"Yale University School of Medicine"},{"author_name":"Danial Ahmad","author_inst":"Yale University - MEDSUR Cardiac-Adult Cardiac"},{"author_name":"Viswajit Kandula","author_inst":"Columbia University Vagelos College of Physicians and Surgeons"},{"author_name":"Sriharsha Talapaneni","author_inst":"Yale University - MEDSUR Cardiac-Adult Cardiac"},{"author_name":"Ebony Jernigan","author_inst":"Yale University - MEDSUR Surgical Education"},{"author_name":"Marc Pelletier","author_inst":"Yale University - MEDSUR Cardiac-Adult Cardiac"},{"author_name":"Nasir Rahim","author_inst":"Yale University - MEDSUR Cardiac-Adult Cardiac"},{"author_name":"Arnar Geirsson","author_inst":"Columbia University Irving Medical Center"},{"author_name":"Makoto Mori","author_inst":"Yale School of Medicine"}],"rel_date":"2026-11-18","rel_site":"medrxiv"},{"rel_title":"Combined genome-wide association studies in humans and cattle: Cross-species genetic insights into dizygotic twinning","rel_doi":"10.64898\/2026.11.16.26367253","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.16.26367253","rel_abs":"To leverage independent genetic evidence from multiple species, we developed a cross-species gene-based GWAS meta-analysis framework and applied this to Dizygotic Twinning (DZT) in humans and cattle. After meta-analysis within species, we converted human and cattle GWAS summary statistics to gene-level association signals within each species, mapped genes across species through human-cattle orthology, and then combined gene-level evidence for orthologous genes across the two species. DZT is defined as giving birth to multiple offspring after a single pregnancy resulting from spontaneous multiple ovulation. In humans, DZT occurs in about 1% of pregnancies with heritability estimates of 20% to 30% whilst in cattle DZT occurs in 1-5% of pregnancies and heritability is estimated at about 11%. Here, we present the largest human GWAS meta-analysis including data from 1,395,285 participants. We identified 16 genetic regions of interest, including 12 independent loci from the SNP based analyses and 4 genes identified in the gene-based MAGMA analyses. Among the prioritized genes are follicle stimulation hormone receptor (FSHR) and growth differentiation factor 9 (GDF9), that both are involved in ovarian folliculogenesis. Cattle GWAS summary statistics were based on data from 2,656 Irish Holstein bulls with estimated breeding values for predisposition to twinning based on 2,238,936 birth records, and 86,391 German Holstein dams. After combining the gene-level analyses for 13,225 genes mapped as orthologous across the human and cattle data we identify FSHR as a central locus for DZT in both humans and cattle. We find evidence of additional associations, including ACVR2A, which plays a role in embryonic implantation and TUFM, which has previously been implicated in premature ovarian insufficiency. Our approach provides a promising framework for future cross-species comparative GWAS studies. It shows benefits for gene discovery and gene prioritization and in our application expands available functional follow-up data, allowing us to leverage cattle eQTL data to resolve human GWAS loci. The method and underlying philosophy presented here are transferable to other shared phenotypes across several species.","rel_num_authors":64,"rel_authors":[{"author_name":"Nikki Hubers","author_inst":"National Centre for Registry Based Research, Aarhus University, Aarhus, Denmark; The SMARTBiomed Pioneer Centre, Aarhus University, Aarhus, Denmark"},{"author_name":"Marijn Schipper","author_inst":"Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam, the Neth"},{"author_name":"Scott Gordon","author_inst":"QIMR Berghofer Medical Research Institute"},{"author_name":"Jaakko Leinonen","author_inst":"FIMM, HiLife, University of Helsinki, Finland"},{"author_name":"Arni Gunnarsson","author_inst":"deCODE Genetics"},{"author_name":"Christian M Page","author_inst":"Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway; Department of Physical Health and Aging, Norwegian Institute of Public Heal"},{"author_name":"Marianne Nygaard","author_inst":"The Danish Twin Registry, Department of Public Health, University of Southern Denmark, Odense, Denmark"},{"author_name":"Charlotte KL Pahnke","author_inst":"Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany"},{"author_name":"Robert Karlsson","author_inst":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"author_name":"Teemu Palviainen","author_inst":"FIMM, HiLife, University of Helsinki, Finland"},{"author_name":"Jamee M Berg","author_inst":"Dept. of Otolaryngology-Head & Neck Surgery, Vanderbilt University Medical Center"},{"author_name":"Tanguy Rubat du Merac","author_inst":"Human Genetics Ph.D. Program, Vanderbilt School of Medicine, Vanderbilt University, Nashville, TN, USA; Department of Otolaryngology - Head & Neck Surgery, Vand"},{"author_name":"Kaito Kawakami","author_inst":"Social, Genetic and Developmental Psychiatry Centre, King's College London"},{"author_name":"Wangjingyi Liao","author_inst":"Queen Mary University of London"},{"author_name":"Elham Assary","author_inst":"King's College London"},{"author_name":"Maryam Kazemi Naeini","author_inst":"Department of Twin Research, Kings College London"},{"author_name":"Martje Bos","author_inst":"Department of Psychiatry, University of Groningen, University Medical Center Groningen, The Netherlands"},{"author_name":"Ilja M Nolte","author_inst":"Department of Epidemiology, University of Groningen, University Medical Center Groningen, The Netherlands"},{"author_name":"Peter J van der Most","author_inst":"Department of Epidemiology, University of Groningen, University Medical Center Groningen, The Netherlands"},{"author_name":"- Lifelines Cohort Study and Biobank","author_inst":""},{"author_name":"Scott Gallagher","author_inst":"Harvard Medical School, Harvard University"},{"author_name":"Samantha LP Schilit","author_inst":"Harvard Medical School, Harvard University, Brigham and Womens Hospital, Boston"},{"author_name":"Anastasia A. Goula","author_inst":"Amsterdam University Medical Center"},{"author_name":"Yuri Milaneschi","author_inst":"Amsterdam UMC - VUMC location: Amsterdam UMC Locatie VUmc"},{"author_name":"Rene Pool","author_inst":"Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands, Amsterdam public health research institute, Amsterdam, the Nether"},{"author_name":"Jenny van Dongen","author_inst":"Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands, Amsterdam Reproduction & Development research institute, Amsterda"},{"author_name":"Christiaan de Leeuw","author_inst":"Vrije Universiteit Amsterdam"},{"author_name":"Jeffrey Beck","author_inst":"Avera McKennan Hospital & University Health Center, Sioux Falls, South Dakota, USA."},{"author_name":"Erik Ehli","author_inst":"Avera McKennan Hospital & University Health Center, Sioux Falls, South Dakota, USA."},{"author_name":"Vera Fuentes-Moreno","author_inst":"Institute of Parasitology and Biomedicine Lopez-Neyra, CSIC, Granada, Spain"},{"author_name":"Emma Vlasiuk","author_inst":"Department of Pathology and Molecular Medicine, University of Otago, Christchurch, New Zealand"},{"author_name":"Yoon Mi Hur","author_inst":"Kookmin University, Seongbok-gu, Seoul, KR"},{"author_name":"Bruno REVERSADE","author_inst":"GIS, A*STAR"},{"author_name":"Velja Mijatovic","author_inst":"Department of Reproductive Medicine, Amsterdam UMC, The Netherlands"},{"author_name":"Claudio D Stern","author_inst":"Department of Cell & Developmental Biology, University College London, Gower Street, London WC1E 6BT, U.K."},{"author_name":"Harold Snieder","author_inst":"Department of Epidemiology, University of Groningen, University Medical Center Groningen, The Netherlands"},{"author_name":"Kaare Christensen","author_inst":"The Danish Twin Registry, Department of Public Health, University of Southern Denmark, Odense, Denmark;Department of Clinical Genetics, Odense University Hospit"},{"author_name":"Frances MK Williams","author_inst":"King's College London"},{"author_name":"Robert Plomin","author_inst":"Social, Genetic and Developmental Psychiatry Centre, King's College London"},{"author_name":"Miina Ollikainen","author_inst":"FIMM, HiLife, University of Helsinki, Finland & Minerva Foundation Institute for Medical Research, Helsinki, Finland"},{"author_name":"Patrik KE Magnusson","author_inst":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"author_name":"Mirko Ruks","author_inst":"Faculty of Sociology, Bielefeld University, Bielefeld, Germany"},{"author_name":"Carlo Maj","author_inst":"Centre for Human Genetics, University of Marburg, Marburg, Germany   Institute for Genomic Statistics and Bioinformatics, University of Bonn, Bonn,  Germany"},{"author_name":"Christian Kandler","author_inst":"Faculty of Psychology and Sports Sciences, Department of Psychology, Bielefeld University, Bielefeld Germany"},{"author_name":"Andreas J Forstner","author_inst":"Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany; Institute of Neuroscience and Medicine (INM-1), R"},{"author_name":"Cynthia Casson Morton","author_inst":"Brigham and Women's Hospital"},{"author_name":"Daniel I. Chasman","author_inst":"Brigham and Women's Hospital and Harvard Medical School"},{"author_name":"William Iacono","author_inst":"Department of Psychology, University of Minnesota"},{"author_name":"Jennifer R Harris","author_inst":"Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway"},{"author_name":"Taru Tukiainen","author_inst":"Institute for Molecular Medicine Finland"},{"author_name":"Martin A Kennedy","author_inst":"University of Otago, Christchurch"},{"author_name":"Gonneke Willemsen","author_inst":"Faculty of Health, Sports and Social Work, Inholland University of Applied Sciences, Haarlem, the Netherlands; Amsterdam Reproduction & Development Research Ins"},{"author_name":"Cornelis B Lambalk","author_inst":"Amsterdam Reproduction & Development research institute, Amsterdam, the Netherlands"},{"author_name":"Hreinn Stefansson","author_inst":"deCODE Genetics"},{"author_name":"Jaakko Kaprio","author_inst":"University of Helsinki\/FIMM"},{"author_name":"Grant W Montgomery","author_inst":"The Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia."},{"author_name":"Jouke Jan Hottenga","author_inst":"Neurological Disorder Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha P.O. Box 5825, Qa"},{"author_name":"Hamdi Mbarek","author_inst":"Qatar Genome, Doha, Qatar"},{"author_name":"Christin Schmidtmann","author_inst":"IT Solutions for Animal Production w.V. (vit), Verden, Germany"},{"author_name":"Laura Huneke","author_inst":"IT Solutions for Animal Production w.V. (vit), Verden, Germany"},{"author_name":"Donnagh P Berry","author_inst":"Teagasc, Animal & Grassland Research and Innovation Centre, Moorepark, Fermoy, Co. Cork, P61 P302, Ireland."},{"author_name":"Brian W Kirkpatrick","author_inst":"Department of Animal and Dairy Science, University of Wisconsin-Madison, Madison, WI, USA"},{"author_name":"Nicholas G Martin","author_inst":"QIMR Berghofer Medical Research Institute"},{"author_name":"Dorret I Boomsma","author_inst":"Department of complex traits Genetics, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands, Amsterdam Reproduction & Development research institute, Amster"}],"rel_date":"2026-11-18","rel_site":"medrxiv"},{"rel_title":"Combined genome-wide association studies in humans and cattle: Cross-species genetic insights into dizygotic twinning","rel_doi":"10.64898\/2026.11.16.26367253","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.16.26367253","rel_abs":"To leverage independent genetic evidence from multiple species, we developed a cross-species gene-based GWAS meta-analysis framework and applied this to Dizygotic Twinning (DZT) in humans and cattle. After meta-analysis within species, we converted human and cattle GWAS summary statistics to gene-level association signals within each species, mapped genes across species through human-cattle orthology, and then combined gene-level evidence for orthologous genes across the two species. DZT is defined as giving birth to multiple offspring after a single pregnancy resulting from spontaneous multiple ovulation. In humans, DZT occurs in about 1% of pregnancies with heritability estimates of 20% to 30% whilst in cattle DZT occurs in 1-5% of pregnancies and heritability is estimated at about 11%. Here, we present the largest human GWAS meta-analysis including data from 1,395,285 participants. We identified 16 genetic regions of interest, including 12 independent loci from the SNP based analyses and 4 genes identified in the gene-based MAGMA analyses. Among the prioritized genes are follicle stimulation hormone receptor (FSHR) and growth differentiation factor 9 (GDF9), that both are involved in ovarian folliculogenesis. Cattle GWAS summary statistics were based on data from 2,656 Irish Holstein bulls with estimated breeding values for predisposition to twinning based on 2,238,936 birth records, and 86,391 German Holstein dams. After combining the gene-level analyses for 13,225 genes mapped as orthologous across the human and cattle data we identify FSHR as a central locus for DZT in both humans and cattle. We find evidence of additional associations, including ACVR2A, which plays a role in embryonic implantation and TUFM, which has previously been implicated in premature ovarian insufficiency. Our approach provides a promising framework for future cross-species comparative GWAS studies. It shows benefits for gene discovery and gene prioritization and in our application expands available functional follow-up data, allowing us to leverage cattle eQTL data to resolve human GWAS loci. The method and underlying philosophy presented here are transferable to other shared phenotypes across several species.","rel_num_authors":64,"rel_authors":[{"author_name":"Nikki Hubers","author_inst":"National Centre for Registry Based Research, Aarhus University, Aarhus, Denmark; The SMARTBiomed Pioneer Centre, Aarhus University, Aarhus, Denmark"},{"author_name":"Marijn Schipper","author_inst":"Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam, the Neth"},{"author_name":"Scott Gordon","author_inst":"QIMR Berghofer Medical Research Institute"},{"author_name":"Jaakko Leinonen","author_inst":"FIMM, HiLife, University of Helsinki, Finland"},{"author_name":"Arni Gunnarsson","author_inst":"deCODE Genetics"},{"author_name":"Christian M Page","author_inst":"Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway; Department of Physical Health and Aging, Norwegian Institute of Public Heal"},{"author_name":"Marianne Nygaard","author_inst":"The Danish Twin Registry, Department of Public Health, University of Southern Denmark, Odense, Denmark"},{"author_name":"Charlotte KL Pahnke","author_inst":"Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany"},{"author_name":"Robert Karlsson","author_inst":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"author_name":"Teemu Palviainen","author_inst":"FIMM, HiLife, University of Helsinki, Finland"},{"author_name":"Jamee M Berg","author_inst":"Dept. of Otolaryngology-Head & Neck Surgery, Vanderbilt University Medical Center"},{"author_name":"Tanguy Rubat du Merac","author_inst":"Human Genetics Ph.D. Program, Vanderbilt School of Medicine, Vanderbilt University, Nashville, TN, USA; Department of Otolaryngology - Head & Neck Surgery, Vand"},{"author_name":"Kaito Kawakami","author_inst":"Social, Genetic and Developmental Psychiatry Centre, King's College London"},{"author_name":"Wangjingyi Liao","author_inst":"Queen Mary University of London"},{"author_name":"Elham Assary","author_inst":"King's College London"},{"author_name":"Maryam Kazemi Naeini","author_inst":"Department of Twin Research, Kings College London"},{"author_name":"Martje Bos","author_inst":"Department of Psychiatry, University of Groningen, University Medical Center Groningen, The Netherlands"},{"author_name":"Ilja M Nolte","author_inst":"Department of Epidemiology, University of Groningen, University Medical Center Groningen, The Netherlands"},{"author_name":"Peter J van der Most","author_inst":"Department of Epidemiology, University of Groningen, University Medical Center Groningen, The Netherlands"},{"author_name":"- Lifelines Cohort Study and Biobank","author_inst":""},{"author_name":"Scott Gallagher","author_inst":"Harvard Medical School, Harvard University"},{"author_name":"Samantha LP Schilit","author_inst":"Harvard Medical School, Harvard University, Brigham and Womens Hospital, Boston"},{"author_name":"Anastasia A. Goula","author_inst":"Amsterdam University Medical Center"},{"author_name":"Yuri Milaneschi","author_inst":"Amsterdam UMC - VUMC location: Amsterdam UMC Locatie VUmc"},{"author_name":"Rene Pool","author_inst":"Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands, Amsterdam public health research institute, Amsterdam, the Nether"},{"author_name":"Jenny van Dongen","author_inst":"Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands, Amsterdam Reproduction & Development research institute, Amsterda"},{"author_name":"Christiaan de Leeuw","author_inst":"Vrije Universiteit Amsterdam"},{"author_name":"Jeffrey Beck","author_inst":"Avera McKennan Hospital & University Health Center, Sioux Falls, South Dakota, USA."},{"author_name":"Erik Ehli","author_inst":"Avera McKennan Hospital & University Health Center, Sioux Falls, South Dakota, USA."},{"author_name":"Vera Fuentes-Moreno","author_inst":"Institute of Parasitology and Biomedicine Lopez-Neyra, CSIC, Granada, Spain"},{"author_name":"Emma Vlasiuk","author_inst":"Department of Pathology and Molecular Medicine, University of Otago, Christchurch, New Zealand"},{"author_name":"Yoon Mi Hur","author_inst":"Kookmin University, Seongbok-gu, Seoul, KR"},{"author_name":"Bruno REVERSADE","author_inst":"GIS, A*STAR"},{"author_name":"Velja Mijatovic","author_inst":"Department of Reproductive Medicine, Amsterdam UMC, The Netherlands"},{"author_name":"Claudio D Stern","author_inst":"Department of Cell & Developmental Biology, University College London, Gower Street, London WC1E 6BT, U.K."},{"author_name":"Harold Snieder","author_inst":"Department of Epidemiology, University of Groningen, University Medical Center Groningen, The Netherlands"},{"author_name":"Kaare Christensen","author_inst":"The Danish Twin Registry, Department of Public Health, University of Southern Denmark, Odense, Denmark;Department of Clinical Genetics, Odense University Hospit"},{"author_name":"Frances MK Williams","author_inst":"King's College London"},{"author_name":"Robert Plomin","author_inst":"Social, Genetic and Developmental Psychiatry Centre, King's College London"},{"author_name":"Miina Ollikainen","author_inst":"FIMM, HiLife, University of Helsinki, Finland & Minerva Foundation Institute for Medical Research, Helsinki, Finland"},{"author_name":"Patrik KE Magnusson","author_inst":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"author_name":"Mirko Ruks","author_inst":"Faculty of Sociology, Bielefeld University, Bielefeld, Germany"},{"author_name":"Carlo Maj","author_inst":"Centre for Human Genetics, University of Marburg, Marburg, Germany   Institute for Genomic Statistics and Bioinformatics, University of Bonn, Bonn,  Germany"},{"author_name":"Christian Kandler","author_inst":"Faculty of Psychology and Sports Sciences, Department of Psychology, Bielefeld University, Bielefeld Germany"},{"author_name":"Andreas J Forstner","author_inst":"Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany; Institute of Neuroscience and Medicine (INM-1), R"},{"author_name":"Cynthia Casson Morton","author_inst":"Brigham and Women's Hospital"},{"author_name":"Daniel I. Chasman","author_inst":"Brigham and Women's Hospital and Harvard Medical School"},{"author_name":"William Iacono","author_inst":"Department of Psychology, University of Minnesota"},{"author_name":"Jennifer R Harris","author_inst":"Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway"},{"author_name":"Taru Tukiainen","author_inst":"Institute for Molecular Medicine Finland"},{"author_name":"Martin A Kennedy","author_inst":"University of Otago, Christchurch"},{"author_name":"Gonneke Willemsen","author_inst":"Faculty of Health, Sports and Social Work, Inholland University of Applied Sciences, Haarlem, the Netherlands; Amsterdam Reproduction & Development Research Ins"},{"author_name":"Cornelis B Lambalk","author_inst":"Amsterdam Reproduction & Development research institute, Amsterdam, the Netherlands"},{"author_name":"Hreinn Stefansson","author_inst":"deCODE Genetics"},{"author_name":"Jaakko Kaprio","author_inst":"University of Helsinki\/FIMM"},{"author_name":"Grant W Montgomery","author_inst":"The Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia."},{"author_name":"Jouke Jan Hottenga","author_inst":"Neurological Disorder Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha P.O. Box 5825, Qa"},{"author_name":"Hamdi Mbarek","author_inst":"Qatar Genome, Doha, Qatar"},{"author_name":"Christin Schmidtmann","author_inst":"IT Solutions for Animal Production w.V. (vit), Verden, Germany"},{"author_name":"Laura Huneke","author_inst":"IT Solutions for Animal Production w.V. (vit), Verden, Germany"},{"author_name":"Donnagh P Berry","author_inst":"Teagasc, Animal & Grassland Research and Innovation Centre, Moorepark, Fermoy, Co. Cork, P61 P302, Ireland."},{"author_name":"Brian W Kirkpatrick","author_inst":"Department of Animal and Dairy Science, University of Wisconsin-Madison, Madison, WI, USA"},{"author_name":"Nicholas G Martin","author_inst":"QIMR Berghofer Medical Research Institute"},{"author_name":"Dorret I Boomsma","author_inst":"Department of complex traits Genetics, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands, Amsterdam Reproduction & Development research institute, Amster"}],"rel_date":"2026-11-18","rel_site":"medrxiv"},{"rel_title":"Limited English Proficiency and Rates of Dilated Eye Examinations Among U.S. Adults with Diabetes","rel_doi":"10.64898\/2026.11.16.26368231","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.16.26368231","rel_abs":"Purpose: To determine whether English proficiency is associated with diabetic retinopathy screening rates among patients with diabetes in the United States. Design: A retrospective, cross-sectional study. Participants: Individuals with diabetes who responded to the Medicare Expenditure Panel Survey (MEPS), a nationally representative survey of U.S. households (2013-2022). Methods: Survey-weighted, multivariable logistic regression. Main Outcome Measures: Adjusted odds ratio (aOR) of 1) having ever received a dilated fundus examination (DFE) and 2) having received consecutive year DFEs. Results: The analytic sample included 11,441 respondents representing a weighted sample of 15,107,166 U.S. civilians with diabetes per year from 2013-2022. The mean age was 62 years (SD: 14 years), and 50% were female. Individuals with limited English proficiency (LEP) comprised 11.6% of the cohort. Respondents with LEP had lower odds of ever having received a DFE compared to English-proficient respondents (aOR=0.729, 95% CI: 0.541-0.976). The association between having consecutive year DFEs and English proficiency was non-significant (aOR=1.189, 95% CI: 0.917-1.541). In sensitivity analyses using a definition of LEP as speaking English less than well, LEP was associated with lower odds of ever having a DFE (aOR=0.632, 95% CI: 0.460-0.869) and higher odds of consecutive year exams (aOR=1.415, 95% CI: 1.057-1.896). Conclusions: LEP status was associated with lower odds of ever having had a DFE and equal or greater odds of having consecutive year DFEs. Efforts to reduce language-related disparities for patients with LEP should focus on improving initial access to ophthalmologic care.","rel_num_authors":3,"rel_authors":[{"author_name":"Stanley Z Lam","author_inst":"Weill Cornell Medicine"},{"author_name":"Emily Xing","author_inst":"Weill Cornell Medicine"},{"author_name":"Grace Sun","author_inst":"Weill Cornell Medicine"}],"rel_date":"2026-11-18","rel_site":"medrxiv"},{"rel_title":"Modifiable and Context-Specific Factors Associated with Dementia in the Democratic Republic of the Congo: A Community-Derived Cross-Sectional Study","rel_doi":"10.64898\/2026.11.16.26368211","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.16.26368211","rel_abs":"Background: Evidence linking social, behavioral, and environmental factors to dementia in Central Africa remains limited. Objective: To examine associations between 16 factors and dementia status in the Democratic Republic of the Congo (DRC), and quantify incremental model fit beyond age and sex. Methods: This cross sectional analysis included 721 participants (232 cognitively unimpaired; 489 with dementia, including 247 with suspected Alzheimers disease). Logistic regression jointly modeled 16 factors, age, sex, and missing-category indicators. Continuous covariates with missing values were mean-imputed and standardized. Model fit was assessed using Nagelkerke pseudo R squared, likelihood-ratio testing, and 1,000 bootstrap replicates. Results: Nagelkerke pseudo-R2 increased from 0.106 with age and sex to 0.368 after adding the factors (change in R2 = 0.262; bootstrap 95% CI: 0.241-0.371; chi-square(27) = 163.62, p < 0.001). Poverty (adjusted odds ratio [aOR] = 2.34, 95% CI: 1.52-3.60), low resilience (aOR = 1.84, 95% CI: 1.18-2.86), and depression (aOR = 1.53, 95% CI: 1.02-2.31) were associated with higher dementia odds. Higher education (aOR = 0.51, 95% CI: 0.39-0.66, per standard deviation increase) and obesity (aOR = 0.31, 95% CI: 0.10-0.90) showed inverse associations; obesity data were 79.9% missing. Alcohol consumption and PM2.5 exposure were not significantly associated with dementia. Conclusions: Poverty, lower resilience, depression, and education were associated with dementia status in this nonrepresentative cohort. Incremental model fit does not quantify preventable dementia burden, and causality cannot be inferred from these cross-sectional data.","rel_num_authors":16,"rel_authors":[{"author_name":"Jean Ikanga","author_inst":"Emory University School of Medicine, Department of Rehabilitation Medicine, Atlanta, GA 30322, USA; University of Kinshasa and Catholic University of Congo, Sch"},{"author_name":"Saranya Sundaram Patel","author_inst":"Emory University School of Medicine, Department of Rehabilitation Medicine, Atlanta, GA 30322, USA; One Rehab, Dallas, TX, USA"},{"author_name":"Peng Zhang","author_inst":"Emory University School of Medicine, Department of Human Genetics, Atlanta, GA 30322, USA"},{"author_name":"Jingjing Yang","author_inst":"Emory University School of Medicine, Department of Human Genetics, Atlanta, GA 30322, USA"},{"author_name":"Caterina Obenauf","author_inst":"Emory University School of Medicine, Department of Rehabilitation Medicine, Atlanta, GA 30322, USA; University of Tennessee, Department of Psychology and Neuros"},{"author_name":"Guy Gikelekele","author_inst":"University of Kinshasa and Catholic University of Congo, School of Medicine, Department of Psychiatry, Kinshasa, Democratic Republic of the Congo"},{"author_name":"Emmanuel Epenge","author_inst":"University of Kinshasa, Department of Neurology, Kinshasa, Democratic Republic of the Congo; Protestant University of Congo, School of Medicine, Kinshasa, Democ"},{"author_name":"Japhet Magolu Potshi","author_inst":"University of Kinshasa, Department of Neurology, Kinshasa, Democratic Republic of the Congo"},{"author_name":"Topina Tomadia","author_inst":"Memory Clinic of Kinshasa, Kinshasa, Democratic Republic of the Congo"},{"author_name":"Joseph Phuati Tsangu","author_inst":"University of Kinshasa, Department of Anesthesiology and Reanimation, Kinshasa, Democratic Republic of the Congo"},{"author_name":"Samuel Mampunza","author_inst":"University of Kinshasa and Catholic University of Congo, School of Medicine, Department of Psychiatry, Kinshasa, Democratic Republic of the Congo; Protestant Un"},{"author_name":"Lelo Mananga","author_inst":"University of Kinshasa, Department of Neurology, Kinshasa, Democratic Republic of the Congo"},{"author_name":"Justine Bukabau","author_inst":"University of Kinshasa, Department of Internal Medicine, Kinshasa, Democratic Republic of the Congo"},{"author_name":"Thomas Karikari","author_inst":"University of Pittsburgh School of Medicine, Department of Psychiatry, Pittsburgh, PA, USA"},{"author_name":"Alden L. Gross","author_inst":"Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, Baltimore, MD, USA"},{"author_name":"Alvaro Alonso","author_inst":"University of Navarra, School of Medicine, Department of Preventive Medicine and Public Health, Pamplona, Spain"}],"rel_date":"2026-11-18","rel_site":"medrxiv"},{"rel_title":"Genetic, Hormonal, and Psychosocial Factors Underly Sex Differences in Psychotic-Like Experience Trajectories in Adolescence","rel_doi":"10.64898\/2026.11.16.26368188","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.16.26368188","rel_abs":"Psychotic-like experiences (PLEs) are common during adolescence (prevalence: 17-60%), however, sex differences in the biopsychosocial factors associated with PLEs, particularly pubertal development and sex hormones, and PLE trajectories remains less understood. Here, we leverage data from the Adolescent Brain Cognitive Development (ABCD) Study to examine genetic, psychosocial, and hormonal correlates of PLE risk and persistence in 7,870 adolescents reporting at least one PLE across BL to Y3 follow-up. Among individuals of European ancestry, higher genetic risk for schizophrenia was positively associated with PLEs. Sex stratified multivariate linear regression analyses revealed sex-specific differences in associations between social factors and the outcome, with parent acceptance (beta= -0.09, p = 2.47x10-02 in males; beta = -0.44, p = 1.5x10-20 in females) and overt aggression (beta = 0.038, p = 1.67x10-02 in males; beta = -0.081, p = 1.53x10-05 in females) showing differing directions and magnitudes of effect in males and females. Pubertal development in males and females and age of menarche are associated with PLE risk, while mediation analyses identified estradiol in females as a mediator of the association between puberty and PLEs in premenarchal females. Lastly, multivariate logistic regression analyses and Analysis of Variance showed that higher exposure to psychosocial risk factors, such as discrimination (OR = 1.47, p = 1.11x10-04) and social victimization (OR = 1.05, p = 2.02x10-02), earlier pubertal development, and earlier age of menarche predict membership to the persistent PLE trajectory. These findings highlight sex-specific social correlates of adolescent PLEs and implicate pubertal timing and hormonal pathways in PLE risk and persistence. Understanding how genetic, social, and biological factors jointly shape PLE trajectories may help inform early identification of psychosis risk.","rel_num_authors":7,"rel_authors":[{"author_name":"Cara Ly","author_inst":"Yale University School of Medicine"},{"author_name":"Chaoyu Liu","author_inst":"Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London"},{"author_name":"Julia Ciarcia","author_inst":"Yale University School of Medicine"},{"author_name":"Seoyeon Lee","author_inst":"Yale University School of Medicine"},{"author_name":"Keira J.A. Johnston","author_inst":"Yale"},{"author_name":"Adrianna P Kepinska","author_inst":"Cardiff University"},{"author_name":"Laura M Huckins","author_inst":"University of Bath"}],"rel_date":"2026-11-18","rel_site":"medrxiv"},{"rel_title":"Widening racial and ethnic disparities in Helicobacter pylori infection in the United States: a Bayesian meta-analytic catalytic model of age-specific forces of infection","rel_doi":"10.64898\/2026.11.16.26367144","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.16.26367144","rel_abs":"Background Helicobacter pylori is the main cause of non-cardia gastric cancer. In the U.S. H. pylori seroprevalence has declined. However, whether all subgroups have benefited equally from this change is unclear. Further, prevalence alone cannot indicate when infection risk is most acute and thus when to target prevention efforts like screening. Methods We synthesized age-stratified H. pylori seroprevalence data from 36 U.S. studies (N=56,845; 1965-2014), identified via literature search through September 2022. We fitted Bayesian hierarchical catalytic epidemic models to estimate, by race\/ethnicity (for each of five race\/ethnicity groups) and birth cohort (pre-1960 vs. 1960+, or continuous), the maximum proportion infected, age-specific force of infection (FOI), and the age at half-maximum seroprevalence. Findings Disparities in maximum prevalence worsened in the 1960+ birth cohort, with the absolute Hispanic-Non-Hispanic White (NHW) gap widening from 33.2 to 51.4 percentage points. FOIs peaked at the youngest ages for the Non-Hispanic American Indian\/Alaska Native (AI\/AN) and Non-Hispanic Black (NHB) populations. Age patterns varied independently of burden; Hispanic and AI\/AN populations reached similar peak prevalence (83.0% vs 76.1%) for the 1960+ birth cohort, yet the age at half-maximum seroprevalence was 19.3 years (95%CrI: 14.9, 23.5) vs 3.20 years (95%CrI: 1.99, 4.63). Continuous birth-cohort analyses supported these findings. Interpretation National declines in H. pylori mask widening racial and ethnic disparities. In AI\/AN and NHB populations, seroprevalence rises steeply in early childhood, well before adulthood-targeted screen-and-treat programs would intervene. Moreover, similar peak prevalence can mask different age patterns of infection, and should be accounted for when guiding prevention strategies. Funding National Cancer Institute U01CA265729 and U01CA319219","rel_num_authors":10,"rel_authors":[{"author_name":"Tigist Menkir","author_inst":"Stanford University"},{"author_name":"Jorge Roa-Contreras","author_inst":"Stanford University"},{"author_name":"Yadira Peralta","author_inst":"Center for Research and Teaching in Economics"},{"author_name":"Chelsea Taylor","author_inst":"Boston Children's Hospital"},{"author_name":"Mercedes McMahon","author_inst":"Boston Children's Hospital"},{"author_name":"Jennifer Yeh","author_inst":"Boston Children's Hospital"},{"author_name":"M Constanza Camargo","author_inst":"National Cancer Institute"},{"author_name":"Robert Huang","author_inst":"Stanford University"},{"author_name":"Uri Ladabaum","author_inst":"Stanford University"},{"author_name":"Fernando Alarid-Escudero","author_inst":"Stanford University"}],"rel_date":"2026-11-18","rel_site":"medrxiv"},{"rel_title":"Swab-based molecular testing near the point-of-care for childhood tuberculosis: a prospective diagnostic accuracy study","rel_doi":"10.64898\/2026.11.16.26368102","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.16.26368102","rel_abs":"Background: Swab-based molecular testing for tuberculosis (TB) could provide a near point-of-care (nPOC) diagnostic for children. We evaluated the accuracy of two swab-based nPOC platforms to detect pediatric pulmonary TB. Methods: We prospectively enrolled children under 15 years with presumptive TB in Uganda and South Africa. They completed TB evaluation including sputum molecular testing and culture. Two tongue swabs were collected and tested with MiniDock MTB (Pluslife Biotech, China) and Truenat MTB Ultima (Molbio Diagnostics, India), and one swab was dipped in sputum for testing with MiniDock MTB. We calculated the sensitivity and specificity of each index test against a culture-based standard and compared them with sputum molecular testing and smear microscopy. Findings: We included 335 children, among whom median age was 3 years (IQR 1-6), 53% were female, 11% were living with HIV, and 16% had microbiologically confirmed TB. Tongue swabs were collected in all children, with invalid test rates of less than 3%. Against a culture-based standard, the sensitivities of tongue swab MiniDock MTB and MTB Ultima were 50% (95% CI 33.4-66.6) and 50% (95% CI 28.2-71.8), respectively, and specificities were [&ge;]98% for both. Sputum swab MiniDock MTB had similar sensitivity to sputum Xpert Ultra (85.7% vs. 75.0%, p=0.45), but substantially higher sensitivity than tongue swab MiniDock MTB (+23.1%, p=0.03) and sputum smear microscopy (+46.4%, p<0.001). Interpretation: Sputum swab testing had similar accuracy to sputum Xpert Ultra in children. Tongue swab testing had moderate accuracy, and has value to identify microbiologically confirmed cases when sputum is not available.","rel_num_authors":14,"rel_authors":[{"author_name":"Devan Jaganath","author_inst":"Department of Pediatrics, Division of Pediatric Infectious Diseases, University of California, San Francisco"},{"author_name":"Aggrey Ainebyona","author_inst":"Uganda Tuberculosis Implementation Research Consortium, WALIMU"},{"author_name":"Juaneta Luiz","author_inst":"Department of Paediatrics and Child Health, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town"},{"author_name":"Hayley Poore","author_inst":"Department of Medicine, Division of Pulmonary Diseases and Critical Care, University of California Irvine"},{"author_name":"Denise Banze","author_inst":"Instituto Nacional de Saude (INS), Centro de Investigacao e Treino em Saude da Polana Canico (CISPOC)"},{"author_name":"Robert Castro","author_inst":"Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California San Francisco"},{"author_name":"Seda Yerlikaya","author_inst":"Heidelberg University Medical Faculty Heidelberg, Heidelberg University Hospital, Department of Infectious Disease and Tropical Medicine"},{"author_name":"Payam Nahid","author_inst":"Institute for Global Health Sciences, University of California San Francisco"},{"author_name":"Claudia Denkinger","author_inst":"Heidelberg University Medical Faculty Heidelberg, Heidelberg University Hospital, Department of Infectious Disease and Tropical Medicine"},{"author_name":"Cattamanchi Adithya","author_inst":"Department of Medicine, Division of Pulmonary Diseases and Critical Care, University of California Irvine"},{"author_name":"Celso Khosa","author_inst":"Instituto Nacional de Saude (INS), Centro de Investigacao e Treino em Saude da Polana Canico (CISPOC)"},{"author_name":"Heather J Zar","author_inst":"Department of Paediatrics and Child Health, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town"},{"author_name":"Nilesh Bhatt","author_inst":"Elizabeth Glaser Pediatric AIDS Foundation, Washington DC"},{"author_name":"Eric Wobudeya","author_inst":"Uganda Tuberculosis Implementation Research Consortium, WALIMU"}],"rel_date":"2026-11-18","rel_site":"medrxiv"},{"rel_title":"Transparent Implementation and Benchmarking of ACMG\/AMP Variant Classification in fastVEP","rel_doi":"10.64898\/2026.11.16.26368228","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.16.26368228","rel_abs":"Background: The ACMG\/AMP framework is the standard for germline sequence variant interpretation, but applying it in scalable automated software requires operational choices that the original framework and later ClinGen guidance do not always specify. We implemented an ACMG\/AMP classification engine within fastVEP and evaluated which implementation choices improved agreement with expert-curated classifications without increasing concerning opposite-direction calls. Methods: The classifier implements all 28 ACMG\/AMP criteria and can evaluate 15 from a sites-only VCF using nine public evidence sources. For selecting the optimal classifier, we compared symmetric and hybrid evidence-combining schemes, pathogenic class cutoffs, population-frequency thresholds, and benign-evidence thresholds against 673,660 ClinVar variants with review status of two stars or higher from April 2026. Clinical geneticists reviewed opposite-direction calls. We then applied the selected final classifier unchanged to 116,078 variants that newly reached the two-star threshold in the October 2026 ClinVar release. Results: The final fastVEP ACMG\/AMP classifier uses the Tavtigian point scale on the pathogenic side and the 2015 ACMG\/AMP combining table on the benign side. Using the 2015 table on both sides reduced pathogenic-side recall from 62.5 to 57.1 percent and lost 4,900 same-direction calls while avoiding 10 opposite-direction pathogenic calls. Using points on both sides increased benign-side recall from 66.4 to 77.0 percent, but increased opposite-direction benign calls from 27 to 399 and reduced recall of ClinVar uncertain variants from 97.1 to 69.5 percent. The 6-point Likely pathogenic cutoff was retained because lowering it to 5 points increased pathogenic-side recall to 73.9 percent but also classified 6,003 additional ClinVar uncertain variants and 17 additional ClinVar benign-side variants as pathogenic-side. The final classifier reproduced ClinVar's exact five-tier class for 431,727 variants or 64.1 percent and its pathogenic, benign, or uncertain direction for 534,335 variants or 79.3 percent. Only 51 calls or 0.0076 percent were opposite in direction to ClinVar. On the later variants, same-direction agreement was 72.6 percent and 20 calls were opposite in direction. Conclusions: The rules used to combine evidence affected classification more than several individual numeric thresholds. The hybrid scheme increased pathogenic-side recall while preventing a single Supporting benign criterion from producing a directional call. This conservative operating profile is suited to large-scale variant triage because it makes high-confidence calls while leaving variants uncertain when the available evidence does not support expert-level resolution. fastVEP is a research and decision-support tool and does not replace case-specific expert review.","rel_num_authors":3,"rel_authors":[{"author_name":"Kuan-lin Huang","author_inst":"Icahn School of Medicine at Mount Sinai"},{"author_name":"Mythily Ganapathi","author_inst":"Columbia University"},{"author_name":"Wendy Chung","author_inst":"Boston Children's Hospital"}],"rel_date":"2026-11-18","rel_site":"medrxiv"},{"rel_title":"Adverse Events and Baseline Psychological Distress Among Dementia Family Care Partners in the Tele-STELLA Study","rel_doi":"10.64898\/2026.11.16.26368229","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.16.26368229","rel_abs":"Background: Adverse event (AE) narratives may reveal physical and psychological challenges experienced by family care partners of people living with Alzheimer's disease and related dementias. Objective: To characterize care partner AEs during the national Tele-STELLA study and explore differences in baseline psychological characteristics by AE category and subcategory. Methods: This descriptive, exploratory analysis included 43 AEs reported by 36 care partners. Narratives were classified as Physical, Psychological, or Random\/Other. Baseline depressive symptoms, grief, and behavioral reactivity were compared between care partners with and without each AE type within this sample. Results: Physcial events accounted for 48.8% of AEs, Psychological events for 39.5%, and Random\/Other events for 11.6%. Infections predominated among Physical events; stress\/distress accounted for half of the Psychological events. Psychological AEs were associated with higher baseline grief and behavioral reactivity. Stress\/distress-related AEs were associated with higher depressive symptoms and reactivity, whereas aggression-related Aes were associated with greater grief. Conclusions: Care partner AE narratives captured heterogeneous physical and psychological experiences. Classification may complement conventional assessments of care partner health and distress. These exploratory findings do not establish causality or predictive validity and warrant prospective study.","rel_num_authors":5,"rel_authors":[{"author_name":"Christine McClure","author_inst":"Oregon Health & Science University"},{"author_name":"Hailey Chatterton","author_inst":"Oregon Health & Science University"},{"author_name":"Heather Franklin","author_inst":"Oregon Health & Science University"},{"author_name":"Aimee Mooney","author_inst":"Oregon Health & Science University"},{"author_name":"Allison Lindauer","author_inst":"OHSU - Oregon Health & Science University"}],"rel_date":"2026-11-18","rel_site":"medrxiv"},{"rel_title":"Central motor cortical repetitive transcranial magnetic stimulation at 5 Hz or 10 Hz combined with cerebellar 1 Hz stimulation for ataxia in multiple system atrophy of the cerebellar type: a retrospective cohort study of efficacy and predictors of response","rel_doi":"10.64898\/2026.11.16.26368149","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.16.26368149","rel_abs":"Objective: To evaluate the efficacy of central motor cortical repetitive transcranial magnetic stimulation (rTMS) at different frequencies (5 Hz and 10 Hz) combined with cerebellar 1 Hz stimulation on the core domains of ataxia in patients with multiple system atrophy of the cerebellar type (MSA-C), and to explore the independent predictors of the response. Methods: In this retrospective study, 48 patients with a confirmed diagnosis of MSA-C were included. All patients received bilateral cerebellar hemispheric 1 Hz rTMS as background therapy and were divided according to the frequency of central cortical stimulation into a control group (cerebellar 1 Hz stimulation only, n=15), a 5 Hz combination group (n=16) and a 10 Hz combination group (n=17). Ataxia severity before and after treatment was assessed with the International Cooperative Ataxia Rating Scale (ICARS); absolute improvements and improvement rates were calculated for each subscore and for the total score. Continuous variables were described as mean +\/- standard deviation (SD) or median (interquartile range) according to normality; within-group pre-post comparisons used the Wilcoxon signed-rank test, and between-group comparisons used one-way analysis of variance (ANOVA) or the Kruskal-Wallis H test with Bonferroni correction. Clinical response was defined by an absolute improvement threshold (delta-ICARS total score >= 8 points), and independent influencing factors were analysed by Firth-penalised logistic regression; sensitivity analyses were performed with a total-score improvement rate >= 20% (and with >= 15% and >= 30% as alternative thresholds), and robustness results are reported for the delta-ICARS >= 10-point criterion. Missing cognitive and mood scale scores were imputed by multiple imputation by chained equations (MICE; m=5; the mean of the five imputations constituted the analysis dataset) and then included in the analysis. Subgroup and interaction analyses were performed according to the median disease duration (2 years) and median age (57 years). Results: After treatment, the ICARS total score in the overall cohort was significantly lower than at baseline (median difference 7.0 points, P<0.001), and posture and gait (ICARS1), limb kinetic function (ICARS2) and speech function (ICARS3) all improved significantly (P<0.001 for all), whereas oculomotor disorders (ICARS4) did not improve significantly (P=0.799). Efficacy differed significantly among the three groups: median total-score improvement rates were 10.7%, 20.3% and 21.9%, respectively (P=0.004); when a total-score improvement rate >= 20% was used to define clinically significant efficacy, the response rates of the three groups were 6.7%, 50.0% and 58.8% (P=0.006), and both the 10 Hz and 5 Hz groups were significantly better than the control group (Bonferroni-corrected P=0.006 and P=0.040), with no statistically significant difference between the two frequencies. Domain-specific comparison showed statistically significant between-group differences in both the absolute improvement and the improvement rate of limb kinetic function (P=0.013 and P=0.005), with the 10 Hz group significantly better than the control group. When clinical response was defined as delta-ICARS >= 8 points, the response rates of the three groups were 20.0%, 56.2% and 64.7% (P=0.029); Firth-penalised multivariable regression showed that baseline ICARS total score was an independent predictor of clinical response (OR=1.076, 95% CI 1.013-1.143, P=0.017), whereas 5 Hz (OR=4.298, 95% CI 0.757-24.412, P=0.100) and 10 Hz (OR=5.847, 95% CI 0.885-38.640, P=0.067) stimulation did not reach independent statistical significance after adjustment. When response was defined as delta-ICARS >= 10 points, the response rates were 0%, 43.8% and 47.1% (P=0.007), and there were no responders in the control group. Subgroup analysis showed a significant group-by-age interaction (P=0.020); the clinical response rate of patients aged >= 57 years receiving 10 Hz stimulation was 85.7% (exploratory finding; small subgroup sample). The group-by-duration interaction was not statistically significant (P=0.210). Conclusions: Central 5 Hz and 10 Hz rTMS combined with cerebellar 1 Hz stimulation both significantly improved the symptoms of ataxia in patients with MSA-C, and the efficacy was domain-specific, with the greatest improvement in the limb kinetic domain; sensitivity analyses across multiple criteria (delta-ICARS >= 8 points, improvement rate >= 20%, delta-ICARS >= 10 points) consistently supported the efficacy benefit of high-frequency stimulation in the same direction, but stimulation frequency did not reach independent predictive statistical significance after adjustment, and baseline ICARS total score was significantly associated with absolute improvement. Age may have a modifying effect on the efficacy of stimulation frequency (exploratory finding; small sample). This study provides preliminary support for the efficacy of the central 10 Hz combined with cerebellar 1 Hz regimen; the optimal stimulation parameters and independent predictors remain to be verified in larger prospective studies.","rel_num_authors":6,"rel_authors":[{"author_name":"Mengyang Wang","author_inst":"Sanbo Brain Hospital, Capital Medical University"},{"author_name":"Yongli Wang","author_inst":"Sanbo Brain Hospital, Capital Medical University"},{"author_name":"Minghui Wang","author_inst":"Sanbo Brain Hospital, Capital Medical University"},{"author_name":"Yixian Han","author_inst":"Sanbo Brain Hospital, Capital Medical University"},{"author_name":"Jiali Pan","author_inst":"Sanbo Brain Hospital, Capital Medical University"},{"author_name":"Yongkang Zhou","author_inst":"Sanbo Brain Hospital, Capital Medical University"}],"rel_date":"2026-11-18","rel_site":"medrxiv"},{"rel_title":"Traumatic microbleeds are associated with unfavorable outcome out to 1 year after mild traumatic brain injury","rel_doi":"10.64898\/2026.11.15.26367999","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.15.26367999","rel_abs":"Importance: Traumatic microbleeds (TMB) are commonly observed in mild TBI (mTBI). However, questions remain regarding their long-term prognostic significance. Objective: Determine whether traumatic microbleeds predict unfavorable outcome after mild traumatic brain injury (mTBI) Design: The prospective longitudinal observational Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study enrolled acute TBI patients presenting to Emergency Departments (ED) at 18 U.S. Level 1 trauma centers between 2\/26\/2014-08\/08\/2018. CT and MRI were evaluated using the National Institutes of Health National Institute of Neurological Disorders and Stroke (NIH NINDS) TBI Common Data Elements. Outcome was assessed using the Glasgow Outcome Scale Extended (GOSE-TBI) at 2 weeks and 3, 6, and 12 months post-injury. Setting: 18 U.S. Level 1 trauma centers Participants: 929 GCS 13-15 patients at least 17 years of age (38.5 +\/- 16.5 years, 66% male) who underwent clinical head CT <24 hours after injury and brain MRI at 2 weeks post-injury and had at least one GOSE-TBI outcome score during 1 year follow-up. Exposure(s): Acute non-penetrating head trauma Main Outcome(s) and Measure(s): Frequency and co-occurrence of CT and MR features; incomplete recovery (GOSE-TBI <8 vs. 8) and unfavorable outcome (GOSE-TBI <5 vs. >=5) at 2 weeks and 3, 6, and 12 months Results: Generalized estimating equation models showed that TMBs and\/or IVH were strongly associated with unfavorable outcome (GOSE-TBI <5 vs. >=5) at 3, 6, and 12 months post-injury, but not with incomplete recovery (GOSE-TBI <8 vs. =8). For prediction of GOSE-TBI <5 vs. >=5 TMBs surpassed the importance of all demographic and baseline clinical predictors throughout the 1-year follow-up period. For prediction of incomplete recovery (GOSE-TBI <8 vs. =8), brain contusions, subarachnoid hemorrhage, and subdural hematoma were more important throughout the 12-month follow-up period. Conclusions and Relevance: Traumatic microbleeds (TMB) are common in mTBI. The presence of 4 or more TMBs and\/or IVH is strongly associated with unfavorable outcome (GOSE-TBI <5) after mTBI out to at least 1 year, even after controlling for other neuroimaging abnormalities and demographic and clinical predictors. Better understanding of the implications of TMBs for long-term functional outcome may inform rehabilitation planning.","rel_num_authors":19,"rel_authors":[{"author_name":"Esther L. Yuh","author_inst":"Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA"},{"author_name":"Sonia Jain","author_inst":"Biostatistics Research Center, Herbert Wertheim School of Public Health, University of California, San Diego, CA"},{"author_name":"Xiaoying Sun","author_inst":"Biostatistics Research Center, Herbert Wertheim School of Public Health, University of California, San Diego, CA"},{"author_name":"Sandra P. Rincon","author_inst":"Department of Radiology, Massachusetts General Hospital, Boston, MA"},{"author_name":"Pratik Mukherjee","author_inst":"Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA"},{"author_name":"John K. Yue","author_inst":"Department of Neurological Surgery, University of California, San Francisco, CA"},{"author_name":"Amy J. Markowitz","author_inst":"Department of Neurological Surgery, University of California, San Francisco, CA"},{"author_name":"Christine L. Mac Donald","author_inst":"Department of Neurological Surgery, University of Washington, Seattle, WA"},{"author_name":"Gabriela G. Satris","author_inst":"Department of Neurological Surgery, University of California, San Francisco, CA"},{"author_name":"Sabrina R. Taylor","author_inst":"Department of Neurological Surgery, University of California, San Francisco, CA"},{"author_name":"Joseph T. Giacino","author_inst":"Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA"},{"author_name":"Michael W. McCrea","author_inst":"Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, WI"},{"author_name":"Murray B. Stein","author_inst":"Department of Psychiatry, University of California at San Diego, CA"},{"author_name":"Nancy R. Temkin","author_inst":"Department of Neurological Surgery, University of Washington, Seattle, WA"},{"author_name":"Ramon R. Diaz-Arrastia","author_inst":"Department of Neurology, University of Pennsylvania, Philadelphia, PA"},{"author_name":"Claudia S. Robertson","author_inst":"Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, TX"},{"author_name":"David O. Okonkwo","author_inst":"Department of Neurological Surgery, University of Pittsburgh, PA"},{"author_name":"Geoffrey T. Manley","author_inst":"Department of Neurological Surgery, University of California, San Francisco, CA"},{"author_name":"- TRACK-TBI Investigators","author_inst":""}],"rel_date":"2026-11-18","rel_site":"medrxiv"},{"rel_title":"Traumatic microbleeds are associated with unfavorable outcome out to 1 year after mild traumatic brain injury","rel_doi":"10.64898\/2026.11.15.26367999","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.15.26367999","rel_abs":"Importance: Traumatic microbleeds (TMB) are commonly observed in mild TBI (mTBI). However, questions remain regarding their long-term prognostic significance. Objective: Determine whether traumatic microbleeds predict unfavorable outcome after mild traumatic brain injury (mTBI) Design: The prospective longitudinal observational Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study enrolled acute TBI patients presenting to Emergency Departments (ED) at 18 U.S. Level 1 trauma centers between 2\/26\/2014-08\/08\/2018. CT and MRI were evaluated using the National Institutes of Health National Institute of Neurological Disorders and Stroke (NIH NINDS) TBI Common Data Elements. Outcome was assessed using the Glasgow Outcome Scale Extended (GOSE-TBI) at 2 weeks and 3, 6, and 12 months post-injury. Setting: 18 U.S. Level 1 trauma centers Participants: 929 GCS 13-15 patients at least 17 years of age (38.5 +\/- 16.5 years, 66% male) who underwent clinical head CT <24 hours after injury and brain MRI at 2 weeks post-injury and had at least one GOSE-TBI outcome score during 1 year follow-up. Exposure(s): Acute non-penetrating head trauma Main Outcome(s) and Measure(s): Frequency and co-occurrence of CT and MR features; incomplete recovery (GOSE-TBI <8 vs. 8) and unfavorable outcome (GOSE-TBI <5 vs. >=5) at 2 weeks and 3, 6, and 12 months Results: Generalized estimating equation models showed that TMBs and\/or IVH were strongly associated with unfavorable outcome (GOSE-TBI <5 vs. >=5) at 3, 6, and 12 months post-injury, but not with incomplete recovery (GOSE-TBI <8 vs. =8). For prediction of GOSE-TBI <5 vs. >=5 TMBs surpassed the importance of all demographic and baseline clinical predictors throughout the 1-year follow-up period. For prediction of incomplete recovery (GOSE-TBI <8 vs. =8), brain contusions, subarachnoid hemorrhage, and subdural hematoma were more important throughout the 12-month follow-up period. Conclusions and Relevance: Traumatic microbleeds (TMB) are common in mTBI. The presence of 4 or more TMBs and\/or IVH is strongly associated with unfavorable outcome (GOSE-TBI <5) after mTBI out to at least 1 year, even after controlling for other neuroimaging abnormalities and demographic and clinical predictors. Better understanding of the implications of TMBs for long-term functional outcome may inform rehabilitation planning.","rel_num_authors":19,"rel_authors":[{"author_name":"Esther L. Yuh","author_inst":"Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA"},{"author_name":"Sonia Jain","author_inst":"Biostatistics Research Center, Herbert Wertheim School of Public Health, University of California, San Diego, CA"},{"author_name":"Xiaoying Sun","author_inst":"Biostatistics Research Center, Herbert Wertheim School of Public Health, University of California, San Diego, CA"},{"author_name":"Sandra P. Rincon","author_inst":"Department of Radiology, Massachusetts General Hospital, Boston, MA"},{"author_name":"Pratik Mukherjee","author_inst":"Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA"},{"author_name":"John K. Yue","author_inst":"Department of Neurological Surgery, University of California, San Francisco, CA"},{"author_name":"Amy J. Markowitz","author_inst":"Department of Neurological Surgery, University of California, San Francisco, CA"},{"author_name":"Christine L. Mac Donald","author_inst":"Department of Neurological Surgery, University of Washington, Seattle, WA"},{"author_name":"Gabriela G. Satris","author_inst":"Department of Neurological Surgery, University of California, San Francisco, CA"},{"author_name":"Sabrina R. Taylor","author_inst":"Department of Neurological Surgery, University of California, San Francisco, CA"},{"author_name":"Joseph T. Giacino","author_inst":"Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA"},{"author_name":"Michael W. McCrea","author_inst":"Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, WI"},{"author_name":"Murray B. Stein","author_inst":"Department of Psychiatry, University of California at San Diego, CA"},{"author_name":"Nancy R. Temkin","author_inst":"Department of Neurological Surgery, University of Washington, Seattle, WA"},{"author_name":"Ramon R. Diaz-Arrastia","author_inst":"Department of Neurology, University of Pennsylvania, Philadelphia, PA"},{"author_name":"Claudia S. Robertson","author_inst":"Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, TX"},{"author_name":"David O. Okonkwo","author_inst":"Department of Neurological Surgery, University of Pittsburgh, PA"},{"author_name":"Geoffrey T. Manley","author_inst":"Department of Neurological Surgery, University of California, San Francisco, CA"},{"author_name":"- TRACK-TBI Investigators","author_inst":""}],"rel_date":"2026-11-18","rel_site":"medrxiv"},{"rel_title":"The Caenorhabditis elegans pangenome elucidates hyper-divergent region gene content to reveal extensive gene copy-number variation and a novel anthelmintic resistance locus","rel_doi":"10.64898\/2026.11.17.767430","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.17.767430","rel_abs":"Caenorhabditis elegans has been a keystone model in biological research since the early 1970s, and it was the first metazoan to have its genome sequenced and assembled in 1998. Over the last few decades, the genetic and genomic resources developed for C. elegans made it one of the most powerful models for understanding metazoan biology. Recently, the C. elegans community has collected over 2,000 globally distributed wild strains, which after whole-genome sequencing, were found to contain punctuated regions of extreme genetic variation, called hyper-divergent regions (HDRs). HDRs have been described in organisms across the tree of life, including plants and humans, and genes in HDRs appear to be involved in adaptation, such as environmental response genes, parasitism genes, or immunity genes. However, the extreme genetic divergence at these loci complicates short-read alignments, and the genomic content of these regions in non-reference strains is largely uncharacterized. To define the gene content in HDRs, we de novo assembled and annotated genomes of 140 genetically diverse strains. These data enabled the construction of the first gene-based pangenome for the species. Among these strains, we characterized the landscape of structural variation and developed novel methods to quantify gene content diversity. We found that both variable copy-number and stable-copy environmental response genes were enriched in HDRs. These results further suggest that these regions have an important evolutionary role in adaptation to heterogeneous environments. We leveraged this pangenome to elucidate gene content in previously identified quantitative trait loci associated with adaptive traits. In one HDR, we found large deletions, spanning multiple genes, that are correlated with resistance to the anthelmintic drug abamectin. The C. elegans pangenome provides novel insights into genome and gene family evolution in a genetically diverse animal species, and empowers deeper investigations of genotype-phenotype relationships underlying adaptive traits, particularly in the context of structural and gene copy-number variation.","rel_num_authors":10,"rel_authors":[{"author_name":"Lance M. O'Connor","author_inst":"Department of Biology, Johns Hopkins University, Baltimore, MD, 21218, USA. Cell, Molecular, Developmental Biology, and Biophysics doctoral program, Johns Hopki"},{"author_name":"Nicolas D. Moya","author_inst":"Department of Biology, Johns Hopkins University, Baltimore, MD, 21218, USA."},{"author_name":"Robyn E. Tanny","author_inst":"Department of Biology, Johns Hopkins University, Baltimore, MD, 21218, USA."},{"author_name":"Amanda O. Shaver","author_inst":"Department of Biology, Johns Hopkins University, Baltimore, MD, 21218, USA."},{"author_name":"Ayeh Khorshidian","author_inst":"Department of Biology, Johns Hopkins University, Baltimore, MD, 21218, USA."},{"author_name":"Ryan Pellow","author_inst":"School of Biological Science and Center for Cell and Genome Science, University of Utah, Salt Lake City, UT, USA."},{"author_name":"Ofer Rog","author_inst":"School of Biological Science and Center for Cell and Genome Science, University of Utah, Salt Lake City, UT, USA."},{"author_name":"Stefan Zdraljevic","author_inst":"Department of Human Genetics, University of California, Los Angeles, CA, USA. Department of Biological Chemistry, University of California, Los Angeles, CA, USA"},{"author_name":"Leonid Kruglyak","author_inst":"Department of Human Genetics, University of California, Los Angeles, CA, USA. Department of Biological Chemistry, University of California, Los Angeles, CA, USA"},{"author_name":"Erik C. Andersen","author_inst":"Department of Biology, Johns Hopkins University, Baltimore, MD, 21218, USA."}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"The global geometry of optimal neural representations","rel_doi":"10.64898\/2026.11.17.767450","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.17.767450","rel_abs":"Efficient coding hypothesizes that neural activity optimally represents information under resource constraints. The global structures of such optimal population codes are difficult to study theoretically, and previous works have usually resorted to either focusing on local properties like fine discrimination or placing restrictions on the parametric forms of neural tuning. We address the general problem by analytically deriving the neural representation that minimizes the all-pairs average classification error of a one-dimensional circular variable under various forms of neural response noise. Our method is based on formulating the space of neural response distributions as a statistical manifold whose geometry can be simplified through a generalized version of variance-stabilizing transformations. The theory fully characterizes the complete family of optimal population codes and allows us to make two novel predictions. First, an optimal code should allow the existence of oppositely peaked bimodal tuning curves. Second, there should be a correlation between spike count variability and tuning sharpness. We validate both of these predictions in the mouse head direction system.","rel_num_authors":2,"rel_authors":[{"author_name":"Gengshuo John Tian","author_inst":"University of Chicago"},{"author_name":"Brent Doiron","author_inst":"University of Chicago"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Auditory bullae enlarge along an aridity gradient in a diverse subfamily of small carnivorous mammals","rel_doi":"10.64898\/2026.11.17.767213","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.17.767213","rel_abs":"The world`s arid regions are home to diverse assemblages of small mammals, many of which possess a range of physiological, behavioral, and sensory adaptations to the harsh selective pressures imposed by arid environments. The mammalian skull facilitates a range of sensory functions, meaning that arid-dwelling species likely possess distinct skull adaptations which have evolved in response to the unique selective pressures imposed by arid environments. Studies on arid-adapted rodents have highlighted hearing as being important for arid adaptation; however, the adaptive potential of the entire skull is rarely considered. Here, we used 3D geometric morphometrics to test for signatures of arid adaptation using 168 skulls across 30 species of the Sminthopsinae, a subfamily of small insectivorous marsupials, found across Australia. We found that relative bulla size increased by 20% along an aridity gradient from mesic to hyper arid. We also found that species further from the equator tended to have wider posterior nasal cavities, which may be related to selection for thermoregulatory capabilities. Our findings demonstrate the role of the skull in facilitating adaptation to aridity and provide further evidence that selection for improved low-frequency hearing appears to be a key driver of skull shape in arid-zone small mammals.","rel_num_authors":8,"rel_authors":[{"author_name":"Cameron S Dodd","author_inst":"University of Western Australia"},{"author_name":"Vera Wesibecker","author_inst":"Flinders University, South Australia"},{"author_name":"Andrew M Baker","author_inst":"Queensland University of Technology, Queensland, Australia"},{"author_name":"Meg L Martin","author_inst":"Flinders University"},{"author_name":"Kenny J Travouillon","author_inst":"Western Australian Museum, Western Australia"},{"author_name":"Linette S Umbrello","author_inst":"Western Australian Museum, Western Australia"},{"author_name":"Michael Westerman","author_inst":"La Trobe University, Victoria, Australia"},{"author_name":"Renee A Catullo","author_inst":"University of Western Australia, Western Australia"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Modern speech recognition systems exhibit human-like word recognition but superhuman use of statistical dependencies between words","rel_doi":"10.64898\/2026.11.17.767420","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.17.767420","rel_abs":"Advances in machine learning have yielded machine systems that approach human performance on real-world perception tasks. For speech recognition, it remains unclear whether such models' behavior resembles that of humans. We addressed this question by measuring word recognition abilities in humans and models across 272 speech distortions, providing a detailed behavioral fingerprint. Three recent industry speech recognition models trained on hundreds of years of speech outperformed humans. However, in conditions where linguistic context was removed, they matched human performance well, suggesting that the models are superhuman in their ability to leverage statistical dependencies between words. Experiments manipulating model training data suggest that training data variability and realism contribute to the match to human perception. Overall, the results show that superhuman performance is now possible with systems that are optimized over enough data and suggest that accurate models of human speech recognition require optimization over appropriate tasks and amounts of speech.","rel_num_authors":6,"rel_authors":[{"author_name":"Annika Magaro","author_inst":"MIT"},{"author_name":"Gasser Elbanna","author_inst":"MIT"},{"author_name":"Erica Shook","author_inst":"Columbia University"},{"author_name":"Alex Kell","author_inst":"MIT"},{"author_name":"Mark R Saddler","author_inst":"Technical University of Denmark"},{"author_name":"Josh H McDermott","author_inst":"Massachusetts Institute of Technology"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Thrombin cleavage of circulating osteopontin in the lung drives hippocampal neuroinflammation and acute delirium-like neurologic dysfunction after acute kidney injury","rel_doi":"10.64898\/2026.11.17.767415","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.17.767415","rel_abs":"Acute kidney injury (AKI) is a common clinical problem with high morbidity and mortality due to frequently occurring secondary organ complications, including acute neurologic dysfunction, such as delirium. Specific mechanisms responsible for this kidney-brain crosstalk are unknown but hypothesized to include uremic toxins and neuroinflammation secondary to systemic inflammation. Here we show that uremic mice with AKI show hippocampal monocytic neuroinflammation associated with acute delirium-like neurologic dysfunction only in the presence of circulating osteopontin fragments. Mechanistically, circulating osteopontin (OPN\/Spp1) released by the injured kidney was cleaved by thrombin in the lung into OPN-N and OPN-C-terminal fragments. Both OPN fragments were required to drive upregulation of the monocyte chemoattractant chemokine-ligand-2 (CCL2) in hippocampal endothelial cells. AKI mice lacking OPN or unable to activate OPN by thrombin cleavage showed kidney injury and serum uremic toxin elevations like wt controls but were protected from hippocampal CCL2 upregulation, monocyte recruitment, and delirium-like symptoms. Systemic application of an OPN or CCL2 neutralizing antibody was protective. Our results suggest that a specific kidney-released circulating factor, osteopontin, drives acute neurologic dysfunction after AKI and challenge the widely held hypothesis that uremic toxins play a dominant role. They also identify thrombin cleavage of OPN as a potential therapeutic target and critical switch for the remote functions of circulating OPN.","rel_num_authors":12,"rel_authors":[{"author_name":"Poornima Dilhani Ekanayake Weerasinghe Mudiyanselage","author_inst":"Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA and VA Saint Louis Health Care System, John Cochran"},{"author_name":"Rupal Ojha","author_inst":"Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA and VA Saint Louis Health Care System, John Cochran"},{"author_name":"Liang Ning","author_inst":"Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA and VA Saint Louis Health Care System, John Cochran"},{"author_name":"Marta Celorrio Navarro","author_inst":"Division of Critical Care Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA"},{"author_name":"Leah Tolby","author_inst":"Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA"},{"author_name":"Anusha Suresh","author_inst":"Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA"},{"author_name":"John Morser","author_inst":"3.\tDivision of Critical Care Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA and 4.\tDivision of Hematology, Sta"},{"author_name":"Lawrence Leung","author_inst":"Division of Critical Care Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA and Division of Hematology, Stanford "},{"author_name":"Machiko Honda","author_inst":"Department of Molecular Immunology, Faculty of Pharmaceutical Sciences, Fukuyama University, 985-1 Azasanzo, Higashimura-cho, Fukuyama, Hiroshima 729-0292, Japa"},{"author_name":"Shigeyuki Kon","author_inst":"Department of Molecular Immunology, Faculty of Pharmaceutical Sciences, Fukuyama University, 985-1 Azasanzo, Higashimura-cho, Fukuyama, Hiroshima 729-0292, Japa"},{"author_name":"Stuart H. Friess","author_inst":"Division of Critical Care Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA"},{"author_name":"Andreas Herrlich","author_inst":"Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA and VA Saint Louis Health Care System, John Cochran"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Aging remodels the neuronal activity-dependent transcriptome","rel_doi":"10.64898\/2026.11.17.767442","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.17.767442","rel_abs":"Experience-driven neuronal activity induces coordinated transcriptional programs in neurons and glia that support plasticity and memory. How aging reshapes these activity-regulated gene (ARG) programs, and whether activity mitigates or exacerbates aging phenotypes, remain open questions with implications for cognitive decline. Here, we develop novel-environment and chemogenetic paradigms to characterize age-dependent remodeling of ARG transcriptomes in the mouse hippocampus at single-cell resolution. Aging contracts youthful ARG programs in both gene number and dynamic range, a contraction that persists under controlled chemogenetic stimulation independent of behavior. In parallel, novel experience in older mice reveals a latent transcriptional competence. First, distinct sets of genes respond to neuronal activity selectively in older cells. Second, enhancing activity in older animals partially reverses, or buffers, basal aging-associated changes across the transcriptome. Novel experience counteracts aging-associated changes in the target genes of the memory regulator CREB1 and the ER-stress sensor ATF6 across cell types. These data constitute a resource for neuronal activity-dependent transcription across the lifespan and identify a basis for the benefits of cognitive engagement: novel experience buffers age-related transcriptional drift.","rel_num_authors":6,"rel_authors":[{"author_name":"Joowon Um","author_inst":"Washington University School of Medicine in St. Louis"},{"author_name":"Hanyue Cecilia Lei","author_inst":"Washington University School of Medicine in St. Louis"},{"author_name":"Kodai Nakamura","author_inst":"Washington University School of Medicine in St. Louis"},{"author_name":"Eric Tycksen","author_inst":"Washington University School of Medicine in St. Louis"},{"author_name":"Jacob W. Adelman","author_inst":"Washington University School of Medicine in St. Louis"},{"author_name":"Elizabeth Pollina","author_inst":"Washington University School of Medicine in St. Louis"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"PROGMF: Progressive Multimodal Fusion and Representation Learning for Incomplete Neuroimaging Data","rel_doi":"10.64898\/2026.11.17.767205","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.17.767205","rel_abs":"Multimodal neuroimaging studies often involve cohorts with partially overlapping data modalities. Many conventional multimodal fusion methods rely on participants with complete observations across the selected modalities. We introduce Progressive Multimodal Fusion (ProgMF), a novel fusion framework for learning multimodal source representations from incomplete neuroimaging data without imputing missing observations. ProgMF integrates modalities sequentially through independent vector analysis (IVA), cross-stage component alignment, and anchor-guided representation transfer, allowing information learned from earlier-stage cohorts to inform subsequent multimodal decompositions. We evaluated ProgMF on four neuroimaging-inspired synthetic modalities, while varying subject overlap, observation noise, modality relatedness, and fusion orders. ProgMF generally achieved lower source-recovery errors than complete-case IVA and the evaluated imputation-based methods, with larger improvements as multimodal subject overlap decreased. We further applied ProgMF to structural MRI gray matter, resting-state functional network connectivity, and 18F-florbetapir (AV45) amyloid positron emission tomography data from the Alzheimer's Disease Neuroimaging Initiative. ProgMF achieved higher mean cross-modal fusion scores than the imputation-based baselines and a modest improvement over complete-case IVA. Among the 293 participants with complete multimodal observations, two recovered source component vectors showed significant associations with clinical diagnosis across cognitively normal, mild cognitive impairment, and dementia groups. Both sources were also significantly associated with cognitive performance and dementia severity. The recovered sources exhibited diagnosis-related structural and amyloid PET patterns involving regions such as the hippocampi, precuneus, and cingulate cortices. Our findings support progressive representation transfer as an effective approach for recovering coherent, interpretable multimodal sources from participants with incomplete modality coverage.","rel_num_authors":6,"rel_authors":[{"author_name":"Victor Solomon","author_inst":"Department of Computer Science, Georgia State University, Atlanta, GA, United States"},{"author_name":"Vince D Calhoun","author_inst":"Tri-Institutional Center for Translational Research in Neuroimaging and Data Science (TReNDS), Georgia State University, Georgia Institute of Technology, and Em"},{"author_name":"Tulay Adali","author_inst":"Department of Computer Science and Electrical Engineering, University of Maryland Baltimore County, Baltimore, MD, United States"},{"author_name":"Rogers F Silva","author_inst":"Department of Computer Science, Georgia State University, Atlanta, GA, United States"},{"author_name":"Rafal A Angryk","author_inst":"Department of Computer Science, Georgia State University, Atlanta, GA, United States"},{"author_name":"Jingyu Liu","author_inst":"Department of Computer Science, Georgia State University, Atlanta, GA, United States"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"GenVinci reconstructs 3D molecular tissue scenes from histology to map senescence across aging and disease","rel_doi":"10.64898\/2026.11.17.767412","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.17.767412","rel_abs":"Spatial omics has generated measurements at unprecedented scale, yet computational approaches remain largely confined to individual modalities and 2D representations. Here we assemble ImageOmicsNet-300M, a corpus of 300 million single-cell and spatial transcriptomic profiles, including 24.9 million H&E-predicted virtual spatial transcriptomics profiles, and 4,623 H&E sections. Of these H&E sections, we generated 1,782 from aging mouse organs and serially sectioned human skin spanning five decades, with matched spatial transcriptomics and snRNA-seq. Building on this resource, we develop GenVinci, a multimodal tissue foundation model that reconstructs 3D tissue scenes from routine 2D histology. GenVinci predicts spatial gene expression from H&E with zero-shot generalization and maps senescence-associated states across 85.8 million cells, revealing cell-type-specific patterns and disease-associated remodeling. Integration with human genetics implicates suprabasal keratinocytes in atopic dermatitis and keratinocyte carcinomas, linked to higher and lower p16 and p21 expression, respectively. These findings establish GenVinci as a framework mapping senescence in 3D across scales.","rel_num_authors":33,"rel_authors":[{"author_name":"Xingjian Chen","author_inst":"Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Electrical Engineering and Computer Sc"},{"author_name":"Charles Comiter","author_inst":"Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Electrical Engineering and Computer Sc"},{"author_name":"Haochun Huang","author_inst":"Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"},{"author_name":"Yinghan Wu","author_inst":"Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"},{"author_name":"Ying-Li Su","author_inst":"Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"},{"author_name":"Judy Zhou","author_inst":"Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"},{"author_name":"Francesco Monticolo","author_inst":"Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"},{"author_name":"Max Condouret","author_inst":"Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"},{"author_name":"Styliani Sapantzi","author_inst":"Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"},{"author_name":"Jianhuan Qi","author_inst":"Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"},{"author_name":"Xuemeng Li","author_inst":"Department of Chemistry, Columbia University, New York, NY, USA"},{"author_name":"Yanwan Cao","author_inst":"Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"},{"author_name":"Yanran Zhou","author_inst":"Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"},{"author_name":"Ke Zhang","author_inst":"Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, U"},{"author_name":"Ryota Tanaka","author_inst":"Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Krantz Family Center for Cancer Research, Massachuse"},{"author_name":"Kristina Todorova","author_inst":"Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"},{"author_name":"Stefano Sol","author_inst":"Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"},{"author_name":"Justin Ziegler","author_inst":"The Ae Laboratories, Cambridge, MA, USA"},{"author_name":"Denny Sakkas","author_inst":"Everleap Fertility, IVI Institute, Waltham, MA, USA"},{"author_name":"Christine Lian","author_inst":"Department of Pathology, Brigham and Women's Hospital, Mass General Brigham, Harvard Medical School, Boston, MA, USA"},{"author_name":"Shadmehr Demehri","author_inst":"Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Krantz Family Center for Cancer Research, Massachuse"},{"author_name":"Anna Mandinova","author_inst":"Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"},{"author_name":"Wei Min","author_inst":"Department of Chemistry, Columbia University, New York, NY, USA"},{"author_name":"Jonathan C. Silverstein","author_inst":"Department of Biomedical Informatics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA"},{"author_name":"Hemali Phatnani","author_inst":"Center for Genomics of Neurodegenerative Disease, New York Genome Center, New York, NY, USA; Department of Neurology, Columbia University, New York, NY, USA"},{"author_name":"Zhixun Dou","author_inst":"Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA, USA; "},{"author_name":"Jeon Woong Kang","author_inst":"Laser Biomedical Research Center, G. R. Harrison Spectroscopy Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA"},{"author_name":"Heng Yang","author_inst":"School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA"},{"author_name":"Aviv Regev","author_inst":"Broad Institute of MIT and Harvard, Cambridge, MA, USA; Current address: Genentech, South San Francisco, CA, USA"},{"author_name":"Collin M. Stultz","author_inst":"Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA; Division of Cardiology, Massachusetts Gene"},{"author_name":"- NIH SenNet Consortium","author_inst":""},{"author_name":"Peter T. C. So","author_inst":"Laser Biomedical Research Center, G. R. Harrison Spectroscopy Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA; Department of Mechanical En"},{"author_name":"Jian Shu","author_inst":"Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, U"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Learning spatial cellular state through 3D reconstruction of the cell","rel_doi":"10.64898\/2026.11.09.765489","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.09.765489","rel_abs":"Subcellular-resolution spatial transcriptomics localizes individual RNA transcripts within cells with high-precision. Existing methods for identifying spatially organized cell populations rely on cellular niches defined by neighboring cells, leaving open whether such populations can be identified from individual-cell representations alone. Moreover, representations that jointly capture transcript identity and three-dimensional (3D) spatial organization have not been systematically learned or biologically evaluated. Here we present a representation learning framework that models each cell as a gene-annotated point cloud of transcripts and trains a rotation-equivariant neural network to reconstruct 3D cell shape, yielding spatially informed transcript embeddings. We further aggregate these embeddings into a cell-state representation that summarizes transcript-level spatial patterns. Our framework outperforms existing point-cloud-based 3D reconstruction methods on cell-shape reconstruction. In MERFISH human uterine cancer, combining the learned embeddings with gene expression improved prediction of CD45RO protein intensity over both gene expression alone and niche-based embeddings. Applied to MERFISH human liver cancer and Xenium human lung datasets, our framework identified distinct spatial patterns between cell populations, including spatially organized subpopulations marked by disease-associated gene expression and patterns associated with pathological tissue structures. Together, these results show that learning transcript representations through 3D cell reconstruction provides a novel approach to capture cell-state heterogeneity and biologically relevant spatial organization in subcellular spatial transcriptomics.","rel_num_authors":4,"rel_authors":[{"author_name":"Young Je Lee","author_inst":"Carnegie Mellon University"},{"author_name":"Kanupriya Anad","author_inst":"Nvidia"},{"author_name":"Seonghui Min","author_inst":"Carnegie Mellon University"},{"author_name":"Jose Lugo-Martinez","author_inst":"Carnegie Mellon University"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"spicyR enables robust, well-powered co-localisation tests in large spatial omics cohorts","rel_doi":"10.64898\/2026.11.17.767438","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.17.767438","rel_abs":"Spatial omics technologies can now profile finely resolved cell populations in patient tissue at scale, offering a way to link their arrangement to outcomes. Yet images often differ in size, shape and cell content, and existing tests between patient groups mistake these differences for co-localisation or weight every image equally. We present spicyR v2, which avoids both problems with a fast, permutation-free test that accounts for these differences and weights each image by how precisely it measures co-localisation. In simulations and 74 analyses of 42 public datasets, it controlled false discoveries, had more power than spicyR v1 and was robust to tears, holes and differences in cell number that misled other methods. These analyses also revealed that many studies relating co-localisation to clinical outcomes are underpowered, and spicyR v2 can estimate the number of patients a new study needs. spicyR v2 analyses 100 million cells in minutes, making robust, well-powered tests of co-localisation practical for large spatial omics cohorts.","rel_num_authors":6,"rel_authors":[{"author_name":"Sadiq Dohadwalla","author_inst":"The University of Sydney"},{"author_name":"Shreya Rao","author_inst":"The University of Sydney"},{"author_name":"Farhan Ameen","author_inst":"The University of Sydney"},{"author_name":"Elijah Willie","author_inst":"The University of Sydney"},{"author_name":"John T Ormerod","author_inst":"The University of Sydney"},{"author_name":"Ellis Patrick","author_inst":"The University of Sydney"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Breedbase: An Integrated Breeding Informatics System with Statistical Analysis and Decision-Support Tools","rel_doi":"10.64898\/2026.11.11.765829","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.11.765829","rel_abs":"Breeding programs are becoming increasingly data-intensive, digital and collaborative. One-stop digital breeding ecosystems, in which data storage, field workflow tools, statistical analysis and breeding decision-support tools are seamlessly integrated, are increasingly important. Breedbase (https:\/\/breedbase.org) is one of the few open-source platforms that integrate these functionalities within a single system. It provides tools for phenotypic data quality control, descriptive, inferential and predictive statistical analyses. Integrated into the database are tools for single-trial analysis of variance (ANOVA), linear mixed modeling, stability analysis, correlation analysis, principal component analysis, k-means and hierarchical clustering, kinship and inbreeding analysis, genome-wide association study (GWAS), and genomic prediction. Input data and outputs from these analysis tools are visualized in interactive plots and are also available in text files for downloading and sharing. By persisting analysis datasets in the database and applying standardized and automated data preprocessing and analysis workflows, Breedbase is designed to improve efficiency, help maintain data integrity, and support reproducible analyses that can be readily shared among collaborators. Breedbase is open-source software, containerized using Docker, and available for self-hosting or cloud hosting and management by the Mueller lab.","rel_num_authors":21,"rel_authors":[{"author_name":"Isaak Y Tecle","author_inst":"Boyce Thompson Institute, Cornell University, Ithaca, NY 14853, USA"},{"author_name":"Titima Tantikanjan","author_inst":"Boyce Thompson Institute, Cornell University, Ithaca, NY 14853, USA"},{"author_name":"Christiano Simoes","author_inst":"Boyce Thompson Institute, Cornell University, Ithaca, NY 14853, USA"},{"author_name":"Clay Birkett","author_inst":"USDA-ARS, R.W. Holley Center for Agriculture and Health, Ithaca, NY 14853, USA"},{"author_name":"Amanda Hulse-Kemp","author_inst":"USDA-ARS Genomics and Bioinformatics Research Unit, Stoneville, MS 38776, USA"},{"author_name":"Jean-Luc Jannink","author_inst":"USDA-ARS, R.W. Holley Center for Agriculture and Health, Ithaca, NY 14853, USA"},{"author_name":"Srikanth Kumar Karaikal","author_inst":"School of Integrative Plant Sciences, Section of Plant Breeding and Genetics, Cornell University, 236 Tower Road, Ithaca, NY 14853, USA"},{"author_name":"Keo Corak","author_inst":"USDA-ARS Genomics and Bioinformatics Research Unit, Stoneville, MS 38776, USA"},{"author_name":"Amber Lockrow","author_inst":"Boyce Thompson Institute, Cornell University, Ithaca, NY 14853, USA"},{"author_name":"Heather Manching","author_inst":"Department of Crop and Soil Sciences, North Carolina State University, Raleigh, NC 27695-7620, USA"},{"author_name":"Ben Maza","author_inst":"Boyce Thompson Institute, Cornell University, Ithaca, NY 14853, USA"},{"author_name":"Naama Menda","author_inst":"Boyce Thompson Institute, Cornell University, Ithaca, NY 14853, USA"},{"author_name":"Christine Nyaga","author_inst":"School of Integrative Plant Sciences, Section of Plant Breeding and Genetics, Cornell University, 236 Tower Road, Ithaca, NY 14853, USA"},{"author_name":"Prasad Peteti","author_inst":"International Institute of Tropical Agriculture (IITA), Ibadan, Oyo State, Nigeria"},{"author_name":"Adrian Powell","author_inst":"Boyce Thompson Institute, Cornell University, Ithaca, NY 14853, USA"},{"author_name":"Ryan Preble","author_inst":"Boyce Thompson Institute, Cornell University, Ithaca, NY 14853, USA"},{"author_name":"Ismail Y Rabbi","author_inst":"International Institute of Tropical Agriculture (IITA), Ibadan, Oyo State, Nigeria"},{"author_name":"Mercedes Thieme","author_inst":"Friedrich-Alexander-Universitat Erlangen-Nurnberg, Department of Biochemistry, Erlangen, Germany"},{"author_name":"David Waring","author_inst":"Boyce Thompson Institute, Cornell University, Ithaca, NY 14853, USA"},{"author_name":"Wolfgang Zierer","author_inst":"Friedrich-Alexander-Universitat Erlangen-Nurnberg, Department of Biochemistry, Erlangen, Germany"},{"author_name":"Lukas A Mueller","author_inst":"Boyce Thompson Institute, Cornell University, Ithaca, NY 14853, USA"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Spatiotemporal profiling reveals emergence of cell type-specific molecular aging and senescence programs in the spinal cord","rel_doi":"10.64898\/2026.11.17.767384","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.17.767384","rel_abs":"The spinal cord is the primary relay center between the periphery and the brain, playing a critical role in sensory, motor and autonomic function. Despite its functional importance, the cellular and molecular changes underlying spinal cord aging and their relationship to cellular senescence - a hallmark associated with aging - remain incompletely understood. Here, we generated a cross-species, multi-omic atlas of spinal cord aging in mice and humans by integrating a combination of liquid chromatography-tandem mass spectrometry, Visium spatial transcriptomics, single-nucleus RNA-sequencing, and multiplexed immunofluorescence imaging. We identified converging age-associated increases in fibrinogen, laminin, and immune activation-associated proteins across the mouse and human spinal cord. Over the mouse lifespan, we further identified distinct spatiotemporal patterns of aging. Downregulated transcriptional programs, including synaptic signaling, mitochondrion organization, and autophagy, were most highly expressed in grey matter regions and in neurons. Upregulated transcriptional programs, including vascular and immune processes, were enriched in white matter regions and in endothelial cells and microglia, respectively. Notably, these increasing spatial modules were also enriched for senescence-associated genes. In the human spinal cord, endothelial cells and microglia were also most enriched for canonical senescence markers CDKN1A and CDKN2A, respectively. Overall, this study defines the shared, spatially-resolved, cell type-specific features associated with aging and senescence in the mouse and human spinal cord.","rel_num_authors":16,"rel_authors":[{"author_name":"Olena Kuksenko","author_inst":"Center for Genomics of Neurodegenerative Disease, New York Genome Center, 101 Avenue of the Americas, New York, NY 10013; Department of Neurology, Columbia Univ"},{"author_name":"Maya Xia","author_inst":"Center for Genomics of Neurodegenerative Disease, New York Genome Center, 101 Avenue of the Americas, New York, NY 10013; Department of Neurology, Columbia Univ"},{"author_name":"Aidan C. Daly","author_inst":"Center for Genomics of Neurodegenerative Disease, New York Genome Center, 101 Avenue of the Americas, New York, NY 10013; Department of Neurology, Columbia Univ"},{"author_name":"Christopher A. Jackson","author_inst":"Center for Genomics of Neurodegenerative Disease, New York Genome Center, 101 Avenue of the Americas, New York, NY 10013; Department of Neurology, Columbia Univ"},{"author_name":"Natalie Barretto","author_inst":"Center for Genomics of Neurodegenerative Disease, New York Genome Center, 101 Avenue of the Americas, New York, NY 10013; Department of Neurology, Columbia Univ"},{"author_name":"Imdadul Haq","author_inst":"Center for Genomics of Neurodegenerative Disease, New York Genome Center, 101 Avenue of the Americas, New York, NY 10013; Department of Neurology, Columbia Univ"},{"author_name":"Mark A. Watson","author_inst":"The Buck Institute for Research on Aging, Novato, CA 94945, USA."},{"author_name":"Christina D. King","author_inst":"The Buck Institute for Research on Aging, Novato, CA 94945, USA."},{"author_name":"Mariela Bejan","author_inst":"Center for Genomics of Neurodegenerative Disease, New York Genome Center, 101 Avenue of the Americas, New York, NY 10013; Department of Neurology, Columbia Univ"},{"author_name":"Patricia Santos","author_inst":"Center for Genomics of Neurodegenerative Disease, New York Genome Center, 101 Avenue of the Americas, New York, NY 10013; Department of Neurology, Columbia Univ"},{"author_name":"Courteney Mattison","author_inst":"Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA."},{"author_name":"Maria Hauge Pedersen","author_inst":"Center for Genomics of Neurodegenerative Disease, New York Genome Center, 101 Avenue of the Americas, New York, NY 10013; Department of Neurology, Columbia Univ"},{"author_name":"Neil A. Shneider","author_inst":"Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA."},{"author_name":"Vilas Menon","author_inst":"Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA."},{"author_name":"Birgit Schilling","author_inst":"The Buck Institute for Research on Aging, Novato, CA 94945, USA."},{"author_name":"Hemali Phatnani","author_inst":"Center for Genomics of Neurodegenerative Disease, New York Genome Center, 101 Avenue of the Americas, New York, NY 10013; Department of Neurology, Columbia Univ"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Regulatory grammar design of tissue-specific enhancers across species","rel_doi":"10.64898\/2026.11.17.767007","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.17.767007","rel_abs":"Enhancers encode tissue-specific gene expression through the combinatorial identity, number, and arrangement of transcription factor motifs, collectively known as regulatory grammar. However, existing deep-learning methods directly optimize nucleotide sequences, leaving enhancer regulatory grammar implicit. Here we introduce REgulatory Grammar Architecture via reinforcement Learning (REGAL), a framework that explicitly programs enhancer grammar under sequence-to-function oracles. REGAL generated tissue-specific enhancers across species using the same placement architecture with interchangeable oracles and motif vocabularies. Experimental validation and perturbation revealed that tissue specificity requires coordinated target-tissue activation and off-target repression, depends on both motif composition and spatial organization, and employs distinct regulatory strategies across tissues. REGAL-designed enhancers drove predicted lineage-specific expression in transgenic mouse embryos, outperformed a nucleotide-level optimizer in human cells, and matched or exceeded leading designs in zebrafish and Drosophila at notably shorter length. Together, these findings establish regulatory grammar as a programmable and experimentally testable substrate underlying enhancer design and specificity.","rel_num_authors":9,"rel_authors":[{"author_name":"Liwen Yao","author_inst":"Department of Microbial Sciences in Health, Cleveland Clinic Research, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA"},{"author_name":"Mai Ngoc Tran","author_inst":"Department of Microbial Sciences in Health, Cleveland Clinic Research, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA"},{"author_name":"Alexandra S. Ruffus","author_inst":"Department of Inflammation and Immunity, Cleveland Clinic Research, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA"},{"author_name":"Le Xiong","author_inst":"Department of Microbial Sciences in Health, Cleveland Clinic Research, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA"},{"author_name":"Aniket Jana","author_inst":"Department of Microbial Sciences in Health, Cleveland Clinic Research, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA"},{"author_name":"Sanaa Bhuleshkar","author_inst":"Department of Biology, Case Western Reserve University, Cleveland, OH 44106, USA"},{"author_name":"Ronald A. Conlon","author_inst":"Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA"},{"author_name":"Takuya F. Sakaguchi","author_inst":"Department of Inflammation and Immunity, Cleveland Clinic Research, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA"},{"author_name":"Liangqi Xie","author_inst":"Department of Microbial Sciences in Health, Cleveland Clinic Research, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Altered age-dependent somatic mutational trajectories in ALS motor cortex neurons","rel_doi":"10.64898\/2026.11.17.767052","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.17.767052","rel_abs":"Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease in which disease onset is influenced by genetic, age-associated and environmental factors. Somatic mutations accumulate throughout life and may provide a molecular link between aging and neuronal vulnerability. Here, we investigated neuronal somatic mutational patterns in ALS and control motor cortex using three previously generated 10X single-nucleus RNA and ATAC sequencing datasets. Within the genomic regions accessible to 10X sequencing, variant calls showed established features of neuronal somatic mutagenesis, including neuronal enrichment, age-associated accumulation and recovery of the clock-like SBS5 mutational signature. ALS was associated with a disease-specific age-dependent trajectory of neuronal somatic mutation burden, with higher burden in younger ALS donors and a decreasing difference with age. SBS5 represented the largest fitted mutational component and showed a corresponding age-dependent difference. A similar pattern was observed in an independent single-cell whole-genome sequencing dataset. These findings support age-dependent alterations in neuronal somatic mutational patterns in ALS.","rel_num_authors":8,"rel_authors":[{"author_name":"Liyueyue Liu","author_inst":"University Medical Center Utrecht, UMC Utrecht, Utrecht, NL"},{"author_name":"Charlotte van Dijk","author_inst":"University Medical Center Utrecht, UMC Utrecht, Utrecht, NL"},{"author_name":"Sam Bonsall","author_inst":"Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK"},{"author_name":"Rodrigo Siqueira Kazu","author_inst":"Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK"},{"author_name":"Sai Zhang","author_inst":"Department of Biomedical Informatics and Data Science, Yale School of Medicine, New Haven, CT, USA"},{"author_name":"Johnathan Cooper-Knock","author_inst":"Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK"},{"author_name":"Jan Veldink","author_inst":"University Medical Center Utrecht, UMC Utrecht, Utrecht, NL"},{"author_name":"Kevin Patrick Kenna","author_inst":"Department of translational neuroscience, UMC Utrecht, Utrecht, NL"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Heterogeneous short-term plasticity reformats latent temporal information into an explicit population clock","rel_doi":"10.64898\/2026.11.17.767281","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.17.767281","rel_abs":"Short-term plasticity (STP) supports diverse synaptic-level computations, but how its organization across a circuit shapes emergent, network-level dynamics remains poorly understood. Here, we first characterize STP across sparse inputs to Kenyon cells in the Drosophila mushroom body, revealing an unstructured and near-random organization that could not be explained by either pre- or postsynaptic cell identity. Rather than representing biological noise, an experimentally constrained network model instead shows how this heterogeneous organization reformats temporal information embedded in presynaptic spike rate trajectories into a behaviorally relevant population clock. Although an ideal observer could recover the same degree of temporal information from most alternative models, only the STP-mediated transformation made that information accessible to a biologically realistic decoder. Together, our results identify heterogeneous STP as a distributed biophysical mechanism that collectively functions as a temporal basis set to support circuit computations across variable input statistics.","rel_num_authors":2,"rel_authors":[{"author_name":"Nathan P Buerkle","author_inst":"Yale University"},{"author_name":"James M Jeanne","author_inst":"Yale University"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"False-negative assessment of NanoNewron's NewroBus blood-brain barrier delivery platform in the JAX apical-domain-humanized TfR1 mouse","rel_doi":"10.64898\/2026.11.17.767331","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.17.767331","rel_abs":"Humanized transferrin receptor 1 (TfR1) mice are frequently used to evaluate blood-brain barrier (BBB) delivery, yet available strains differ in the extent and design of receptor humanization. We compared two NanoNewron NewroBus-based anti-TNF constructs, NN-841 (D3 TfR1-binding module) and NN-843 (A2 module), in JAX #038212 (humanized apical domain), Cyagen C001584 (human extracellular-domain CDS model), Cyagen C001860 (human extracellular-domain genomic replacement model), and wild-type controls. Thirty mice received intravenous injections and were evaluated 24 h later. Brain parenchymal-fraction signals were reported in all 12 Cyagen mice, but in none of six JAX or 12 wild-type animals. Serum concentrations were measurable in every group and followed the same rank order for both constructs: Cyagen-CDS>Cyagen-HU>wild type >JAX. Mean CDS-to-JAX serum ratios were approximately 13--fold for both constructs. Compared with the Cyagen-HU strain, the CDS strain showed higher parenchymal concentrations; the ratio of mean parenchymal to mean serum concentration increased prominently for NN-841, but only modestly for NN-843. These findings indicate that model choice influences 24-h circulating concentrations and apparent BBB delivery. Circulating soluble human TfR1-mediated stabilization and endothelial TfR1-dependent transport are plausible, untested explanations for strain-dependent differences. A negative brain-delivery result in JAX #038212 alone cannot be taken as evidence that NewroBus lacks BBB delivery activity","rel_num_authors":3,"rel_authors":[{"author_name":"Ishita Chakraborty","author_inst":"Department of Pharmacology, Physiology & Neuroscience, New Jersey Medical School, Brain Health Institute, Rutgers, The State University of New Jersey, Newark, N"},{"author_name":"Tao Yin","author_inst":"Department of Pharmacology, Physiology & Neuroscience, New Jersey Medical School, Brain Health Institute, Rutgers, The State University of New Jersey, Newark, N"},{"author_name":"Luciano D'Adamio","author_inst":"Rutgers"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Shared-Encoder Residual Task-Bridging Network for Motor Execution to Motor Imagery EEG Transfer in Brain-Computer Interfaces","rel_doi":"10.64898\/2026.11.17.767217","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.17.767217","rel_abs":"Motor-imagery brain-computer interfaces (MI-BCIs) hold promising application prospects in the fields of limb motor rehabilitation and human-computer interaction. However, the reliability of MI calibration data is limited by the difficulty of verifying participants' engagement during motor imagerywhereas motor execution (ME) provides a more readily supervised source of motor-related information.To investigate the potential of ME-derived knowledge for assisting MI decoding, we propose a Shared-Encoder Residual Task-Bridge Network (SE-RTBNet) to achieve accurate intra-subject cross-task knowledge transfer from ME to MI. The proposed framework consists of two major components: a shared encoder and a residual task-bridge module. The shared encoder extracts stable general motor representations from multi-band EEG signals and explores the shared feature patterns underlying ME and MI tasks. The residual task-bridge module is equipped with a performance-aware routing mechanism. It adaptively compensates for task-specific discrepancies between the two tasks, enabling precise cross-task feature alignment and knowledge transfer. To validate the effectiveness of the proposed model, experiments are conducted on three public datasets. The proposed method achieves average classification accuracies of 69.39%, 74.61%, and 98.94%, respectively, and outperforms existing transfer-learning algorithms in overall performance. Our model provides an effective strategy for reducing dependence on extensive MI calibration data through intra-subject cross-task knowledge transfer.The source code of the proposed SE-RTBNet is publicly available at https:\/\/github.com\/Daisyzyx2002\/SE-RTBNet","rel_num_authors":6,"rel_authors":[{"author_name":"Pengpai Wang","author_inst":"NanjingTech University"},{"author_name":"Yuxuan Zhu","author_inst":"Nanjing Tech University"},{"author_name":"Tiantian Xie","author_inst":"City University of Hong Kong"},{"author_name":"Wenlong Shen","author_inst":"Nanjing Tech University"},{"author_name":"Yueying Zhou","author_inst":"Liaocheng University"},{"author_name":"Xiaorui Zhang","author_inst":"Nanjing Tech University"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Modeling CNS inflammatory demyelination using myelin-directed CAR T cells","rel_doi":"10.64898\/2026.11.16.767139","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767139","rel_abs":"Multiple sclerosis therapies remain confined to immunomodulatory agents that reduce inflammatory activity; none restores lost myelin, and disability can continue to accumulate independently of relapses. Development of remyelinating therapies has been hindered by models that incompletely reproduce the persistently inflamed lesions in which remyelination fails. Here we show that chimeric antigen receptor (CAR) T cells targeting myelin oligodendrocyte glycoprotein (MOG) build such lesions on demand. Human CD4+ CAR T cells transferred into immunodeficient mice infiltrated the brain, spinal cord, and optic nerve, producing perivascular demyelinating lesions, with reproducible optic nerve involvement. Within these discrete optic nerve lesions, treatment with the remyelinating compound clemastine reduced lesion size and improved optic nerve conduction, despite persistent inflammation. Thus, this MOG CAR T model reproduces key features of inflammatory demyelinating disease and enables testing of remyelinating therapies; more broadly, it introduces CAR T cells as programmable perturbative agents for building defined pathology in vivo.","rel_num_authors":22,"rel_authors":[{"author_name":"Christian Cordano","author_inst":"University of California, San Francisco"},{"author_name":"Sasha Gupta","author_inst":"University of California, San Fransisco"},{"author_name":"Caroline Guglielmetti","author_inst":"Washington University"},{"author_name":"Chanelle Shepherd","author_inst":"University of California, San Francisco"},{"author_name":"Madison Heady","author_inst":"Washington University"},{"author_name":"Jason Duecker","author_inst":"University of California, San Francisco"},{"author_name":"Ahmed Abdelhak","author_inst":"University of California, San Francisco"},{"author_name":"Ben Ng","author_inst":"University of California, San Francisco"},{"author_name":"Robert Zhu","author_inst":"University of California, San Francisco"},{"author_name":"Wei Yu","author_inst":"University of California, San Francisco"},{"author_name":"Sharon Sagan","author_inst":"University of California, San Francisco"},{"author_name":"David Stefanoff","author_inst":"University of California, San Francisco"},{"author_name":"Jung Sin","author_inst":"University of California, San Francisco"},{"author_name":"Alexandra Beaudry-Richard","author_inst":"University of California, San Francisco"},{"author_name":"Angelica Montevirgen","author_inst":"University of California, San Francisco"},{"author_name":"Liana Kozanno","author_inst":"University of Chicago"},{"author_name":"Stephen Hauser","author_inst":"University of California, San Francisco"},{"author_name":"Michael Wilson","author_inst":"UCSF"},{"author_name":"Scott Zamvil","author_inst":"University of California, San Francisco"},{"author_name":"Ari Green","author_inst":"University of California, San Francisco"},{"author_name":"Wendell A Lim","author_inst":"UCSF"},{"author_name":"Milos Simic","author_inst":"University of Chicago"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Modeling CNS inflammatory demyelination using myelin-directed CAR T cells","rel_doi":"10.64898\/2026.11.16.767139","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767139","rel_abs":"Multiple sclerosis therapies remain confined to immunomodulatory agents that reduce inflammatory activity; none restores lost myelin, and disability can continue to accumulate independently of relapses. Development of remyelinating therapies has been hindered by models that incompletely reproduce the persistently inflamed lesions in which remyelination fails. Here we show that chimeric antigen receptor (CAR) T cells targeting myelin oligodendrocyte glycoprotein (MOG) build such lesions on demand. Human CD4+ CAR T cells transferred into immunodeficient mice infiltrated the brain, spinal cord, and optic nerve, producing perivascular demyelinating lesions, with reproducible optic nerve involvement. Within these discrete optic nerve lesions, treatment with the remyelinating compound clemastine reduced lesion size and improved optic nerve conduction, despite persistent inflammation. Thus, this MOG CAR T model reproduces key features of inflammatory demyelinating disease and enables testing of remyelinating therapies; more broadly, it introduces CAR T cells as programmable perturbative agents for building defined pathology in vivo.","rel_num_authors":22,"rel_authors":[{"author_name":"Christian Cordano","author_inst":"University of California, San Francisco"},{"author_name":"Sasha Gupta","author_inst":"University of California, San Fransisco"},{"author_name":"Caroline Guglielmetti","author_inst":"Washington University"},{"author_name":"Chanelle Shepherd","author_inst":"University of California, San Francisco"},{"author_name":"Madison Heady","author_inst":"Washington University"},{"author_name":"Jason Duecker","author_inst":"University of California, San Francisco"},{"author_name":"Ahmed Abdelhak","author_inst":"University of California, San Francisco"},{"author_name":"Ben Ng","author_inst":"University of California, San Francisco"},{"author_name":"Robert Zhu","author_inst":"University of California, San Francisco"},{"author_name":"Wei Yu","author_inst":"University of California, San Francisco"},{"author_name":"Sharon Sagan","author_inst":"University of California, San Francisco"},{"author_name":"David Stefanoff","author_inst":"University of California, San Francisco"},{"author_name":"Jung Sin","author_inst":"University of California, San Francisco"},{"author_name":"Alexandra Beaudry-Richard","author_inst":"University of California, San Francisco"},{"author_name":"Angelica Montevirgen","author_inst":"University of California, San Francisco"},{"author_name":"Liana Kozanno","author_inst":"University of Chicago"},{"author_name":"Stephen Hauser","author_inst":"University of California, San Francisco"},{"author_name":"Michael Wilson","author_inst":"UCSF"},{"author_name":"Scott Zamvil","author_inst":"University of California, San Francisco"},{"author_name":"Ari Green","author_inst":"University of California, San Francisco"},{"author_name":"Wendell A Lim","author_inst":"UCSF"},{"author_name":"Milos Simic","author_inst":"University of Chicago"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Modeling CNS inflammatory demyelination using myelin-directed CAR T cells","rel_doi":"10.64898\/2026.11.16.767139","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767139","rel_abs":"Multiple sclerosis therapies remain confined to immunomodulatory agents that reduce inflammatory activity; none restores lost myelin, and disability can continue to accumulate independently of relapses. Development of remyelinating therapies has been hindered by models that incompletely reproduce the persistently inflamed lesions in which remyelination fails. Here we show that chimeric antigen receptor (CAR) T cells targeting myelin oligodendrocyte glycoprotein (MOG) build such lesions on demand. Human CD4+ CAR T cells transferred into immunodeficient mice infiltrated the brain, spinal cord, and optic nerve, producing perivascular demyelinating lesions, with reproducible optic nerve involvement. Within these discrete optic nerve lesions, treatment with the remyelinating compound clemastine reduced lesion size and improved optic nerve conduction, despite persistent inflammation. Thus, this MOG CAR T model reproduces key features of inflammatory demyelinating disease and enables testing of remyelinating therapies; more broadly, it introduces CAR T cells as programmable perturbative agents for building defined pathology in vivo.","rel_num_authors":22,"rel_authors":[{"author_name":"Christian Cordano","author_inst":"University of California, San Francisco"},{"author_name":"Sasha Gupta","author_inst":"University of California, San Fransisco"},{"author_name":"Caroline Guglielmetti","author_inst":"Washington University"},{"author_name":"Chanelle Shepherd","author_inst":"University of California, San Francisco"},{"author_name":"Madison Heady","author_inst":"Washington University"},{"author_name":"Jason Duecker","author_inst":"University of California, San Francisco"},{"author_name":"Ahmed Abdelhak","author_inst":"University of California, San Francisco"},{"author_name":"Ben Ng","author_inst":"University of California, San Francisco"},{"author_name":"Robert Zhu","author_inst":"University of California, San Francisco"},{"author_name":"Wei Yu","author_inst":"University of California, San Francisco"},{"author_name":"Sharon Sagan","author_inst":"University of California, San Francisco"},{"author_name":"David Stefanoff","author_inst":"University of California, San Francisco"},{"author_name":"Jung Sin","author_inst":"University of California, San Francisco"},{"author_name":"Alexandra Beaudry-Richard","author_inst":"University of California, San Francisco"},{"author_name":"Angelica Montevirgen","author_inst":"University of California, San Francisco"},{"author_name":"Liana Kozanno","author_inst":"University of Chicago"},{"author_name":"Stephen Hauser","author_inst":"University of California, San Francisco"},{"author_name":"Michael Wilson","author_inst":"UCSF"},{"author_name":"Scott Zamvil","author_inst":"University of California, San Francisco"},{"author_name":"Ari Green","author_inst":"University of California, San Francisco"},{"author_name":"Wendell A Lim","author_inst":"UCSF"},{"author_name":"Milos Simic","author_inst":"University of Chicago"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Modeling CNS inflammatory demyelination using myelin-directed CAR T cells","rel_doi":"10.64898\/2026.11.16.767139","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767139","rel_abs":"Multiple sclerosis therapies remain confined to immunomodulatory agents that reduce inflammatory activity; none restores lost myelin, and disability can continue to accumulate independently of relapses. Development of remyelinating therapies has been hindered by models that incompletely reproduce the persistently inflamed lesions in which remyelination fails. Here we show that chimeric antigen receptor (CAR) T cells targeting myelin oligodendrocyte glycoprotein (MOG) build such lesions on demand. Human CD4+ CAR T cells transferred into immunodeficient mice infiltrated the brain, spinal cord, and optic nerve, producing perivascular demyelinating lesions, with reproducible optic nerve involvement. Within these discrete optic nerve lesions, treatment with the remyelinating compound clemastine reduced lesion size and improved optic nerve conduction, despite persistent inflammation. Thus, this MOG CAR T model reproduces key features of inflammatory demyelinating disease and enables testing of remyelinating therapies; more broadly, it introduces CAR T cells as programmable perturbative agents for building defined pathology in vivo.","rel_num_authors":22,"rel_authors":[{"author_name":"Christian Cordano","author_inst":"University of California, San Francisco"},{"author_name":"Sasha Gupta","author_inst":"University of California, San Fransisco"},{"author_name":"Caroline Guglielmetti","author_inst":"Washington University"},{"author_name":"Chanelle Shepherd","author_inst":"University of California, San Francisco"},{"author_name":"Madison Heady","author_inst":"Washington University"},{"author_name":"Jason Duecker","author_inst":"University of California, San Francisco"},{"author_name":"Ahmed Abdelhak","author_inst":"University of California, San Francisco"},{"author_name":"Ben Ng","author_inst":"University of California, San Francisco"},{"author_name":"Robert Zhu","author_inst":"University of California, San Francisco"},{"author_name":"Wei Yu","author_inst":"University of California, San Francisco"},{"author_name":"Sharon Sagan","author_inst":"University of California, San Francisco"},{"author_name":"David Stefanoff","author_inst":"University of California, San Francisco"},{"author_name":"Jung Sin","author_inst":"University of California, San Francisco"},{"author_name":"Alexandra Beaudry-Richard","author_inst":"University of California, San Francisco"},{"author_name":"Angelica Montevirgen","author_inst":"University of California, San Francisco"},{"author_name":"Liana Kozanno","author_inst":"University of Chicago"},{"author_name":"Stephen Hauser","author_inst":"University of California, San Francisco"},{"author_name":"Michael Wilson","author_inst":"UCSF"},{"author_name":"Scott Zamvil","author_inst":"University of California, San Francisco"},{"author_name":"Ari Green","author_inst":"University of California, San Francisco"},{"author_name":"Wendell A Lim","author_inst":"UCSF"},{"author_name":"Milos Simic","author_inst":"University of Chicago"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Biological Embedding of Social Experience Over Genomic and Neural Time Scales","rel_doi":"10.64898\/2026.11.17.767304","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.17.767304","rel_abs":"The \"Neurons for Today, Genes for Tomorrow model\" (NTGT) predicts how the brain's neural and molecular control systems interact to regulate biological embedding, whereby social experience alters the brain to shape future behavior. We report here on the first test of this model, using honey bee queen retinue pheromone (QRP) and behavioral, single-nucleus transcriptomic, and electrophysiological analyses. Consistent with theory, weaker exposure triggered a simple attraction response and transcriptomic changes primarily in the antennal lobes (AL), whereas stronger exposure induced transcriptomic changes in the mushroom bodies, a brain region affecting more complex behavior. In addition, AL electrophysiological responses to QRP were enhanced after stronger exposure, also consistent with theory. We also showed how individual differences in biological embedding can be explained by NTGT, with individual differences in brain gene regulatory network topology, especially in specific sensory cell clusters, supporting a new mechanistic framework for behavioral regulation.","rel_num_authors":9,"rel_authors":[{"author_name":"Tianfei Peng","author_inst":"University College London"},{"author_name":"Amy C Cash Ahmed","author_inst":"University of Illinois at Urbana-Champaign"},{"author_name":"Melissa E Flores","author_inst":"University of Illinois at Urbana-Champaign"},{"author_name":"Naroa Legarra-Marcos","author_inst":"University of Navarra"},{"author_name":"Mikel Hernaez","author_inst":"University of Navarra"},{"author_name":"Autumn K McLane-Svoboda","author_inst":"Michigan State University"},{"author_name":"Summer B McLane-Svoboda","author_inst":"Michigan State University"},{"author_name":"Debajit Saha","author_inst":"Michigan State University"},{"author_name":"Gene E Robinson","author_inst":"University of Illinois at Urbana-Champaign"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Genomes to Fields 2026: Genomic resources for investigating genotype-phenotype relationships in Zea mays","rel_doi":"10.64898\/2026.11.15.766802","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766802","rel_abs":"Maize (Zea mays L.) is a major global crop characterized by high genetic and phenotypic diversity across accessions. To better understand this diversity, the Genomes-to-Fields initiative has produced paired genotypic and phenotypic datasets annually since 2014. Here, we present 15 genome assemblies representing 13 maize lines, including founders and testers from the 2022-2023, 2024-2025, and 2026-2027 Genomes-to-Fields evaluation cycles and additional breeding germplasm, together with gene and repeat annotations. Assemblies ranged from 2.19 to 2.38 Gb, with BUSCO completeness of 97.9-99.0%. Excluding the more fragmented LH287 assembly (contig N50 = 5.3 Mb; 90.8% chromosome placement), contig N50 values ranged from 31.1 to 195.8 Mb, with 95.9-99.4% of sequence placed on chromosomes. Gene annotation identified approximately 40,000 gene models per genotype, of which 93.6-93.9% were classified as protein-coding, with 95.9-97.3% complete BUSCOs. Comparison with B73 identified 27,606-30,517 one-to-one syntenic orthologs per genotype, representing 69.4-76.8% of B73 genes. Transposable elements occupied 83.6-88.6% of the genomes, with LTR retrotransposons representing the predominant class. Comparative genome alignments revealed three large inversions, including a 12.65-Mb inversion on chromosome 3 present in six of the 13 lines. Together, these resources expand the genomic representation of maize breeding germplasm and provide a foundation for investigating genetic variation underlying agronomic traits.","rel_num_authors":13,"rel_authors":[{"author_name":"Nicholas A. Johnson","author_inst":"Institute for Genomic Diversity, Cornell University, 130 Biotechnology Building, Ithaca, NY 14853, USA"},{"author_name":"Ann Murithi","author_inst":"Department of Ecology, Evolution, and Organismal Biology, Iowa State University, Ames, IA 50011, USA"},{"author_name":"Corrinne E. Grover","author_inst":"Department of Ecology, Evolution, and Organismal Biology, Iowa State University, Ames, IA 50011, USA"},{"author_name":"Shawn Kaeppler","author_inst":"Wisconsin Crop Innovation Center, University of Wisconsin-Madison, 8520 University Green, Middleton, WI 53562, USA; Department of Plant and Agroecosystem Scienc"},{"author_name":"Dayane Cristina Lima","author_inst":"Wisconsin Crop Innovation Center, University of Wisconsin-Madison, 8520 University Green, Middleton, WI 53562, USA"},{"author_name":"Hirva Bhayani","author_inst":"Department of Ecology, Evolution, and Organismal Biology, Iowa State University, Ames, IA 50011, USA"},{"author_name":"Dinuri Lokuwalpola","author_inst":"Department of Ecology, Evolution, and Organismal Biology, Iowa State University, Ames, IA 50011, USA"},{"author_name":"Heidi Chen","author_inst":"The Plant Molecular and Cellular Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037, USA"},{"author_name":"Nicholas Allsing","author_inst":"The Plant Molecular and Cellular Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037, USA"},{"author_name":"Todd P. Michael","author_inst":"The Plant Molecular and Cellular Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037, USA"},{"author_name":"Edward S. Buckler","author_inst":"Institute for Genomic Diversity, Cornell University, 130 Biotechnology Building, Ithaca, NY 14853, USA; USDA-ARS Plant, Soil and Nutrition Research Unit, RW Hol"},{"author_name":"Matthew B. Hufford","author_inst":"Department of Ecology, Evolution, and Organismal Biology, Iowa State University, Ames, IA 50011, USA"},{"author_name":"Maria C. Romay","author_inst":"Institute for Genomic Diversity, Cornell University, 130 Biotechnology Building, Ithaca, NY 14853, USA"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"QuadSeq: A duplicated-duplex DNA-synthesis technology for high-fidelity nanopore sequencing of linear DNA amplicons","rel_doi":"10.64898\/2026.11.17.767292","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.17.767292","rel_abs":"Long-read nanopore sequencing is a highly versatile technology that is currently constrained by high error-rates, which can impair accurate genotyping of complex DNA samples. Common mitigation strategies based on creating consensus sequences from tandem duplications synthesized by rolling-circle or multiple-displacement amplification are prone to create both chimeric DNA molecules and require an initial DNA-circularization. Here we present QuadSeq, a three-step DNA-synthesis technology that can convert linear DNA amplicons into duplicated DNA duplexes that encode two forward and two reverse strand copies of a sequence-of-interest. Intramolecular consensus sequences generated from QuadSeq duplicated DNA duplexes yielded a median single-amplicon accuracy of up to 0.9992 (Q31), without requiring a cumbersome DNA-circularization of the amplicon-of-interest. We can also show that the primary bottleneck for achieving accurate nanopore amplicon sequencing is not the mutation rate of the initial PCR-amplification, but the fidelity of the nanopore sequencing. QuadSeq consensus sequences generated from amplicons synthesized by a low-fidelity DNA polymerase (Taq) had a 6.6-fold lower median error-rate compared to amplicon simplex reads synthesized by a high-fidelity DNA polymerase (Phusion U). Going forward, we predict that the QuadSeq DNA-synthesis technology will enable the use of almost any low-fidelity DNA polymerase for high-fidelity nanopore amplicon sequencing.","rel_num_authors":6,"rel_authors":[{"author_name":"Marcus Waneskog","author_inst":"The Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University"},{"author_name":"Knud Nor Nielsen","author_inst":"The Novo Nordisk Foundation Biotechnology Research Institute for the Green Transition, Technical University of Denmark"},{"author_name":"Achille Julienne","author_inst":"The Novo Nordisk Foundation Biotechnology Research Institute for the Green Transition, Technical University of Denmark"},{"author_name":"Carlos G. Acevedo-Rocha","author_inst":"The Novo Nordisk Foundation Biotechnology Research Institute for the Green Transition, Technical University of Denmark"},{"author_name":"Emre Ozdemir","author_inst":"The Novo Nordisk Foundation Biotechnology Research Institute for the Green Transition, Technical University of Denmark"},{"author_name":"Emil Damgaard Jensen","author_inst":"The Novo Nordisk Foundation Biotechnology Research Institute for the Green Transition, Technical University of Denmark"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"A plasma proteomic atlas of rare genetic neurodevelopmental disorders reveals convergent molecular signatures, neurodegenerative overlap, and a cross-disorder severity index","rel_doi":"10.64898\/2026.11.16.767059","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767059","rel_abs":"Rare genetic neurodevelopmental disorders are individually too small for well-powered biomarker studies, and each is typically studied alone. We present a harmonized plasma proteomic resource that treats them together: over 10,000 proteins measured across 27 rare genetic neurodevelopmental disorders and unaffected family members, 26 of them with enough participants for differential abundance analysis, paired with standardized adaptive behaviour phenotypes and released with the full analysis pipeline. Aggregating across disorders makes shared biology visible that single-disorder studies cannot resolve. Genetically distinct disorders converge onto two proteomic clusters separated along a single dominant axis, distinguishing cytoskeletal and vesicle-trafficking proteins from metabolic and hepatic ones; the grouping is independent of gene function and of clinical classification, indicating convergence on shared downstream biology rather than gene-specific pathology. Epilepsy leaves a reproducible plasma signature detectable across disorders and largely independent of genotype, identifying candidate markers of seizure burden that are shared rather than syndrome specific. These proteomes also overlap those of adult neurodegenerative disease: most disorders are enriched against at least one signature of Alzheimer disease, Parkinson disease, frontotemporal dementia or amyotrophic lateral sclerosis, more often inversely than concordantly, placing early-life monogenic disorders on a shared axis with late-onset degeneration. A multivariate severity index built from plasma proteins tracks adaptive communication ability in disorders held out entirely from model training and distinguishes severity among individuals who share a diagnosis rather than only separating disorders from one another. Twenty-four of the prioritised cross-disorder proteins have a recorded drug interaction, several with agents already approved for other indications. Recruitment was concentrated at single sites for a subset of disorders, and results for those disorders are reported separately and descriptively throughout. Collectively, these findings support a shift from single-gene to pathway-based, cross-disorder trial strategies that leverage convergent biomarker panels and mechanistically informed, potentially repurposed interventions.","rel_num_authors":37,"rel_authors":[{"author_name":"Ricardo N Ramirez","author_inst":"MED13L Foundation"},{"author_name":"Megan Aumann","author_inst":"Vanderbilt University Medical Center"},{"author_name":"Lindsay Wieczorek","author_inst":"COMBINEDBrain"},{"author_name":"Sasha Elmizadeh","author_inst":"COMBINEDBrain"},{"author_name":"Albert Misko","author_inst":"Novartis"},{"author_name":"Yael Weiss","author_inst":"Mahzi Therapeutics"},{"author_name":"Stephanie Szobota","author_inst":"Mahzi Therapeutics"},{"author_name":"Berit Powers","author_inst":"Ionis Pharmaceuticals"},{"author_name":"Shruti Sasaki","author_inst":"Ionis Pharmaceuticals"},{"author_name":"Marco Rizzo","author_inst":"Biogen"},{"author_name":"Smitha Jagadish","author_inst":"Bial"},{"author_name":"Mariana Laranjo","author_inst":"Bial"},{"author_name":"Nicole Davis","author_inst":"Ultragenyx"},{"author_name":"Jeremy Manry","author_inst":"Servier"},{"author_name":"Marie Elodie Cattin Messaoudi","author_inst":"Servier"},{"author_name":"Joerg Hipp","author_inst":"Roche"},{"author_name":"Rachael Hawtin","author_inst":"Acadia Pharmaceuticals"},{"author_name":"Brett Younginger","author_inst":"Acadia Pharmaceuticals"},{"author_name":"Nichol Miller","author_inst":"Actio Biosciences"},{"author_name":"Kevin Wright","author_inst":"Actio Biosciences"},{"author_name":"Grace Viggiano","author_inst":"COMBINEDBrain"},{"author_name":"Sarah Poliquin","author_inst":"COMBINEDBrain"},{"author_name":"Taylor Morris","author_inst":"COMBINEDBrain"},{"author_name":"Zollie Yavarow","author_inst":"COMBINEDBrain"},{"author_name":"Nicholas Aguilar","author_inst":"COMBINEDBrain"},{"author_name":"Ananya Terala","author_inst":"COMBINEDBrain"},{"author_name":"William Keener","author_inst":"COMBINEDBrain"},{"author_name":"Kristin Hatcher","author_inst":"COMBINEDBrain"},{"author_name":"Christopher Ricupero","author_inst":"Columbia University"},{"author_name":"Jennifer Bain","author_inst":"Columbia University"},{"author_name":"Elizabeth Berry Kravis","author_inst":"Rush University"},{"author_name":"Jacqueline Harris","author_inst":"Kennedy Krieger Institute"},{"author_name":"Natasha Ludwig","author_inst":"Kennedy Krieger Institute"},{"author_name":"Angela Duong","author_inst":"Neucyte"},{"author_name":"Wayne Poon","author_inst":"Neucyte"},{"author_name":"Terry Jo V Bichell","author_inst":"COMBINEDBrain"},{"author_name":"Anna C Pfalzer","author_inst":"Vanderbilt University Medical Center"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"A plasma proteomic atlas of rare genetic neurodevelopmental disorders reveals convergent molecular signatures, neurodegenerative overlap, and a cross-disorder severity index","rel_doi":"10.64898\/2026.11.16.767059","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767059","rel_abs":"Rare genetic neurodevelopmental disorders are individually too small for well-powered biomarker studies, and each is typically studied alone. We present a harmonized plasma proteomic resource that treats them together: over 10,000 proteins measured across 27 rare genetic neurodevelopmental disorders and unaffected family members, 26 of them with enough participants for differential abundance analysis, paired with standardized adaptive behaviour phenotypes and released with the full analysis pipeline. Aggregating across disorders makes shared biology visible that single-disorder studies cannot resolve. Genetically distinct disorders converge onto two proteomic clusters separated along a single dominant axis, distinguishing cytoskeletal and vesicle-trafficking proteins from metabolic and hepatic ones; the grouping is independent of gene function and of clinical classification, indicating convergence on shared downstream biology rather than gene-specific pathology. Epilepsy leaves a reproducible plasma signature detectable across disorders and largely independent of genotype, identifying candidate markers of seizure burden that are shared rather than syndrome specific. These proteomes also overlap those of adult neurodegenerative disease: most disorders are enriched against at least one signature of Alzheimer disease, Parkinson disease, frontotemporal dementia or amyotrophic lateral sclerosis, more often inversely than concordantly, placing early-life monogenic disorders on a shared axis with late-onset degeneration. A multivariate severity index built from plasma proteins tracks adaptive communication ability in disorders held out entirely from model training and distinguishes severity among individuals who share a diagnosis rather than only separating disorders from one another. Twenty-four of the prioritised cross-disorder proteins have a recorded drug interaction, several with agents already approved for other indications. Recruitment was concentrated at single sites for a subset of disorders, and results for those disorders are reported separately and descriptively throughout. Collectively, these findings support a shift from single-gene to pathway-based, cross-disorder trial strategies that leverage convergent biomarker panels and mechanistically informed, potentially repurposed interventions.","rel_num_authors":37,"rel_authors":[{"author_name":"Ricardo N Ramirez","author_inst":"MED13L Foundation"},{"author_name":"Megan Aumann","author_inst":"Vanderbilt University Medical Center"},{"author_name":"Lindsay Wieczorek","author_inst":"COMBINEDBrain"},{"author_name":"Sasha Elmizadeh","author_inst":"COMBINEDBrain"},{"author_name":"Albert Misko","author_inst":"Novartis"},{"author_name":"Yael Weiss","author_inst":"Mahzi Therapeutics"},{"author_name":"Stephanie Szobota","author_inst":"Mahzi Therapeutics"},{"author_name":"Berit Powers","author_inst":"Ionis Pharmaceuticals"},{"author_name":"Shruti Sasaki","author_inst":"Ionis Pharmaceuticals"},{"author_name":"Marco Rizzo","author_inst":"Biogen"},{"author_name":"Smitha Jagadish","author_inst":"Bial"},{"author_name":"Mariana Laranjo","author_inst":"Bial"},{"author_name":"Nicole Davis","author_inst":"Ultragenyx"},{"author_name":"Jeremy Manry","author_inst":"Servier"},{"author_name":"Marie Elodie Cattin Messaoudi","author_inst":"Servier"},{"author_name":"Joerg Hipp","author_inst":"Roche"},{"author_name":"Rachael Hawtin","author_inst":"Acadia Pharmaceuticals"},{"author_name":"Brett Younginger","author_inst":"Acadia Pharmaceuticals"},{"author_name":"Nichol Miller","author_inst":"Actio Biosciences"},{"author_name":"Kevin Wright","author_inst":"Actio Biosciences"},{"author_name":"Grace Viggiano","author_inst":"COMBINEDBrain"},{"author_name":"Sarah Poliquin","author_inst":"COMBINEDBrain"},{"author_name":"Taylor Morris","author_inst":"COMBINEDBrain"},{"author_name":"Zollie Yavarow","author_inst":"COMBINEDBrain"},{"author_name":"Nicholas Aguilar","author_inst":"COMBINEDBrain"},{"author_name":"Ananya Terala","author_inst":"COMBINEDBrain"},{"author_name":"William Keener","author_inst":"COMBINEDBrain"},{"author_name":"Kristin Hatcher","author_inst":"COMBINEDBrain"},{"author_name":"Christopher Ricupero","author_inst":"Columbia University"},{"author_name":"Jennifer Bain","author_inst":"Columbia University"},{"author_name":"Elizabeth Berry Kravis","author_inst":"Rush University"},{"author_name":"Jacqueline Harris","author_inst":"Kennedy Krieger Institute"},{"author_name":"Natasha Ludwig","author_inst":"Kennedy Krieger Institute"},{"author_name":"Angela Duong","author_inst":"Neucyte"},{"author_name":"Wayne Poon","author_inst":"Neucyte"},{"author_name":"Terry Jo V Bichell","author_inst":"COMBINEDBrain"},{"author_name":"Anna C Pfalzer","author_inst":"Vanderbilt University Medical Center"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Bivalent, Copper-Mediated Amyloid-\u03b2 Binding Disruptsthe Prion Protein's Neuroprotective Conformation","rel_doi":"10.64898\/2026.11.16.767124","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767124","rel_abs":"Emerging evidence shows that the cellular prion protein (PrPC) is a major receptor for Amyloid-{beta} (A{beta}) and that this aberrant interaction may influence the progression of Alzheimer's disease (AD). However, the molecular basis of this interaction remains poorly understood. Both proteins strongly bind Cu2+, and we previously discovered that PrPC, A{beta}30, and Cu2+ form a ternary complex at equimolar ratios. Here, using electron paramagnetic resonance (EPR) and nuclear magnetic resonance (NMR) spectroscopy with isotopically labeled proteins, we characterize the stoichiometry, stability, and molecular interactions of this ternary complex. We show that the complex forms preferentially at substoichiometric to equimolar Cu2+ concentrations yet remains stable at high Cu2+ ratios. The formation of the ternary complex is bivalent, requiring the previously identified A{beta}-binding domain on PrPC (residues 95-110) along with mutual Cu2+ coordination to the N-terminal octapeptide repeat domain in PrPC. Line broadening observed in A{beta}30 NMR experiments identifies its negatively charged N-terminal residues and central hydrophobic core (residues 17-21) as the primary PrPC binding sites. Through histidine mutation studies, we determine A{beta}30 coordinates Cu2+ primarily through His14. Critically, the ternary complex formation displaces Cu2+ from a specific His residue on the C-terminal domain of PrPC, disrupting the neuroprotective cis interdomain interaction that otherwise regulates the toxic effector N-terminal domain. Using segmentally isotopically 15N-labeled PrPC, we show that while the cis interaction is not fully eliminated by interaction with A{beta}, it becomes a disfavored conformational state. Together, these findings demonstrate how Cu2+ reinforces the PrPC-A{beta} interaction, in turn destabilizing PrPC's neuroprotective fold, offering a molecular mechanism for A{beta} accumulation at - and potential trafficking across - the plasma membrane.","rel_num_authors":7,"rel_authors":[{"author_name":"Amanda Smart","author_inst":"UC Santa Cruz"},{"author_name":"Francesca Pavlovici","author_inst":"UC San Diego"},{"author_name":"Kevin Singewald","author_inst":"UC Santa Cruz"},{"author_name":"Cody Marshak","author_inst":"UC Santa Cruz"},{"author_name":"Claire Carollo","author_inst":"UC Santa Cruz"},{"author_name":"Samuel Kaplan","author_inst":"UC Santa Cruz"},{"author_name":"Glenn L Millhauser","author_inst":"UC Santa Cruz"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Isolate relatedness is more strongly associated with host and geography compared with phenotypic variation in a broad host range pathogen","rel_doi":"10.64898\/2026.11.16.767110","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767110","rel_abs":"Determining the drivers of diversity in plant pathogen populations is a critical for developing effective management strategies. Sclerotinia sclerotiorum, a cosmopolitan fungus infecting over 400 plant species, causes considerable yield and economic losses worldwide. However, longstanding questions remain about the association between genetic and phenotypic variation in this pathogen, leaving the drivers of its diversification unresolved. Here, we characterized the diversity of S. sclerotiorum isolates from the United States in a global context and tested the hypothesis that phylogenetic relatedness structures phenotypic variation among isolates. Genome-wide variant analysis resolved US isolates into several distinct lineages, with short within-lineage branch lengths consistent with recent common ancestry or clonal propagation. Population structure analysis confirmed two major global clusters, one composed predominantly of Australian isolates and the other largely of isolates from the rest of the world, including the US. Notably, several US isolates grouped within the Australian cluster, suggesting historical intercontinental movement of this pathogen. Contrary to our expectations, isolate relatedness was more strongly associated with data such as host, geographic origin, and year of collection compared with morphological variation, suggesting that phenotypic variation segregates independently of phylogenetic structure. Instead, the distribution of phenotypic variation primarily reflected two trade-offs: rapid radial growth with shorter sclerotial development versus slower growth with prolonged sclerotial development, and the production of many small sclerotia versus fewer larger ones. Together, our results shed light on the complex relationships between phenotypic, ecological, and phylogenetic variation and bring us one step closer to predicting how diversity is structured in natural populations of a global fungal pathogen.","rel_num_authors":8,"rel_authors":[{"author_name":"Amit Sharma","author_inst":"Department of Plant Pathology, University of Wisconsin-Madison, Madison, WI 53706, U.S.A"},{"author_name":"Carol L. Groves","author_inst":"Department of Plant Pathology, University of Wisconsin-Madison, Madison, WI 53706, U.S.A"},{"author_name":"Samuel O'Donnell","author_inst":"Department of Plant Pathology, University of Wisconsin-Madison, Madison, WI 53706, U.S.A"},{"author_name":"Richard W. Webster","author_inst":"Department of Plant Pathology, Microbiology, and Biotechnology, North Dakota State University, Fargo, ND 58102, U.S.A"},{"author_name":"Horacio D. Lopez-Nicora","author_inst":"Department of Plant Pathology, Ohio State University, Columbus, OH 43210, U.S.A."},{"author_name":"Jaime F. Willbur","author_inst":"Department of Plant, Soil, and Microbial Sciences, Michigan State University, East Lansing, MI 48824, U.S.A."},{"author_name":"Damon L. Smith","author_inst":"Department of Plant Pathology, University of Wisconsin-Madison, Madison, WI 53706, U.S.A"},{"author_name":"Emile Gluck-Thaler","author_inst":"Department of Plant Pathology, University of Wisconsin-Madison, Madison, WI 53706, U.S.A and Wisconsin Institute for Discovery, Madison, WI 53706, U.S.A."}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"VINCIT: A virus-incorporated biomaterial niche enables spatially controlled in vivo CAR T cell engineering","rel_doi":"10.64898\/2026.11.16.767176","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767176","rel_abs":"In vivo generation of chimeric antigen receptor (CAR) T cells could bypass the complex manufacturing required for conventional cell therapies, but systemic gene delivery remains limited by off target exposure and inefficient access to target immune cells. Here, we develop VINCIT (Virus Incorporated Niche for Cellular ImmunoTherapy), an injectable nanofiber hydrogel composite that establishes a localized immune-engineering niche for CAR T cell generation in vivo. VINCIT spatially retains viral vectors while recruiting endogenous immune cells, enabling local transduction of T cells, after which the engineered T cells enter the circulation. VINCIT spatially confines transgene expression compared with intravenous viral delivery and markedly enhances T cell transduction compared with subcutaneously injected free virus. VINCIT is compatible with both adeno-associated and lentiviral vectors, and CAR T cells generated in vivo exhibit antigen-specific effector responses and mediate CD19+ B cell depletion. In a humanized mouse model of lymphoma, a single VINCIT administration produces sustained tumor control and extends median survival from 32 to 110 days. Mechanistically, efficient CAR T cell generation requires coordinated interactions among multiple immune populations, with neutrophil depletion markedly reducing cellular recruitment and subsequent T cell programming. These findings establish a localized biomaterial niche for spatially controlled in vivo immune cell engineering.","rel_num_authors":22,"rel_authors":[{"author_name":"Kailei Ding Goodier","author_inst":"Johns Hopkins University"},{"author_name":"Yining Zhu","author_inst":"Johns Hopkins University"},{"author_name":"Christine Wei","author_inst":"Johns Hopkins University"},{"author_name":"Zhuoqing Jiang","author_inst":"Johns Hopkins University"},{"author_name":"Yili Jiang","author_inst":"Johns Hopkins University"},{"author_name":"Xiaoya Lu","author_inst":"Johns Hopkins University"},{"author_name":"Sabrina Chen","author_inst":"Johns Hopkins University"},{"author_name":"Autumn Greco","author_inst":"Johns Hopkins University"},{"author_name":"Di Yu","author_inst":"Johns Hopkins University"},{"author_name":"Xiang Liu","author_inst":"Johns Hopkins University"},{"author_name":"Joseph Choy","author_inst":"Johns Hopkins University"},{"author_name":"Yunhe Su","author_inst":"Johns Hopkins University"},{"author_name":"Jingyao Ma","author_inst":"Johns Hopkins University"},{"author_name":"Jinghan Lin","author_inst":"Johns Hopkins University"},{"author_name":"Jiayuan Kong","author_inst":"Johns Hopkins University"},{"author_name":"Evan Wang","author_inst":"Johns Hopkins University"},{"author_name":"Dylan Luong","author_inst":"Johns Hopkins University"},{"author_name":"D Scott Wilson","author_inst":"Johns Hopkins University"},{"author_name":"Joshua C Doloff","author_inst":"Johns Hopkins University"},{"author_name":"Jonathan Schneck","author_inst":"Johns Hopkins University"},{"author_name":"Maximilian F Konig","author_inst":"The Johns Hopkins University School of Medicine"},{"author_name":"Hai-Quan Mao","author_inst":"Johns Hopkins University"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"CCDC81 is a conserved microtubule-binding protein that maintains centriole integrity","rel_doi":"10.64898\/2026.11.16.766940","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.766940","rel_abs":"Centrioles are microtubule-based organelles that exhibit a highly conserved architecture that is essential for their function. However, the molecular mechanisms maintaining their structural integrity remain incompletely understood. Here, we characterize CCDC81 as a conserved microtubule-binding protein that contributes to centriole organization. Using expansion microscopy, we localize CCDC81 to the A-C linker of Chlamydomonas basal bodies, where it associates with POC11, the homolog of human A-C linker protein CCDC77. We demonstrate that CCDC81 directly binds microtubules through its N-terminal HU domains, promotes microtubule bundling, and stabilizes microtubules by reducing depolymerization and increasing rescue frequency. Cryo-electron microscopy further reveals its association with the outer microtubule lattice. We identify distinct domains mediating CCDC81 interaction with POC11 and propose a molecular organization of this complex within the A-C linker. Importantly, CCDC81 also localizes to human centrioles, where its depletion disrupts centriole architecture and A-C linker organization, with defects exacerbated by co-depletion of CCDC77. Together, our findings establish CCDC81 as a conserved regulator of microtubule organization and centriole structural integrity.","rel_num_authors":5,"rel_authors":[{"author_name":"Virginie Hamel","author_inst":"University of Geneva"},{"author_name":"Umut Batman","author_inst":"University of Geneva"},{"author_name":"Daria Khuntsariya","author_inst":"University of Geneva"},{"author_name":"SUSANNE BORGERS","author_inst":"University of Geneva"},{"author_name":"Paul Guichard","author_inst":"Universit\u00e9 de Gen\u00e8ve"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Continuous generation of short-lived resident effector CD8 T cells sustains alopecia areata","rel_doi":"10.64898\/2026.11.16.766888","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.766888","rel_abs":"CD8 T cells mediating chronic tissue inflammation have been thought to depend on stem-like progenitors that self-renew and replenish cytotoxic effector cells or exhausted progeny. Here, we show that stem-independent, short-lived resident effector CD8 T (TRE) cells sustain alopecia areata (AA), a common autoimmune disease that destroys hair follicles. AA-TRE cells exhibit TCR-dependent cytotoxicity, undergo rapid apoptosis in the skin, and lack memory or stem-like properties. Following adoptive transfer, donor TRE cells serve only as an initial trigger, whereas the host-derived CD103CD101 pathogenic pool is rebuilt continuously in skin-draining lymph nodes (sdLNs). Single-cell multiome and CUT&Tag profiling revealed that AA-TRE cells epigenetically silence Tox and upregulate RUNX2 to initiate the TRE differentiation program in sdLNs, while RUNX3 and AP-1s sustain it in the skin. Notably, CD8 T cells from patients with AA share this conserved regulatory network. Altogether, these findings define a distinct CD8 T cell differentiation state, offering new therapeutic implications for autoimmune diseases.","rel_num_authors":17,"rel_authors":[{"author_name":"Yoonji Lee","author_inst":"Seoul National University"},{"author_name":"Junghwan Choi","author_inst":"Seoul National University"},{"author_name":"Myeong-seok Lee","author_inst":"Seoul National University"},{"author_name":"Soonjoung Kim","author_inst":"Yonsei University College of Medicine"},{"author_name":"Jin Joo Kang","author_inst":"Yonsei University College of Medicine"},{"author_name":"Suhjeon Shin","author_inst":"Seoul National University"},{"author_name":"Tae Hyun Kim","author_inst":"Seoul National University"},{"author_name":"Sang Hyeok Ji","author_inst":"Seoul National University"},{"author_name":"Suyeong Park","author_inst":"Seoul National University"},{"author_name":"Sihyung Joo","author_inst":"Seoul National University"},{"author_name":"Kunhee Lee","author_inst":"Sungkyunkwan University School of Medicine"},{"author_name":"Cheol Lee","author_inst":"Seoul National University College of Medicine"},{"author_name":"Hanjae Lee","author_inst":"Seoul National University College of Medicine"},{"author_name":"Se Jin Im","author_inst":"Sungkyunkwan University School of Medicine"},{"author_name":"Ohsang Kwon","author_inst":"Seoul National University College of Medicine"},{"author_name":"June-Yong Lee","author_inst":"Yonsei University College of Medicine"},{"author_name":"You Jeong Lee","author_inst":"Seoul National University"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Spatial atlas of gut-draining lymph nodes reveals the developmental organization of intestinal tolerance and immunity","rel_doi":"10.64898\/2026.11.16.767093","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767093","rel_abs":"Early life offers a window to establish lasting tolerance to dietary and commensal microbial antigens. How developing gut lymph nodes balance tolerance and immunity remains unclear. Using spatial transcriptomics, we map small intestine- and colon-draining nodes during weaning and adulthood, resolving rare immune and stromal populations and their niches, including Thetis cells (TCs), an antigen-presenting lineage critical for intestinal tolerance. We uncover a peri-weaning subcapsular compartment enriched for TC I but depleted of classical antigen-relaying macrophages, coincident with attenuated follicular responses. Peri-weaning colonic nodes are hubs of T cell activation enriched for peripherally-induced regulatory T (pTreg) cell responses. We resolve distinct classical dendritic cell (cDC) and TC niches, including a pTreg-associated niche shared by TC IV and CCR7 cDC2. We further characterize a distinct population of intestinal tissue TCs, and establish TC migration to draining lymph nodes. Together, our atlas provides a framework for understanding how the timing of intestinal antigen exposure intersects with developing lymph node niches to shape tolerance or immunity.","rel_num_authors":12,"rel_authors":[{"author_name":"Yun Lo","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Priyanka Lakhiani","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Anushka Yadav","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Greyson Feather","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Aiswarya C. Binoy","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Yoselin A. Paucar Iza","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Yollanda Parisotto","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Tilman Hoelting","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Gayathri Shibu","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Vanja Cabric","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Tyler Park","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Chrysothemis Brown","author_inst":"Memorial Sloan Kettering Cancer Center"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"\u03b2-catenin\/TCF signaling represses GUCY2C hormone expression through a p38\u03b1-GATA2 axis in colorectal cancer","rel_doi":"10.64898\/2026.11.16.767112","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767112","rel_abs":"Guanylin (GUCA2A) and uroguanylin (GUCA2B) are paracrine hormone ligands of the tumor-suppressor receptor guanylyl cyclase C (GUCY2C). In early colorectal tumorigenesis, expression of GUCA2A and GUCA2B is silenced through transcriptional repression by APC-regulated {beta}-catenin\/TCF signaling, a pathway activated early in malignant transformation. This repression depends on a locus control region (LCR) 1,000-3,683 bp upstream of GUCA2A. Here, we used dCas9-APEX2 biotinylation at genomic elements by restricted spatial tagging (C-BERST) in colorectal cancer (CRC) cell lines with inducible suppression of {beta}-catenin\/TCF signaling to identify {beta}-catenin\/TCF-regulated proteins associated with the GUCA2A regulatory region that mediate repression of GUCY2C ligand transcription. Guide RNAs were used to direct dCas9-APEX2 for locus-specific proximity biotinylation of proteins. Quantitative mass spectrometry identified p38 (MAPK14) as a candidate regulator enriched near the GUCA2A promoter following {beta}-catenin\/TCF suppression. Loss-of-function and rescue experiments established that p38 supports GUCA2A and GUCA2B induction following {beta}-catenin\/TCF suppression. Importantly, GATA2 was identified as a p38-dependent activator of GUCA2A and GUCA2B transcription that remained enriched near the GUCA2A promoter independent of {beta}-catenin\/TCF signaling. Indeed, GATA2 S192 phosphorylation was reduced by p38 loss and by active {beta}-catenin\/TCF signaling. Thus, a p38\/GATA2 axis links oncogenic {beta}-catenin\/TCF signaling to repression of GUCY2C hormone expression in CRC.","rel_num_authors":11,"rel_authors":[{"author_name":"Adi Caspi","author_inst":"Thomas Jefferson University"},{"author_name":"Andrew E Evans","author_inst":"Thomas Jefferson University"},{"author_name":"Ariana A Entezari","author_inst":"Thomas Jefferson University"},{"author_name":"Jasmine R Alvarez","author_inst":"Thomas Jefferson University"},{"author_name":"Anne K Londregan","author_inst":"Thomas Jefferson University"},{"author_name":"Thomas J M Kuret","author_inst":"Thomas Jefferson University"},{"author_name":"Robert D Carlson","author_inst":"Thomas Jefferson University"},{"author_name":"Jeffrey A Rappaport","author_inst":"Johns Hopkins University"},{"author_name":"Ramkrishna Mitra","author_inst":"Thomas Jefferson University"},{"author_name":"Adam E Snook","author_inst":"Thomas Jefferson University"},{"author_name":"Scott A Waldman","author_inst":"Thomas Jefferson University"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"ERM proteins antagonistically control cancer invasion and metastasis via mechanosensing regulation","rel_doi":"10.64898\/2026.11.16.767111","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767111","rel_abs":"Metastasis requires cancer cells to overcome anchorage dependence and rewire mechanosensing pathways. Here, we identify the ERM proteins ezrin, radixin, and moesin as key but antagonistic regulators of breast cancer metastasis. Expression profiling across matched low- and high-metastatic breast cancer models revealed consistent upregulation of all three ERM proteins in highly metastatic cells. Despite this, ezrin depletion reduced colony formation, invasion, and lung metastasis, whereas radixin or moesin depletion enhanced these phenotypes. Loss of radixin or moesin increased ezrin localization at the cell edge, while ezrin depletion reduced membrane-associated moesin, indicating a dynamic balance among ERM proteins. Ezrin depletion also increased focal adhesion size and number, FAK activation, and force transmission to the extracellular matrix, whereas radixin or moesin silencing produced opposite effects. Cellular force magnitude was inversely correlated with invasion, and pharmacological modulation of contractility reverted the effects of ERM depletion. These findings reveal an ERM-dependent mechanosensing checkpoint that regulates metastasis through control of adhesion dynamics and force transmission.","rel_num_authors":5,"rel_authors":[{"author_name":"Malak Amer","author_inst":"Johns Hopkins University"},{"author_name":"James V McCann","author_inst":"Johns Hopkins University"},{"author_name":"Tina Napso Shogan","author_inst":"Technion Israel Institute of Technology"},{"author_name":"Andrew J Ewald","author_inst":"Johns Hopkins University"},{"author_name":"Haguy Wolfenson","author_inst":"Technion - Israel Institute of Technology"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Gene set selection for classification with single-cell RNA-seq","rel_doi":"10.64898\/2026.11.16.767160","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767160","rel_abs":"Marker genes are important for analyzing and interpreting single-cell RNA-seq (scRNAseq) experiments. They are used to identify and categorize cell types and can also be useful for the design of downstream experiments. We present CellSieve, which tackles the problem of finding effective gene sets rather than distilling markers one at a time. While several \"combinatorial\" approaches to gene set selection have been proposed, we find that our approach, which leverages a combination of multinomial logistic regression and linear programming, is much more effective at finding small gene sets that can classify cell types.","rel_num_authors":2,"rel_authors":[{"author_name":"Nikhila P Swarna","author_inst":"California Institute of Technology"},{"author_name":"Lior Pachter","author_inst":"California Institute of Technology"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Identifying disease-associated dysbiosis in image-based spatial microbiome via MiSA","rel_doi":"10.64898\/2026.11.16.767125","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767125","rel_abs":"Background: Extensive studies have revealed the associations of microbiome dysbiosis with disease through compositional analysis of 16S rRNA amplicon or shotgun metagenomic sequencing data. However, dysbiosis in spatial organization of microbiome inhabiting the body sites and its implication for diseases remain understudied. Recently developed high phylogenetic resolution fluorescence in situ hybridization (HiPR-FISH) is an image-based mapping technology that provides spatial microbiome data at single-cell resolution, which allows for visualizing and quantifying spatial arrangement of microbial cells. Despite the growing availability of such data, no methods have been tailored to studying spatial dysbiosis in image-based microbiome data. Results: Here we introduce MiSA (Microbiome Spatial Aberration), the first statistical framework for identifying disease-associated spatial dysbiosis and the individual taxa that may contribute to it, based on differing degrees of clustering or regularity, i.e., microbial cells being more aggregated or more evenly spaced than expected under complete spatial randomness, between diagnostic groups. In simulations based on a real dataset, MiSA was robust across diverse and noisy spatial configurations, achieving substantially higher statistical power than a method borrowed from spatial proteomics, while controlling type I error at both the individual-taxon and community levels. When applied to an oral biofilm study, MiSA detected peri-implant mucositis-associated spatial dysbiosis at the community level and identified five taxa as potential contributors, including Actinomyces, which showed increased clustering in mucositis. Conclusions: MiSA is a powerful and robust framework for identifying spatial dysbiosis and the contributing taxa in image-based microbiome data, offering new insights into the spatial organization of microbial communities in disease.","rel_num_authors":10,"rel_authors":[{"author_name":"Ruoqian Liu","author_inst":"Weill Cornell Medicine"},{"author_name":"Benjamin Grodner","author_inst":"University of Washington"},{"author_name":"Sarah Samorodnitsky","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Daxuan Deng","author_inst":"Johns Hopkins University"},{"author_name":"Asmita Roy","author_inst":"Johns Hopkins University"},{"author_name":"Yuzheng Dun","author_inst":"Fred Hutchinson Cancer Center"},{"author_name":"Boyi Guo","author_inst":"University of Utah"},{"author_name":"Iwijn De Vlaminck","author_inst":"Cornell University"},{"author_name":"Ni Zhao","author_inst":"Johns Hopkins University"},{"author_name":"Wodan Ling","author_inst":"Weill Cornell Medicine"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Identifying disease-associated dysbiosis in image-based spatial microbiome via MiSA","rel_doi":"10.64898\/2026.11.16.767125","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767125","rel_abs":"Background: Extensive studies have revealed the associations of microbiome dysbiosis with disease through compositional analysis of 16S rRNA amplicon or shotgun metagenomic sequencing data. However, dysbiosis in spatial organization of microbiome inhabiting the body sites and its implication for diseases remain understudied. Recently developed high phylogenetic resolution fluorescence in situ hybridization (HiPR-FISH) is an image-based mapping technology that provides spatial microbiome data at single-cell resolution, which allows for visualizing and quantifying spatial arrangement of microbial cells. Despite the growing availability of such data, no methods have been tailored to studying spatial dysbiosis in image-based microbiome data. Results: Here we introduce MiSA (Microbiome Spatial Aberration), the first statistical framework for identifying disease-associated spatial dysbiosis and the individual taxa that may contribute to it, based on differing degrees of clustering or regularity, i.e., microbial cells being more aggregated or more evenly spaced than expected under complete spatial randomness, between diagnostic groups. In simulations based on a real dataset, MiSA was robust across diverse and noisy spatial configurations, achieving substantially higher statistical power than a method borrowed from spatial proteomics, while controlling type I error at both the individual-taxon and community levels. When applied to an oral biofilm study, MiSA detected peri-implant mucositis-associated spatial dysbiosis at the community level and identified five taxa as potential contributors, including Actinomyces, which showed increased clustering in mucositis. Conclusions: MiSA is a powerful and robust framework for identifying spatial dysbiosis and the contributing taxa in image-based microbiome data, offering new insights into the spatial organization of microbial communities in disease.","rel_num_authors":10,"rel_authors":[{"author_name":"Ruoqian Liu","author_inst":"Weill Cornell Medicine"},{"author_name":"Benjamin Grodner","author_inst":"University of Washington"},{"author_name":"Sarah Samorodnitsky","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Daxuan Deng","author_inst":"Johns Hopkins University"},{"author_name":"Asmita Roy","author_inst":"Johns Hopkins University"},{"author_name":"Yuzheng Dun","author_inst":"Fred Hutchinson Cancer Center"},{"author_name":"Boyi Guo","author_inst":"University of Utah"},{"author_name":"Iwijn De Vlaminck","author_inst":"Cornell University"},{"author_name":"Ni Zhao","author_inst":"Johns Hopkins University"},{"author_name":"Wodan Ling","author_inst":"Weill Cornell Medicine"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"ALI MEA60: A porous thin-film microelectrode array for air-liquid interface electrophysiology of 3D excitable tissues","rel_doi":"10.64898\/2026.11.16.766976","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.766976","rel_abs":"Objective: Conventional microelectrode arrays (MEAs) are suboptimal for long-term electrophysiology of three-dimensional (3D) excitable tissues, as limited oxygenation, nutrient diffusion, and tissue-electrode coupling compromise recording stability. Air-liquid interface (ALI) culture mitigates these constraints, but existing ALI MEA platforms are limited in channel count, flexibility, and compatibility with commercial multichannel acquisition systems. We developed and comprehensively characterized a next-generation ALI MEA for standardized, long-term recordings across multiple 3D excitable tissue models. Approach: The novel ALI MEA60 is composed of a porous polyimide membrane that integrates an array of 60 thin film microelectrodes (59 recording, one reference) and a basal perfusion chamber with Luer-lock connectors for controlled medium exchange and pharmacological wash-in\/wash-out. It is compatible with the MEA2100-Mini data acquisition system (Multi Channel Systems). We characterized electrode impedance and noise across 41 ALI MEA60 devices, assessed 60-day stability with human iPSC-derived neural spheroids (N = 7 MEAs, 121 recordings) using a standardized longitudinal framework and linear mixed-effects models, and evaluated its versatility through pharmacological assays and recordings from human neural spheroids, brain organoids, ex vivo brain slices, and cardiac organoids. Main results: The platform showed reproducible electrical performance (median impedance 56 kOhms; at 1 kHz) and low noise (approx. 5uV Root Mean Square (RMS) in saline, 10-20 uV in medium), resolving spikes and local field potentials simultaneously. Recording remained stable for at least 60 days, with a stable noise floor and ~85% persistence of initial functional channels. Neural spheroids reproduced the standard qualitative signatures to gabazine, 4-aminopyridine (4-AP), and 6-Cyano-7-nitroquinoxaline-2,3-dione\/D-2-amino-5-phosphonovalerate (CNQX\/D-AP5), while cardiac organoids showed the expected beta-adrenergic response to isoproterenol. The ALI MEA60 can similarly record signals from human brain slices and organoids without hardware modification. Significance: The ALI MEA60 combines ALI culture, chronic recording stability, standardized pharmacological testing and cross-tissue compatibility in a single ready-to-use platform. It also establishes a reproducible framework for benchmarking long-term electrophysiological performance, thereby supporting disease modelling, drug discovery, organ-on-chip technologies and future chronic 3D electrophysiology systems. Keywords: microelectrode array (MEA); air-liquid interface (ALI); 3D excitable tissues; neural spheroids; cardiac organoids; chronic electrophysiology.","rel_num_authors":18,"rel_authors":[{"author_name":"Fabien Friscourt","author_inst":"HES-SO - University of Applied Sciences and Arts Western Switzerland"},{"author_name":"Luc Stoppini","author_inst":"School of Engineering, Architecture and Landscape of Geneva (HEPIA), HES-SO - University of Applied Sciences and Arts Western Switzerland"},{"author_name":"Shaginth Sivakumar","author_inst":"School of Engineering, Architecture and Landscape of Geneva (HEPIA), HES-SO - University of Applied Sciences and Arts Western Switzerland"},{"author_name":"Marc O. Heuschkel","author_inst":"School of Engineering, Architecture and Landscape of Geneva (HEPIA), HES-SO - University of Applied Sciences and Arts Western Switzerland"},{"author_name":"Laetitia Nikles","author_inst":"School of Engineering, Architecture and Landscape of Geneva (HEPIA), HES-SO - University of Applied Sciences and Arts Western Switzerland"},{"author_name":"Theo Ribierre","author_inst":"NeuroNA Human Cellular Neuroscience Platform (HCNP), Fondation Campus Biotech, Geneva, Switzerland"},{"author_name":"Thi-Thom Nguyen","author_inst":"INSERM U1263 INRAE U1260 Aix-Marseille Universite, France"},{"author_name":"Michel Puceat","author_inst":"INSERM U1263 INRAE U1260 Aix-Marseille Universite, France"},{"author_name":"Marisa Jaconi","author_inst":"Department of Basic Neurosciences, Faculty of Medicine, University of Geneva, Geneva, Switzerland."},{"author_name":"Leonardo Scapozza","author_inst":"Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland"},{"author_name":"Adam Armada-Moreira","author_inst":"Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Via Campi 287, 41125 Modena, Italy."},{"author_name":"Laura Monni","author_inst":"Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Via Campi 287, 41125 Modena, Italy."},{"author_name":"Alessio Di Clemente","author_inst":"Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Via Campi 287, 41125 Modena, Italy."},{"author_name":"Michele Giugliano","author_inst":"Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Via Campi 287, 41125 Modena, Italy."},{"author_name":"Julio Alvarez-Collazo","author_inst":"Multi Channel Systems MCS GmbH, Harvard Bioscience, Reutlingen, Germany"},{"author_name":"Jannis E. Meents","author_inst":"Multi Channel Systems MCS GmbH, Harvard Bioscience, Reutlingen, Germany"},{"author_name":"Sven Schoenecker","author_inst":"Multi Channel Systems MCS GmbH, Harvard Bioscience, Reutlingen, Germany"},{"author_name":"Adrien Roux","author_inst":"School of Engineering, Architecture and Landscape of Geneva (HEPIA), HES-SO - University of Applied Sciences and Arts Western Switzerland"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Resource enrichment and utilization underlie widely observed production and biomass scaling relationships","rel_doi":"10.64898\/2026.11.16.767026","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767026","rel_abs":"Broadly observed trophic scaling patterns relate the biomass of predators to the biomass of prey, and biomass to productivity. The consistency with which these patterns are observed suggests the existence of governing principles that apply across ecosystems. We present a model for the trophic interaction between phytoplankton and zooplankton that produces the scaling patterns as an emergent property of resource enrichment without invoking the influence of phenotypic or genotypic diversity on system structure. Using formulations with broad empirical support, the model incorporates processes that are common to all ecosystems: resource enrichment, feeding, growth, maintenance, and mortality. Thus, our interpretation of widely observed scaling relationships provides constraints for models that quantify the coupling between ecosystem structure and elemental cycles across terrestrial and aquatic environments.","rel_num_authors":4,"rel_authors":[{"author_name":"Jiayi Song","author_inst":"University of Michigan"},{"author_name":"Oliver Atkinson","author_inst":"Case Western Reserve University"},{"author_name":"David Talmy","author_inst":"University of Tennessee"},{"author_name":"Anne Willem Omta","author_inst":"Case Western Reserve University"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Revealing the platelet transcriptome using Siphon-seq: a sensitive, purity-aware method for RNA-sequencing","rel_doi":"10.64898\/2026.11.16.767104","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767104","rel_abs":"Platelet transcriptomics is limited by the exceptionally low RNA content of platelets and by disproportionate contributions from contaminating cells to bulk RNA-sequencing libraries. We developed Siphon-seq, an approach that deliberately overloads independently barcoded single-cell partitions to increase aggregate platelet RNA input, then computationally identifies and removes partitions containing contaminating RNA after sequencing. Applied to 34 healthy human donors, Siphon-seq increased platelet-marker representation, depleted leukocyte and erythrocyte transcripts, and removed contamination-associated inter-donor transcriptional structure. We defined a 3,436-gene core platelet transcriptome that was strongly related to megakaryocyte expression. However, megakaryocyte transcription did not fully explain the platelet transcriptome, which had specific pathways systematically enriched or depleted that were obscured by leukocyte contamination. These findings were confirmed in an independent cohort and were associated with protein detection in two platelet proteome resources. In a pilot human sepsis cohort, Siphon-seq reduced transcripts associated with leukocytes to reveal increased platelet-associated pathway signals. These contaminating immune pathways were also enriched in samples analyzed by bulk RNA-seq from an independent sepsis cohort, most strongly in the stratum with the highest estimated leukocyte burden. Combined, these results reveal that RNA-level contamination can alter both transcriptome structure and biological inference, and that Siphon-seq bridges the sensitivity-purity tradeoff that has limited platelet RNA sequencing, enabling sensitive, purity-aware studies of platelet biology in health and disease.","rel_num_authors":9,"rel_authors":[{"author_name":"Brittany Moser","author_inst":"UCSF"},{"author_name":"Catharina Conrad","author_inst":"Department of Medicine, University of California, San Francisco, San Francisco, CA, USA"},{"author_name":"Qin Zhu","author_inst":"Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA"},{"author_name":"S. Farshid Moussavi-Harami","author_inst":"Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA"},{"author_name":"Catherine A. Taylor","author_inst":"Department of Medicine, University of California, San Francisco, San Francisco, CA, USA"},{"author_name":"Longhui Qiu","author_inst":"Department of Medicine, University of California, San Francisco, San Francisco, CA, USA"},{"author_name":"Carolyn S. Calfee","author_inst":"Department of Medicine, University of California, San Francisco, San Francisco, CA, USA"},{"author_name":"Zev J. Gartner","author_inst":"Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA"},{"author_name":"Mark R. Looney","author_inst":"Department of Medicine, University of California, San Francisco, San Francisco, CA, USA"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"A minimal common core and dynamic protein associations orchestrate nuclear mRNP maturation","rel_doi":"10.64898\/2026.11.16.767097","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767097","rel_abs":"How nuclear mRNAs are selectively packaged into ribonucleoprotein particles (mRNPs) is fundamental to elucidating the mechanisms that govern gene expression. Here, we interrogate nuclear mRNP maturation in S. cerevisiae by combining a proteomic (34 baits) and transcriptomic (18 baits) affinity-purification survey with sequential purification of individual MS2-tagged nuclear transcripts at successive stages of maturation. Contrary to the prevailing models in which nuclear mRNAs are extensively coated with a stable complement of proteins, we find that they share a minimal core of Yra1p and Pab1p, together with a more dynamically associated cap-binding complex. Most other factors associate transiently and transcript-selectively, assembling as pre-assembled, stage-specific modules. The minimal core is invariant to promoter, coding sequence and transcript length, whereas intron class, rather than intron presence alone, determines spliceosome composition. The breadth of factor association further tracks promoter class and proximity to chromatin-domain boundaries, linking mRNP biogenesis to genome organization.","rel_num_authors":16,"rel_authors":[{"author_name":"Peter C Fridy","author_inst":"Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY, U.S.A."},{"author_name":"Iryna Abramchuk","author_inst":"Department of Biochemistry, Microbiology and Immunology, and Ottawa Institute of Systems Biology, University     of Ottawa, Ottawa, ON, Canada"},{"author_name":"Alexander V Ratushny","author_inst":"Institute for Systems Biology, Seattle, WA, U.S.A."},{"author_name":"Karen E Wei","author_inst":"Laboratory of RNP Biochemistry, Institut de recherches cliniques de Montreal (IRCM), Center for Genetic and    Neurological Diseases, Montreal, QC, Canada"},{"author_name":"Erica Y Jacobs","author_inst":"Laboratory of Mass Spectrometry and Gaseous Ion Chemistry, The Rockefeller University, New York, NY, U.S.A."},{"author_name":"Richard S Rogers","author_inst":"Institute for Systems Biology, Seattle, WA, U.S.A."},{"author_name":"Ramsey A Saleem","author_inst":"Institute for Systems Biology, Seattle, WA, U.S.A."},{"author_name":"Lisbeth-Carolina Aguilar","author_inst":"Laboratory of RNP Biochemistry, Institut de recherches cliniques de Montreal (IRCM), Center for Genetic and    Neurological Diseases, Montreal, QC, Canada"},{"author_name":"Pascal Raymond","author_inst":"Departement de biochimie et medecine moleculaire, Universite de Montreal, Montreal, QC, Canada"},{"author_name":"Robert L. Moritz","author_inst":"Institute for Systems Biology"},{"author_name":"Daniel Zenklusen","author_inst":"Departement de biochimie et medecine moleculaire, Universite de Montreal, Montreal, QC, Canada"},{"author_name":"Brian T Chait","author_inst":"Laboratory of Mass Spectrometry and Gaseous Ion Chemistry, The Rockefeller University, New York, NY, U.S.A."},{"author_name":"Mathieu Lavallee-Adam","author_inst":"Department of Biochemistry, Microbiology and Immunology, and Ottawa Institute of Systems Biology, University of Ottawa, Ottawa, ON, Canada"},{"author_name":"John D Aitchison","author_inst":"Center for Global Infectious Disease Research, Seattle Childrens Research Institute, Seattle, WA, U.S.A."},{"author_name":"Michael P Rout","author_inst":"Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY, U.S.A."},{"author_name":"Marlene Oeffinger","author_inst":"Laboratory of RNP Biochemistry, Institut de recherches cliniques de Montreal (IRCM), Center for Genetic and    Neurological Diseases, Montreal, QC, Canada"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"A minimal common core and dynamic protein associations orchestrate nuclear mRNP maturation","rel_doi":"10.64898\/2026.11.16.767097","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767097","rel_abs":"How nuclear mRNAs are selectively packaged into ribonucleoprotein particles (mRNPs) is fundamental to elucidating the mechanisms that govern gene expression. Here, we interrogate nuclear mRNP maturation in S. cerevisiae by combining a proteomic (34 baits) and transcriptomic (18 baits) affinity-purification survey with sequential purification of individual MS2-tagged nuclear transcripts at successive stages of maturation. Contrary to the prevailing models in which nuclear mRNAs are extensively coated with a stable complement of proteins, we find that they share a minimal core of Yra1p and Pab1p, together with a more dynamically associated cap-binding complex. Most other factors associate transiently and transcript-selectively, assembling as pre-assembled, stage-specific modules. The minimal core is invariant to promoter, coding sequence and transcript length, whereas intron class, rather than intron presence alone, determines spliceosome composition. The breadth of factor association further tracks promoter class and proximity to chromatin-domain boundaries, linking mRNP biogenesis to genome organization.","rel_num_authors":16,"rel_authors":[{"author_name":"Peter C Fridy","author_inst":"Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY, U.S.A."},{"author_name":"Iryna Abramchuk","author_inst":"Department of Biochemistry, Microbiology and Immunology, and Ottawa Institute of Systems Biology, University     of Ottawa, Ottawa, ON, Canada"},{"author_name":"Alexander V Ratushny","author_inst":"Institute for Systems Biology, Seattle, WA, U.S.A."},{"author_name":"Karen E Wei","author_inst":"Laboratory of RNP Biochemistry, Institut de recherches cliniques de Montreal (IRCM), Center for Genetic and    Neurological Diseases, Montreal, QC, Canada"},{"author_name":"Erica Y Jacobs","author_inst":"Laboratory of Mass Spectrometry and Gaseous Ion Chemistry, The Rockefeller University, New York, NY, U.S.A."},{"author_name":"Richard S Rogers","author_inst":"Institute for Systems Biology, Seattle, WA, U.S.A."},{"author_name":"Ramsey A Saleem","author_inst":"Institute for Systems Biology, Seattle, WA, U.S.A."},{"author_name":"Lisbeth-Carolina Aguilar","author_inst":"Laboratory of RNP Biochemistry, Institut de recherches cliniques de Montreal (IRCM), Center for Genetic and    Neurological Diseases, Montreal, QC, Canada"},{"author_name":"Pascal Raymond","author_inst":"Departement de biochimie et medecine moleculaire, Universite de Montreal, Montreal, QC, Canada"},{"author_name":"Robert L. Moritz","author_inst":"Institute for Systems Biology"},{"author_name":"Daniel Zenklusen","author_inst":"Departement de biochimie et medecine moleculaire, Universite de Montreal, Montreal, QC, Canada"},{"author_name":"Brian T Chait","author_inst":"Laboratory of Mass Spectrometry and Gaseous Ion Chemistry, The Rockefeller University, New York, NY, U.S.A."},{"author_name":"Mathieu Lavallee-Adam","author_inst":"Department of Biochemistry, Microbiology and Immunology, and Ottawa Institute of Systems Biology, University of Ottawa, Ottawa, ON, Canada"},{"author_name":"John D Aitchison","author_inst":"Center for Global Infectious Disease Research, Seattle Childrens Research Institute, Seattle, WA, U.S.A."},{"author_name":"Michael P Rout","author_inst":"Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY, U.S.A."},{"author_name":"Marlene Oeffinger","author_inst":"Laboratory of RNP Biochemistry, Institut de recherches cliniques de Montreal (IRCM), Center for Genetic and    Neurological Diseases, Montreal, QC, Canada"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"A minimal common core and dynamic protein associations orchestrate nuclear mRNP maturation","rel_doi":"10.64898\/2026.11.16.767097","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767097","rel_abs":"How nuclear mRNAs are selectively packaged into ribonucleoprotein particles (mRNPs) is fundamental to elucidating the mechanisms that govern gene expression. Here, we interrogate nuclear mRNP maturation in S. cerevisiae by combining a proteomic (34 baits) and transcriptomic (18 baits) affinity-purification survey with sequential purification of individual MS2-tagged nuclear transcripts at successive stages of maturation. Contrary to the prevailing models in which nuclear mRNAs are extensively coated with a stable complement of proteins, we find that they share a minimal core of Yra1p and Pab1p, together with a more dynamically associated cap-binding complex. Most other factors associate transiently and transcript-selectively, assembling as pre-assembled, stage-specific modules. The minimal core is invariant to promoter, coding sequence and transcript length, whereas intron class, rather than intron presence alone, determines spliceosome composition. The breadth of factor association further tracks promoter class and proximity to chromatin-domain boundaries, linking mRNP biogenesis to genome organization.","rel_num_authors":16,"rel_authors":[{"author_name":"Peter C Fridy","author_inst":"Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY, U.S.A."},{"author_name":"Iryna Abramchuk","author_inst":"Department of Biochemistry, Microbiology and Immunology, and Ottawa Institute of Systems Biology, University     of Ottawa, Ottawa, ON, Canada"},{"author_name":"Alexander V Ratushny","author_inst":"Institute for Systems Biology, Seattle, WA, U.S.A."},{"author_name":"Karen E Wei","author_inst":"Laboratory of RNP Biochemistry, Institut de recherches cliniques de Montreal (IRCM), Center for Genetic and    Neurological Diseases, Montreal, QC, Canada"},{"author_name":"Erica Y Jacobs","author_inst":"Laboratory of Mass Spectrometry and Gaseous Ion Chemistry, The Rockefeller University, New York, NY, U.S.A."},{"author_name":"Richard S Rogers","author_inst":"Institute for Systems Biology, Seattle, WA, U.S.A."},{"author_name":"Ramsey A Saleem","author_inst":"Institute for Systems Biology, Seattle, WA, U.S.A."},{"author_name":"Lisbeth-Carolina Aguilar","author_inst":"Laboratory of RNP Biochemistry, Institut de recherches cliniques de Montreal (IRCM), Center for Genetic and    Neurological Diseases, Montreal, QC, Canada"},{"author_name":"Pascal Raymond","author_inst":"Departement de biochimie et medecine moleculaire, Universite de Montreal, Montreal, QC, Canada"},{"author_name":"Robert L. Moritz","author_inst":"Institute for Systems Biology"},{"author_name":"Daniel Zenklusen","author_inst":"Departement de biochimie et medecine moleculaire, Universite de Montreal, Montreal, QC, Canada"},{"author_name":"Brian T Chait","author_inst":"Laboratory of Mass Spectrometry and Gaseous Ion Chemistry, The Rockefeller University, New York, NY, U.S.A."},{"author_name":"Mathieu Lavallee-Adam","author_inst":"Department of Biochemistry, Microbiology and Immunology, and Ottawa Institute of Systems Biology, University of Ottawa, Ottawa, ON, Canada"},{"author_name":"John D Aitchison","author_inst":"Center for Global Infectious Disease Research, Seattle Childrens Research Institute, Seattle, WA, U.S.A."},{"author_name":"Michael P Rout","author_inst":"Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY, U.S.A."},{"author_name":"Marlene Oeffinger","author_inst":"Laboratory of RNP Biochemistry, Institut de recherches cliniques de Montreal (IRCM), Center for Genetic and    Neurological Diseases, Montreal, QC, Canada"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Defining host factors required for dengue virus NS1-induced endothelial hyperpermeability and endothelial glycocalyx layer disruption","rel_doi":"10.64898\/2026.11.16.766930","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.766930","rel_abs":"Dengue virus (DENV) is a mosquito-borne positive-sense RNA virus belonging to the Flaviviridae family that poses a significant threat to global health. Clinical manifestations of DENV infection range from febrile to severe disease characterized by vascular leakage. The secreted DENV nonstructural protein 1 (NS1) contributes to endothelial dysfunction through interactions with endothelial cells, leading to disruption of the endothelial glycocalyx and intercellular junction complexes (IJC). However, host factors required for NS1-triggered endothelial dysfunction are not well understood. It is also unclear if NS1 highjacks different host factors and signaling pathways for glycocalyx and IJC disruption. To address these questions, we used a targeted genetic approach to identify host factors required either for NS1-triggered endothelial glycocalyx layer (EGL) disruption, as assessed by immunofluorescence assays, or for IJC disruption, as measured by transendothelial electrical resistance. After demonstrating the decoupled nature of EGL and IJC disruption in our models, we genetically depleted host factors with known roles in regulating endothelial barrier function and\/or involvement in NS1 pathogenesis, including heparanase, cathepsin L, sialidases, and the PI3K\/AKT\/mTOR and {beta}-catenin signaling pathways. Our results reveal a complex genetic landscape where NS1-induced disruption of EGL and IJCs involves both unique and shared host factors. Further, our data identify a direct role for {beta}-catenin in NS1-induced endothelial dysfunction in vitro and in vivo. Overall, this work advances understanding of host factors required for DENV NS1-triggered endothelial dysfunction, revealing distinct intracellular pathways that are highjacked by NS1 to modulate barrier function, thus providing new insights into dengue-associated vascular leak.","rel_num_authors":12,"rel_authors":[{"author_name":"Laurentia V. Tjang","author_inst":"University of California Berkeley"},{"author_name":"Jordan Quellec","author_inst":"University of California Berkeley"},{"author_name":"Xinyi Feng","author_inst":"University of California Berkeley"},{"author_name":"Felix Pahmeier","author_inst":"University of California Berkeley"},{"author_name":"Vasiliya Kril","author_inst":"University of California, San Diego"},{"author_name":"Kayla Leung","author_inst":"University of California Berkeley"},{"author_name":"R\u00e9mi H\u00e9nocque","author_inst":"University of California San Diego School of Biological Sciences"},{"author_name":"Samhita Bhat","author_inst":"University of California Berkeley"},{"author_name":"Jeffrey Li","author_inst":"University of California Berkeley"},{"author_name":"Pedro H. Carneiro","author_inst":"University of California Berkeley"},{"author_name":"Scott B. Biering","author_inst":"University of California San Diego"},{"author_name":"Eva Harris","author_inst":"University of California, Berkeley"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Defining host factors required for dengue virus NS1-induced endothelial hyperpermeability and endothelial glycocalyx layer disruption","rel_doi":"10.64898\/2026.11.16.766930","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.766930","rel_abs":"Dengue virus (DENV) is a mosquito-borne positive-sense RNA virus belonging to the Flaviviridae family that poses a significant threat to global health. Clinical manifestations of DENV infection range from febrile to severe disease characterized by vascular leakage. The secreted DENV nonstructural protein 1 (NS1) contributes to endothelial dysfunction through interactions with endothelial cells, leading to disruption of the endothelial glycocalyx and intercellular junction complexes (IJC). However, host factors required for NS1-triggered endothelial dysfunction are not well understood. It is also unclear if NS1 highjacks different host factors and signaling pathways for glycocalyx and IJC disruption. To address these questions, we used a targeted genetic approach to identify host factors required either for NS1-triggered endothelial glycocalyx layer (EGL) disruption, as assessed by immunofluorescence assays, or for IJC disruption, as measured by transendothelial electrical resistance. After demonstrating the decoupled nature of EGL and IJC disruption in our models, we genetically depleted host factors with known roles in regulating endothelial barrier function and\/or involvement in NS1 pathogenesis, including heparanase, cathepsin L, sialidases, and the PI3K\/AKT\/mTOR and {beta}-catenin signaling pathways. Our results reveal a complex genetic landscape where NS1-induced disruption of EGL and IJCs involves both unique and shared host factors. Further, our data identify a direct role for {beta}-catenin in NS1-induced endothelial dysfunction in vitro and in vivo. Overall, this work advances understanding of host factors required for DENV NS1-triggered endothelial dysfunction, revealing distinct intracellular pathways that are highjacked by NS1 to modulate barrier function, thus providing new insights into dengue-associated vascular leak.","rel_num_authors":12,"rel_authors":[{"author_name":"Laurentia V. Tjang","author_inst":"University of California Berkeley"},{"author_name":"Jordan Quellec","author_inst":"University of California Berkeley"},{"author_name":"Xinyi Feng","author_inst":"University of California Berkeley"},{"author_name":"Felix Pahmeier","author_inst":"University of California Berkeley"},{"author_name":"Vasiliya Kril","author_inst":"University of California, San Diego"},{"author_name":"Kayla Leung","author_inst":"University of California Berkeley"},{"author_name":"R\u00e9mi H\u00e9nocque","author_inst":"University of California San Diego School of Biological Sciences"},{"author_name":"Samhita Bhat","author_inst":"University of California Berkeley"},{"author_name":"Jeffrey Li","author_inst":"University of California Berkeley"},{"author_name":"Pedro H. Carneiro","author_inst":"University of California Berkeley"},{"author_name":"Scott B. Biering","author_inst":"University of California San Diego"},{"author_name":"Eva Harris","author_inst":"University of California, Berkeley"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Defining host factors required for dengue virus NS1-induced endothelial hyperpermeability and endothelial glycocalyx layer disruption","rel_doi":"10.64898\/2026.11.16.766930","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.766930","rel_abs":"Dengue virus (DENV) is a mosquito-borne positive-sense RNA virus belonging to the Flaviviridae family that poses a significant threat to global health. Clinical manifestations of DENV infection range from febrile to severe disease characterized by vascular leakage. The secreted DENV nonstructural protein 1 (NS1) contributes to endothelial dysfunction through interactions with endothelial cells, leading to disruption of the endothelial glycocalyx and intercellular junction complexes (IJC). However, host factors required for NS1-triggered endothelial dysfunction are not well understood. It is also unclear if NS1 highjacks different host factors and signaling pathways for glycocalyx and IJC disruption. To address these questions, we used a targeted genetic approach to identify host factors required either for NS1-triggered endothelial glycocalyx layer (EGL) disruption, as assessed by immunofluorescence assays, or for IJC disruption, as measured by transendothelial electrical resistance. After demonstrating the decoupled nature of EGL and IJC disruption in our models, we genetically depleted host factors with known roles in regulating endothelial barrier function and\/or involvement in NS1 pathogenesis, including heparanase, cathepsin L, sialidases, and the PI3K\/AKT\/mTOR and {beta}-catenin signaling pathways. Our results reveal a complex genetic landscape where NS1-induced disruption of EGL and IJCs involves both unique and shared host factors. Further, our data identify a direct role for {beta}-catenin in NS1-induced endothelial dysfunction in vitro and in vivo. Overall, this work advances understanding of host factors required for DENV NS1-triggered endothelial dysfunction, revealing distinct intracellular pathways that are highjacked by NS1 to modulate barrier function, thus providing new insights into dengue-associated vascular leak.","rel_num_authors":12,"rel_authors":[{"author_name":"Laurentia V. Tjang","author_inst":"University of California Berkeley"},{"author_name":"Jordan Quellec","author_inst":"University of California Berkeley"},{"author_name":"Xinyi Feng","author_inst":"University of California Berkeley"},{"author_name":"Felix Pahmeier","author_inst":"University of California Berkeley"},{"author_name":"Vasiliya Kril","author_inst":"University of California, San Diego"},{"author_name":"Kayla Leung","author_inst":"University of California Berkeley"},{"author_name":"R\u00e9mi H\u00e9nocque","author_inst":"University of California San Diego School of Biological Sciences"},{"author_name":"Samhita Bhat","author_inst":"University of California Berkeley"},{"author_name":"Jeffrey Li","author_inst":"University of California Berkeley"},{"author_name":"Pedro H. Carneiro","author_inst":"University of California Berkeley"},{"author_name":"Scott B. Biering","author_inst":"University of California San Diego"},{"author_name":"Eva Harris","author_inst":"University of California, Berkeley"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"PreSMA population dynamics keep the beat atop the primate audiomotor hierarchy","rel_doi":"10.64898\/2026.11.16.767170","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767170","rel_abs":"Humans move in time with musical beats, yet how the brain builds the internal beat that guides movement is unknown. We recorded 4,719 neurons in six nodes of the audiomotor circuit while monkeys tapped in synchrony with auditory metronomes at different tempos. We found a clear functional dissociation in the temporal-frontal axis. Auditory cortex detected metronome clicks and contained local clocks that tiled each interstimulus interval, whereas parietal, striatal, and motor areas, most strongly the pre-supplementary motor area (preSMA), generated movement-aligned neural sequences that rescaled with tempo. Only in preSMA did population activity formed a cone-shaped manifold that jointly encoded tempo in its height, the produced interval in its width, and the timing of each tap relative to the beat in its position along the trajectory. During timing errors, preSMA activity kept conical shape but drifted toward shorter or longer tempos, revealing a hierarchical neural clock for beat synchronization.","rel_num_authors":5,"rel_authors":[{"author_name":"Pablo Marquez","author_inst":"Instituto de Neurobiologia, Universidad Nacional Autonoma de Mexico"},{"author_name":"Yaneri Ayala","author_inst":"Neurosurgery Department, The University of Iowa, IA USA."},{"author_name":"Luis Prado","author_inst":"Instituto de Neurobiologia, Universidad Nacional Autonoma de Mexico"},{"author_name":"German Mendoza","author_inst":"Instituto de Neurobiologia, Universidad Nacional Autonoma de Mexico"},{"author_name":"Hugo Merchant","author_inst":"Instituto de Neurobiologia, Universidad Nacional Autonoma de Mexico"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Neural rosettes emerge from an interconnected tubular network in human cortical organoids","rel_doi":"10.64898\/2026.11.16.767152","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767152","rel_abs":"Cortical organoids generate multiple neural rosettes, self-organizing and radially arranged structures that resemble ventricular zones of the developing brain. Here, we show that these rosettes, commonly considered as discrete entities, originate from an interconnected tubular network. We demonstrate that the formation of this continuous structure involves neuroepithelial folding, invagination, and internalization, resembling aspects of neural tube formation. Using fluorescently labeled polyethylene nanoplastics as extracellular tracers, we further show that they accumulate within the developing tubular lumen, consistent with its formation through neuroepithelial folding and internalization. These findings provide new insights into early human brain morphogenesis and suggest the potential utility of cortical organoids for investigating developmental processes relevant to neural tube defects.","rel_num_authors":5,"rel_authors":[{"author_name":"Luca Trovo","author_inst":"UCSD"},{"author_name":"Gimena Gomez","author_inst":"UCSD"},{"author_name":"Ashley Einhorn","author_inst":"UCSD"},{"author_name":"Alysson R Muotri","author_inst":"UCSD"},{"author_name":"Lilia M Iakoucheva","author_inst":"University of California San Diego"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Within-Subject Precision Measurement: Theory and Utility of Assessing Change Scores and Their Variance","rel_doi":"10.64898\/2026.11.16.767165","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767165","rel_abs":"Within-subject studies gain statistical power by removing stable between-subject differences from the comparison. However, the metrics commonly used to select measurement instruments and anticipate their within-subject performance are often based on between-subject correlations of raw scores from test-retest designs. Measuring each subject's change directly -- after an intervention, and ideally more than once -- provides a firmer basis for evaluating measurement precision and planning studies of within-subject change. Here we describe the statistical theory behind estimating measurement properties from change scores. In one instantiation, the pre- and post-intervention measurements are each made twice, yielding the duplicate change-score design. Such a design provides an estimate of the mean signal change and enables the decomposition of the total observed variance of change scores into true between-subject response heterogeneity and measurement noise. In extended designs, where multiple measures are collected within and across days, measurement noise can be further decomposed to distinguish within-session from between-day measurement variability. These estimates supply the inputs needed for within-subject study design, including providing a basis for selecting among alternative measurements and comparing processing pipelines, performing power calculations, and estimating the precision limits of detecting change within individual subjects.","rel_num_authors":6,"rel_authors":[{"author_name":"Randy L Buckner","author_inst":"Harvard University"},{"author_name":"Deanna M Barch","author_inst":"Washington University in St. Louis"},{"author_name":"Patrick Mair","author_inst":"Harvard University"},{"author_name":"Thomas E Nichols","author_inst":"University of Oxford"},{"author_name":"Theodore D Satterthwaite","author_inst":"University of Pennsylvania"},{"author_name":"B.T. Thomas Yeo","author_inst":"National University of Singapore"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Common early-life exposure of the colorectal epithelium to the microbiome-derived mutagen colibactin","rel_doi":"10.64898\/2026.11.16.766949","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.766949","rel_abs":"Colibactin is a mutagen produced by bacterial strains in the colorectal microbiomes of some healthy people. It generates somatic mutations characterised by the mutational signatures SBS88 and ID18 in normal human colorectal epithelial cells in vivo. Increasing prevalence of colibactin mutagenesis during the 20th century is hypothesised to have caused recent international increases in early-onset colorectal cancer incidence. Here, we establish the early-life prevalence, timing, mutation burdens and distribution through the colon of colibactin mutagenesis by sequencing normal colorectal epithelial cell genomes to detect SBS88 and ID18 in 90 healthy and inflammatory bowel disease affected children and adolescents. Colibactin-induced mutagenesis was present in ~43%, with or without inflammatory bowel disease. It usually begins shortly after birth and ceases by age five years. Mutation burdens are higher in the left than right colon and show substantial variation, with some children displaying mutation burdens comparable to those of healthy non-exposed individuals greater than 60 years of age. The future public health implications of this common early life mutagen exposure will depend on clarification of its role in colorectal cancer causation.","rel_num_authors":35,"rel_authors":[{"author_name":"Henry N. Marshall","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"My H. Pham","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"Hyunchul Jung","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"Laura Humphreys","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"Yvette Hooks","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"Anh Phuong Le","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"Sarah Moody","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"Yichen Wang","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"Will Knight","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"Stephen Fitzgerald","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"Yan Shao","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"Soyeon Kim","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"Jiali Pang","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"Nicolas Wyvekens","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"Andrew Ramos","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"Calli Latimer","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"Rashesh Sanghvi","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"Ammal Abbasi","author_inst":"Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA"},{"author_name":"Claire Glemas","author_inst":"Department of Paediatrics, University of Cambridge, Cambridge, UK; Cambridge University Hospitals, Cambridge, UK"},{"author_name":"Kelly Spike","author_inst":"Department of Paediatrics, University of Cambridge, Cambridge, UK; Cambridge University Hospitals, Cambridge, UK"},{"author_name":"Komal Nayak","author_inst":"Department of Paediatrics, University of Cambridge, Cambridge, UK; Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK"},{"author_name":"Rob Heuschkel","author_inst":"Department of Paediatrics, University of Cambridge, Cambridge, UK; Cambridge University Hospitals, Cambridge, UK"},{"author_name":"Ievgeniia Chicherova","author_inst":"Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC\/WHO), Lyon, France"},{"author_name":"Peter Campbell","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"Inigo Martincorena","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"Trevor D. Lawley","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"Ludmil B. Alexandrov","author_inst":"Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA"},{"author_name":"Tim H.H. Coorens","author_inst":"European Bioinformatics Institute, European Molecular Biology Laboratory (EMBL-EBI), Hinxton, UK; Broad Institute of MIT and Harvard, Cambridge MA, USA"},{"author_name":"Raheleh Rahbari","author_inst":"Wellcome Sanger Institute, Hinxton, UK"},{"author_name":"Paul Brennan","author_inst":"Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC\/WHO), Lyon, France"},{"author_name":"Maria Dorn-Rasmussen","author_inst":"Department of Paediatric and Adolescent Medicine, Copenhagen University Hospital, Hvidovre, Denmark; Copenhagen Center for Inflammatory Bowel Disease in Childre"},{"author_name":"Vibeke Wewer","author_inst":"Department of Paediatric and Adolescent Medicine, Copenhagen University Hospital, Hvidovre, Denmark; Copenhagen Center for Inflammatory Bowel Disease in Childre"},{"author_name":"Johan Burisch","author_inst":"Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark; D"},{"author_name":"Matthias Zilbauer","author_inst":"Department of Paediatrics, University of Cambridge, Cambridge, UK; Cambridge University Hospitals, Cambridge, UK; Cambridge Stem Cell Institute, University of C"},{"author_name":"Michael R. Stratton","author_inst":"Wellcome Sanger Institute, Hinxton, UK"}],"rel_date":"2026-11-18","rel_site":"biorxiv"},{"rel_title":"Cervicovaginal metabolites mediate the relationship between vaginal microbiota and risk for Chlamydia trachomatis infection","rel_doi":"10.64898\/2026.11.16.26368223","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.16.26368223","rel_abs":"Background: Chlamydia trachomatis (CT) remains the most prevalent bacterial sexually transmitted infection and a cause of adverse reproductive outcomes. Epidemiologic studies describe bacterial vaginosis (BV) as a major risk factor for CT infection. Emerging data suggest that BV-associated bacteria and their metabolites contribute to CT susceptibility. Here, we measured the role of specific bacteria in incident CT and evaluated a hypothesized causal role between the vaginal microbiota, its metabolites, and CT risk. Methods: We conducted a nested case-control study of Kenyan women who engage in transactional sex from the Mombasa Cohort who acquired CT versus those who did not, and compared their vaginal microbiome and metabolome at the visit preceding CT acquisition. We determined CT infection and total bacterial load using qPCRs. 16S rRNA sequencing was used to characterize the genital microbiome, and BV status was determined using Nugent-Hillier and Amsel scoring criteria. Metabolites were measured using targeted liquid chromatography-mass spectrometry from a subset of women. Findings: Women with BV, high vaginal microbial diversity, and community state types III and IV were significantly more likely to have CT at their next visit. CT infection itself did not alter vaginal microbial diversity. More specifically, both concentrations and relative abundances of Lactobacillus crispatus and several BV-associated bacteria (Sneathia sanguinegens, Umbribacter vaginalis, Prevotella amnii, Hoylesella\/Prevotella timonensis, and Ureaplasma urealyticum) were predictive of CT outcomes. Vaginal metabolites differed between cases and controls pre-CT, including Tyramine, reduced and oxidized Glutathione, and sucrose. In a mediation analysis, the vaginal metabolome significantly mediated the relationship between the microbiome and CT infection. Interpretation: We show for the first time that the association between BV and CT risk is mediated by differences in the metabolome. Identification of the mechanisms underlying increased CT risk with BV can inform interventions to reduce infections in high-risk women. Funding: US NIH (R01AI13214401-A1)","rel_num_authors":14,"rel_authors":[{"author_name":"Smritee Dabee","author_inst":"Seattle Childrens Research Institute, Seattle, WA, USA"},{"author_name":"Mor Tsamir-Rimon","author_inst":"Department of Human Genetics and Computational Medicine, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"},{"author_name":"Omolara Akingba","author_inst":"Department of Global Health, University of Washington, Seattle, WA, USA"},{"author_name":"John Kinuthia","author_inst":"Department of Research and Programs, Kenyatta National Hospital, Nairobi, Kenya"},{"author_name":"James W MacDonald","author_inst":"Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA"},{"author_name":"Theo K Bammler","author_inst":"Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA"},{"author_name":"Daniel Raftery","author_inst":"Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA, USA"},{"author_name":"Kevin Hybiske","author_inst":"Department of Global Health, University of Washington, Seattle, WA, USA"},{"author_name":"Ken Tapia","author_inst":"Department of Epidemiology, University of Washington, Seattle, WA, USA"},{"author_name":"Walter Jaoko","author_inst":"Department of Medical Microbiology and Immunology, University of Nairobi, Nairobi, Kenya"},{"author_name":"Elhanan Borenstein","author_inst":"Department of Human Genetics and Computational Medicine, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"},{"author_name":"Jennifer E Balkus","author_inst":"Department of Epidemiology, University of Washington, Seattle, WA, USA"},{"author_name":"R. Scott McClelland","author_inst":"Department of Global Health, University of Washington, Seattle, WA, USA"},{"author_name":"Heather B Jaspan","author_inst":"Seattle Childrens Research Institute, Seattle, WA, USA"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"The genetic architecture of wisdom and its relationship with health, personality, and cognition","rel_doi":"10.64898\/2026.11.10.26367758","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.10.26367758","rel_abs":"Wisdom is a personality trait composed of self-reflection, pro-social behaviors, emotional regulation, acceptance of divergent perspectives, decisiveness, social advising, and spirituality. Greater levels of wisdom are linked to better overall health, well-being, happiness, life satisfaction, and resilience. However, the underlying genetic architecture of wisdom remains unexplored. We assessed wisdom using responses to the SD-WISE-7 in 153,384 23andMe research-consented participants and conducted a multi-ancestry GWAS. We identified one genome-wide significant locus (rs2325631, p=1.41E-08) near MANEA on chromosome 6. Wisdom was heritable (h2SNP=0.03{+\/-}4.50E-03) and genetically correlated with numerous traits, including greater subjective well-being, openness, and risk tolerance, and lower neuroticism and loneliness. Crucially, wisdom was genetically distinct from intelligence and the cognitive component of educational attainment. Wisdom polygenic scores were associated with psychosocial outcomes, but not cognitive performance in All of Us. This study advances our understanding of wisdom as a heritable trait that could guide interventions to improve human health.","rel_num_authors":13,"rel_authors":[{"author_name":"Fabrizio Malatesta","author_inst":"Department of Psychiatry, University of California San Diego, La Jolla, CA, USA"},{"author_name":"Hayley Thorpe","author_inst":"Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada"},{"author_name":"Jean Gonzalez","author_inst":"Department of Psychiatry, University of California San Diego, La Jolla, CA, USA"},{"author_name":"John J Meredith","author_inst":"Department of Psychiatry, University of California San Diego, La Jolla, CA, USA"},{"author_name":"Laura Vilar-Rib\u00f3","author_inst":"Department of Psychiatry, University of California San Diego, La Jolla, CA, USA"},{"author_name":"Natasia Courchesne-Krak","author_inst":"Department of Psychiatry, University of California San Diego, La Jolla, CA, USA"},{"author_name":"Daniel Gustavson","author_inst":"Institute for Behavioral Genetics; Department of Psychology and Neuroscience, University of Colorado Boulder, CO, USA"},{"author_name":"- 23andMe Research Team","author_inst":"-"},{"author_name":"Vinh Tran","author_inst":"23andMe Research Institute, Palo Alto, CA, USA"},{"author_name":"Shubham Saini","author_inst":"23andMe Research Institute, Palo Alto, CA, USA"},{"author_name":"Emily M. Rios","author_inst":"23andMe Research Institute, Palo Alto, CA, USA"},{"author_name":"Abraham Palmer","author_inst":"Department of Psychiatry; Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, USA"},{"author_name":"Sandra Sanchez-Roige","author_inst":"Department of Psychiatry; Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, USA"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Evaluation of System One Models on Biomedical Texts","rel_doi":"10.64898\/2026.11.15.26368126","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.15.26368126","rel_abs":"Objective To compare the performance and cost of System One models (SOMs) with general-purpose large language models (LLMs) on biomedical tasks and evaluate confidence-based routing. Materials and Methods We evaluated three SOMs and three LLMs across seven datasets and eight endpoints covering question answering, error detection, structured extraction, and clinical-note assessment. Outcomes included task-specific performance, recorded inference cost and latency, and confidence calibration. Calibration data determined routing schemes and confidence thresholds to evaluate test predictions, with cost-matched random referral as a comparator. Results Claude Opus 5.5 had the highest primary performance on all eight endpoints. The strongest SOM, Jev, had competitive performance with the evaluated LLMs and cost less than 1% of Opus on most datasets. Three selected SOM-to-LLM routes reduced costs by 30.0%-71.7% relative to the receiving LLM, with modest reductions in performance. On one benchmark, SOM-to-SOM routing achieved 91.1% accuracy, compared with 82.3% and 82.2% for the individual models. Discussion SOMs offered favorable performance-cost tradeoffs for most tasks. The magnitude of the advantages depended on task structure and prompting requirements. Confidence-based routing between SOMs and LLMs can leverage complementary model strengths and offers additional flexibility in performance-cost tradeoffs. The price advantages offered by SOMs can facilitate experimentation and development of workflows. This warrants further evaluation on closed datasets. Conclusion For biomedical tasks with predefined choices, SOMs represent a competitive stand-alone or first-stage approach.","rel_num_authors":6,"rel_authors":[{"author_name":"Anthony F Chen","author_inst":"Stanford"},{"author_name":"Albert Yang","author_inst":"Georgia Institute of Technology"},{"author_name":"Daniel R Guth","author_inst":"Stanford University"},{"author_name":"Frederic M Berl","author_inst":"Helarctos"},{"author_name":"Stephen C Guth","author_inst":"UC Law San Francisco"},{"author_name":"William Yuan","author_inst":"NYU Grossman School of Medicine"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Data-driven modeling of trigeminal nerve shape reveals pain-associated morphology in trigeminal neuralgia","rel_doi":"10.64898\/2026.11.11.26367487","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.11.26367487","rel_abs":"Although the leading theory for the cause of trigeminal neuralgia (TN) is neurovascular compression, compression alone does not fully explain which nerves are painful. Recent work has demonstrated that pain in TN is associated with morphological changes of the trigeminal nerve, which may be a result of specific forms of compression or other disease processes. These changes have so far been quantified by hand-crafted geometric measurements, which can miss higher-order characteristics of the anatomy that are difficult to visualize. In this study, we use a cohort of 479 patients with TN who underwent microvascular decompression and had high-resolution pre-operative MRI scans to determine whether data-driven 3D shape features of the trigeminal nerve capture pain-associated morphology better than predefined metrics. We find that a predictive model using our shape features can distinguish nerves implicated in pain from those without pain in a held-out test cohort with an area under the receiver operating characteristic curve (AUROC) of 0.719, compared with 0.626 for a model using existing hand-crafted measurements (p=0.005). Our study identifies candidate nerve morphology biomarkers of TN pain through data-driven shape analysis and demonstrates that these higher-order features relate better to symptoms of TN than conventional shape metrics.","rel_num_authors":10,"rel_authors":[{"author_name":"Michael E. Xie","author_inst":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD"},{"author_name":"Haoyuan Liang","author_inst":"Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD"},{"author_name":"Xihang Wang","author_inst":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD"},{"author_name":"Vivek Yedavalli","author_inst":"Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD"},{"author_name":"Christopher Jackson","author_inst":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD"},{"author_name":"Michael Lim","author_inst":"Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA"},{"author_name":"Judy Huang","author_inst":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD"},{"author_name":"Chetan Bettegowda","author_inst":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD"},{"author_name":"Peirong Liu","author_inst":"Department of Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD"},{"author_name":"Risheng Xu","author_inst":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Safety of Bio-Interventional Uveoscleral Outflow Enhancement: Twelve-Month Post-Operative Results from 395 Eyes in the CREST Study","rel_doi":"10.64898\/2026.11.12.26367928","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.12.26367928","rel_abs":"PurposeTo characterize 12-month ocular safety of bio-interventional uveoscleral outflow enhancement in open-angle glaucoma (OAG).\n\nDesignProspective, multicenter real-world evidence study (CREST; NCT05506423).\n\nParticipantsAdults with OAG treated by bio-interventional uveoscleral outflow enhancement with acellular scleral allograft spacers (AlloFlo, Iantrek, Inc.), standalone or with phacoemulsification, reaching 12 months of follow-up.\n\nMethodsAdverse events were captured prospectively at each protocol-specified visit against pre-defined definitions; data were analyzed at the eye level.\n\nMain Outcome MeasuresPre-specified ocular safety endpoints: adverse events, clinically significant hypotony, sustained intraocular pressure (IOP) elevation [&ge;] 10 mmHg beyond 30 days, allograft migration, corneal endothelial decompensation, secondary incisional glaucoma surgery, and endothelial cell density.\n\nResultsOf 395 eyes (mean age 72.8 years; 52% female), 267 were combined with phacoemulsification (Cohort 1) and 128 standalone (Cohort 2). Medicated IOP decreased from 19.1 to 14.5 mmHg (p < 0.001) and medications from 1.9 to 1.2, with 42% medication-free. Sustained IOP elevation occurred in 34 eyes (8.6%), BCVA loss [&ge;] 2 lines in 15 (3.8%), hyphema > 2 mm in 6 (1.5%) and hypotony in 1 (0.3%). Two allograft spacers entered the anterior chamber in one eye and were successfully repositioned intraoperatively. Serious events occurred in 12 eyes (3.0%). In the N=91 eyes with paired specular microscopy data, endothelial cell density changed -6.5% (-8.7%, -4.4%). There were no reports of endothelial decompensation, endophthalmitis, or sympathetic ophthalmia.\n\nConclusionsThrough 12 months no endothelial decompensation, endophthalmitis or sympathetic ophthalmia occurred, and most events were self-limiting or medically managed. Endothelial cell loss tracked concurrent cataract surgery rather than the allograft, though that subgroup is small. Follow-up remains shorter than the interval over which an earlier supraciliary microstent diverged from controls.\n\nTrial RegistrationClinicalTrials.gov (NCT05506423.)","rel_num_authors":6,"rel_authors":[{"author_name":"Douglas Rhee","author_inst":"Case Western Reserve University School of Medicine"},{"author_name":"James Lewis","author_inst":"SightMd"},{"author_name":"Ticiana De Francesco","author_inst":"University of Utah John A. Moran Eye Center"},{"author_name":"Kiper Nelson","author_inst":"Southern Eye Center"},{"author_name":"Tsontcho Ianchulev","author_inst":"New York Eye and Ear of Mount Sinai"},{"author_name":"Steven R. Sarkisian Jr.","author_inst":"Oklahoma Eye Surgeons"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"CONSORTiUM-IO: A Phase 1 Study Evaluating VE800 Plus Nivolumab in Treatment of Select Refractory or Metastatic Cancers","rel_doi":"10.64898\/2026.11.13.26368051","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26368051","rel_abs":"Microbiome modulation can augment responses to immunotherapy in advanced cancer. Early studies of anti-PD-1 therapies in combination with fecal microbiota transplantation (FMT) reported efficacy in immunotherapy-naive and -refractory settings. However, FMTs are variable in composition, difficult to scale, and risk the transfer of emerging pathogens. VE800 is a consortium of 11 strains of commensal bacteria derived from healthy donors and grown from clonal cell banks. VE800 increased anti-PD-1 efficacy in preclinical models of cancer. CONSORTiUM-IO was a first-in-human, open-label phase 1 study that evaluated safety and efficacy of VE800 with nivolumab in advanced PD-1-refractory melanoma, PD-1-naive gastric\/gastroesophageal junction (G\/GEJ) adenocarcinoma and PD-1-naive microsatellite-stable colorectal cancer (MSS CRC). VE800 plus nivolumab was well tolerated but offered no improvement over historic response rates. Exploratory analyses in patients with melanoma revealed that VE800 strain engraftment was associated with greater progression-free survival (PFS) and increased immune activation peripherally.","rel_num_authors":17,"rel_authors":[{"author_name":"Carolina Lyon De Ana","author_inst":"Glaxo Smith Klein"},{"author_name":"Rajita Menon","author_inst":"Vedanta Biosciences, Inc., Cambridge, MA, USA"},{"author_name":"Shakti K. Bhattarai","author_inst":"Program in Microbiome Dynamics, Department of Microbiology, University of Massachusetts Chan Medical School, Worcester, MA"},{"author_name":"Amanda L Prince","author_inst":"CSL Behring, Waltham, MA"},{"author_name":"Scott Buresh","author_inst":"Tokyo Chemical Industry, Portland, OR"},{"author_name":"Erica Darrah","author_inst":"Veeva Systems, Boston, MA"},{"author_name":"Jason M Norman","author_inst":"Vedanta Biosciences, Inc., Cambridge, MA, USA"},{"author_name":"Rose L Szabady","author_inst":"Ferring Pharmaceuticals, Parsippany, NJ"},{"author_name":"Dmitri Bobilev","author_inst":"Vedanta Biosciences, Inc., Cambridge, MA, USA"},{"author_name":"Bruce Roberts","author_inst":"Vedanta Biosciences, Inc., Cambridge, MA, USA"},{"author_name":"Judy S Wang","author_inst":"Florida Cancer Specialists\/Sarah Cannon Research Institute, Sarasota, FL"},{"author_name":"Vanni Bucci","author_inst":"UMass Medical School"},{"author_name":"Jeremiah J Faith","author_inst":"Icahn School of Medicine at Mount Sinai"},{"author_name":"Jeffrey L Silber","author_inst":"Vedanta Biosciences, Inc., Cambridge, MA, USA"},{"author_name":"Kenya Honda","author_inst":"RIKEN Center for Integrative Medical Sciences, Yokohama, Japan"},{"author_name":"Bernat Olle","author_inst":"Vedanta Biosciences, Inc., Cambridge, MA, USA"},{"author_name":"Diwakar Davar","author_inst":"UPMC Hillman Cancer Center, Pittsburgh, PA"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Hierarchical Graph Learning with Multimodal Distillation for Breast Cancer Survival Prediction","rel_doi":"10.64898\/2026.11.14.26368121","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368121","rel_abs":"Imaging mass cytometry (IMC) and DNA methylation can provide complementary information for breast cancer prognosis, yet these measurements may be unavailable for new patients. In this paper, we propose HEAL-Surv, a teacher-student framework that uses both modalities during training to predict five-year net disease-specific survival (DSS) from clinical variables and molecular profiles at inference. An additive Cox teacher integrates all four modalities, using a hierarchical IMC graph encoder to capture local cell relationships and coarser tissue organisation. The student learns from observed outcomes and cross-fitted teacher survival curves, giving more weight to targets that agree across random initialisations. In five-fold cross-validation on 423 METABRIC patients, the full teacher achieved a mean five-year Uno's concordance of 0.723. Removing any modality reduced mean concordance and increased mean Brier-based errors. Relative to the matched student trained on observed outcomes alone, distillation increased mean five-year Uno's concordance from 0.658 to 0.704, with higher integrated and five-year Brier scores. In a separate external evaluation, an IMC-clinical variant trained on METABRIC achieved a five-year Uno's concordance of 0.660 on 265 Basel patients without refitting. These findings support multimodal supervision for improving risk discrimination with fewer inference inputs, while external validation of the student remains necessary.","rel_num_authors":6,"rel_authors":[{"author_name":"Binh Minh Tran","author_inst":"The University of Sydney"},{"author_name":"Van An Nguyen","author_inst":"Hanoi Medical University"},{"author_name":"Quynh Anh Dang","author_inst":"Hanoi Medical University"},{"author_name":"Minh Hai Nguyen Ngoc","author_inst":"Hanoi Medical University Hospital"},{"author_name":"Hai Nam Tran","author_inst":"University of New South Wales"},{"author_name":"Dang Hung Tran","author_inst":"Hanoi University of Industry"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Hierarchical Graph Learning with Multimodal Distillation for Breast Cancer Survival Prediction","rel_doi":"10.64898\/2026.11.14.26368121","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368121","rel_abs":"Imaging mass cytometry (IMC) and DNA methylation can provide complementary information for breast cancer prognosis, yet these measurements may be unavailable for new patients. In this paper, we propose HEAL-Surv, a teacher-student framework that uses both modalities during training to predict five-year net disease-specific survival (DSS) from clinical variables and molecular profiles at inference. An additive Cox teacher integrates all four modalities, using a hierarchical IMC graph encoder to capture local cell relationships and coarser tissue organisation. The student learns from observed outcomes and cross-fitted teacher survival curves, giving more weight to targets that agree across random initialisations. In five-fold cross-validation on 423 METABRIC patients, the full teacher achieved a mean five-year Uno's concordance of 0.723. Removing any modality reduced mean concordance and increased mean Brier-based errors. Relative to the matched student trained on observed outcomes alone, distillation increased mean five-year Uno's concordance from 0.658 to 0.704, with higher integrated and five-year Brier scores. In a separate external evaluation, an IMC-clinical variant trained on METABRIC achieved a five-year Uno's concordance of 0.660 on 265 Basel patients without refitting. These findings support multimodal supervision for improving risk discrimination with fewer inference inputs, while external validation of the student remains necessary.","rel_num_authors":6,"rel_authors":[{"author_name":"Binh Minh Tran","author_inst":"The University of Sydney"},{"author_name":"Van An Nguyen","author_inst":"Hanoi Medical University"},{"author_name":"Quynh Anh Dang","author_inst":"Hanoi Medical University"},{"author_name":"Minh Hai Nguyen Ngoc","author_inst":"Hanoi Medical University Hospital"},{"author_name":"Hai Nam Tran","author_inst":"University of New South Wales"},{"author_name":"Dang Hung Tran","author_inst":"Hanoi University of Industry"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Deep learning of point-of-care lung ultrasound and clinical data for pulmonary tuberculosis triage in Uganda","rel_doi":"10.64898\/2026.11.14.26368125","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368125","rel_abs":"Rationale: Point of care lung ultrasound is portable and radiation free and could extend tuberculosis screening to settings without chest radiography, but no standardized criteria exist for interpreting it for tuberculosis. Objectives: To develop and internally evaluate deep learning models that classify pulmonary tuberculosis from lung ultrasound images, alone and combined with routine clinical variables, and to derive an abbreviated scanning protocol. Methods: In a prospective study in Kampala, Uganda (2023 to 2025), we enrolled people aged 13 years or older with microbiologically confirmed pulmonary tuberculosis, their household contacts, and symptomatic people with other respiratory conditions. One still frame from each of 12 lung ultrasound zones was analyzed with an attention-based multiple-instance learning network. We compared clinical-only (random forest), ultrasound only, and combined models and derived a 6 zone protocol from training set attention weights. Participants were allocated to training (n = 223), validation (n = 20), and held-out test (n = 73) sets. Results: Of 318 enrolled participants, 316 were analyzed (118 with and 198 without tuberculosis). In the test set, areas under the receiver operating characteristic curve were 0.88 (95% confidence interval, 0.80 to 0.95) for the clinical-only model; 0.93 (0.86 to 0.97) and 0.95 (0.89 to 0.99) for the 12 zone ultrasound-only and combined models; and 0.91 (0.83 to 0.97) and 0.93 (0.86 to 0.99) for the corresponding 6-zone models. At 90% sensitivity, specificity was 82.2% (34.9 to 97.8) for the 12-zone combined model and 91.1% (25.0 to 98.0) for the 6-zone combined model. Point estimates for all 12-zone models and the 6-zone combined model met the 2025 World Health Organization minimum accuracy targets for a high-sensitivity screening test ([&ge;]90% sensitivity, [&ge;]60% specificity). Conclusion: Lung ultrasound analyzed with attention-based deep learning and combined with clinical variables showed high internal discrimination for pulmonary tuberculosis, and a simplified 6-zone protocol retained most of this performance. External validation in intended-use screening populations is needed","rel_num_authors":13,"rel_authors":[{"author_name":"Akanksha Sharma","author_inst":"Emory University"},{"author_name":"Lydia Nakiyingi","author_inst":"Makerere University Infectious Diseases Institute"},{"author_name":"Elena Jovanovska Janeva","author_inst":"Rutgers university"},{"author_name":"Keith Guevarra","author_inst":"Rutgers New Jersey Medical School"},{"author_name":"Wycliff Nate","author_inst":"Makerere University, Infectious Diseases Institute, Kampala, Uganda"},{"author_name":"Eva Nabawanuka","author_inst":"Mulago National Referral Hospital, Department of Radiology, Kampala, Uganda"},{"author_name":"Raphael Shankman","author_inst":"Rutgers New Jersey Medical School"},{"author_name":"Rohan Dhamdhere","author_inst":"Georgia Institute of Technology and Emory University"},{"author_name":"Guadalupe Astorga","author_inst":"Rutgers New Jersey Medical School,"},{"author_name":"Moses  Lutaakome Joloba","author_inst":"MakCHS: Makerere University College of Health Sciences"},{"author_name":"Jerrold Ellner","author_inst":"Rutgers New Jersey Medical School"},{"author_name":"Anant Madabhushi","author_inst":"Emory University"},{"author_name":"Yingda Linda Xie","author_inst":"Rutgers New Jersey Medical School"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Deep learning of point-of-care lung ultrasound and clinical data for pulmonary tuberculosis triage in Uganda","rel_doi":"10.64898\/2026.11.14.26368125","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368125","rel_abs":"Rationale: Point of care lung ultrasound is portable and radiation free and could extend tuberculosis screening to settings without chest radiography, but no standardized criteria exist for interpreting it for tuberculosis. Objectives: To develop and internally evaluate deep learning models that classify pulmonary tuberculosis from lung ultrasound images, alone and combined with routine clinical variables, and to derive an abbreviated scanning protocol. Methods: In a prospective study in Kampala, Uganda (2023 to 2025), we enrolled people aged 13 years or older with microbiologically confirmed pulmonary tuberculosis, their household contacts, and symptomatic people with other respiratory conditions. One still frame from each of 12 lung ultrasound zones was analyzed with an attention-based multiple-instance learning network. We compared clinical-only (random forest), ultrasound only, and combined models and derived a 6 zone protocol from training set attention weights. Participants were allocated to training (n = 223), validation (n = 20), and held-out test (n = 73) sets. Results: Of 318 enrolled participants, 316 were analyzed (118 with and 198 without tuberculosis). In the test set, areas under the receiver operating characteristic curve were 0.88 (95% confidence interval, 0.80 to 0.95) for the clinical-only model; 0.93 (0.86 to 0.97) and 0.95 (0.89 to 0.99) for the 12 zone ultrasound-only and combined models; and 0.91 (0.83 to 0.97) and 0.93 (0.86 to 0.99) for the corresponding 6-zone models. At 90% sensitivity, specificity was 82.2% (34.9 to 97.8) for the 12-zone combined model and 91.1% (25.0 to 98.0) for the 6-zone combined model. Point estimates for all 12-zone models and the 6-zone combined model met the 2025 World Health Organization minimum accuracy targets for a high-sensitivity screening test ([&ge;]90% sensitivity, [&ge;]60% specificity). Conclusion: Lung ultrasound analyzed with attention-based deep learning and combined with clinical variables showed high internal discrimination for pulmonary tuberculosis, and a simplified 6-zone protocol retained most of this performance. External validation in intended-use screening populations is needed","rel_num_authors":13,"rel_authors":[{"author_name":"Akanksha Sharma","author_inst":"Emory University"},{"author_name":"Lydia Nakiyingi","author_inst":"Makerere University Infectious Diseases Institute"},{"author_name":"Elena Jovanovska Janeva","author_inst":"Rutgers university"},{"author_name":"Keith Guevarra","author_inst":"Rutgers New Jersey Medical School"},{"author_name":"Wycliff Nate","author_inst":"Makerere University, Infectious Diseases Institute, Kampala, Uganda"},{"author_name":"Eva Nabawanuka","author_inst":"Mulago National Referral Hospital, Department of Radiology, Kampala, Uganda"},{"author_name":"Raphael Shankman","author_inst":"Rutgers New Jersey Medical School"},{"author_name":"Rohan Dhamdhere","author_inst":"Georgia Institute of Technology and Emory University"},{"author_name":"Guadalupe Astorga","author_inst":"Rutgers New Jersey Medical School,"},{"author_name":"Moses  Lutaakome Joloba","author_inst":"MakCHS: Makerere University College of Health Sciences"},{"author_name":"Jerrold Ellner","author_inst":"Rutgers New Jersey Medical School"},{"author_name":"Anant Madabhushi","author_inst":"Emory University"},{"author_name":"Yingda Linda Xie","author_inst":"Rutgers New Jersey Medical School"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Deep learning of point-of-care lung ultrasound and clinical data for pulmonary tuberculosis triage in Uganda","rel_doi":"10.64898\/2026.11.14.26368125","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368125","rel_abs":"Rationale: Point of care lung ultrasound is portable and radiation free and could extend tuberculosis screening to settings without chest radiography, but no standardized criteria exist for interpreting it for tuberculosis. Objectives: To develop and internally evaluate deep learning models that classify pulmonary tuberculosis from lung ultrasound images, alone and combined with routine clinical variables, and to derive an abbreviated scanning protocol. Methods: In a prospective study in Kampala, Uganda (2023 to 2025), we enrolled people aged 13 years or older with microbiologically confirmed pulmonary tuberculosis, their household contacts, and symptomatic people with other respiratory conditions. One still frame from each of 12 lung ultrasound zones was analyzed with an attention-based multiple-instance learning network. We compared clinical-only (random forest), ultrasound only, and combined models and derived a 6 zone protocol from training set attention weights. Participants were allocated to training (n = 223), validation (n = 20), and held-out test (n = 73) sets. Results: Of 318 enrolled participants, 316 were analyzed (118 with and 198 without tuberculosis). In the test set, areas under the receiver operating characteristic curve were 0.88 (95% confidence interval, 0.80 to 0.95) for the clinical-only model; 0.93 (0.86 to 0.97) and 0.95 (0.89 to 0.99) for the 12 zone ultrasound-only and combined models; and 0.91 (0.83 to 0.97) and 0.93 (0.86 to 0.99) for the corresponding 6-zone models. At 90% sensitivity, specificity was 82.2% (34.9 to 97.8) for the 12-zone combined model and 91.1% (25.0 to 98.0) for the 6-zone combined model. Point estimates for all 12-zone models and the 6-zone combined model met the 2025 World Health Organization minimum accuracy targets for a high-sensitivity screening test ([&ge;]90% sensitivity, [&ge;]60% specificity). Conclusion: Lung ultrasound analyzed with attention-based deep learning and combined with clinical variables showed high internal discrimination for pulmonary tuberculosis, and a simplified 6-zone protocol retained most of this performance. External validation in intended-use screening populations is needed","rel_num_authors":13,"rel_authors":[{"author_name":"Akanksha Sharma","author_inst":"Emory University"},{"author_name":"Lydia Nakiyingi","author_inst":"Makerere University Infectious Diseases Institute"},{"author_name":"Elena Jovanovska Janeva","author_inst":"Rutgers university"},{"author_name":"Keith Guevarra","author_inst":"Rutgers New Jersey Medical School"},{"author_name":"Wycliff Nate","author_inst":"Makerere University, Infectious Diseases Institute, Kampala, Uganda"},{"author_name":"Eva Nabawanuka","author_inst":"Mulago National Referral Hospital, Department of Radiology, Kampala, Uganda"},{"author_name":"Raphael Shankman","author_inst":"Rutgers New Jersey Medical School"},{"author_name":"Rohan Dhamdhere","author_inst":"Georgia Institute of Technology and Emory University"},{"author_name":"Guadalupe Astorga","author_inst":"Rutgers New Jersey Medical School,"},{"author_name":"Moses  Lutaakome Joloba","author_inst":"MakCHS: Makerere University College of Health Sciences"},{"author_name":"Jerrold Ellner","author_inst":"Rutgers New Jersey Medical School"},{"author_name":"Anant Madabhushi","author_inst":"Emory University"},{"author_name":"Yingda Linda Xie","author_inst":"Rutgers New Jersey Medical School"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Practical evaluation of AI models to forecast a respiratory seasonal epidemic in Canada","rel_doi":"10.64898\/2026.11.14.26368122","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368122","rel_abs":"Public health organizations can benefit greatly from infectious disease epidemic forecasting to guide and support interventions and policies that reduce morbidity. However, accurate and reliable epidemic forecasting remains notoriously challenging and is an evolving field in which new scientific advances continue to support forecasting efforts. Computational models that underpin artificial intelligence (AI) models are promising developments that may improve seasonal epidemic forecasting. This study aims to compare the performance of a selection of AI models previously identified as well adapted to epidemic forecasting, including machine learning (XGBoost), deep learning models (Long Short-Term Memory (LSTM), Gated Recurrent Unit (GRU), Transformer), time-series foundation model (Chronos), and a hybrid model: physics-informed neural networks (PINNs), against statistical models (Autoregressive Integrated Moving Average (ARIMA), Prophet) and a compartmental epidemiological model (CEM) in seasonal epidemic forecasting across Canada. The study uses weekly positivity-rate incidence of seasonal influenza A across eight Canadian provinces during the 2025\/2026 season as a test case. Each model generated short-term (up to 5 weeks ahead) forecasts independently for each province from October 11, 2025, to March 28, 2026. We evaluated performance using mean absolute error (MAE) for each province. Our results show that AI models, specifically GRU, Transformer, and Chronos models, achieve lower MAE than CEM in four of eight provinces (Alberta, British Columbia, Prince Edward Island, and Saskatchewan). Meanwhile, CEM and ARIMA outperform all AI models in three provinces (Ontario, Quebec, Manitoba) and one province (Nova Scotia), respectively. Furthermore, data pooling strategies that leverage multi-province data for the target virus or multi-virus data within individual provinces greatly improve deep learning models, and Chronos performs well under zero-shot forecasting in British Columbia. In contrast, Prophet always has the highest MAE, and PINN is worse than CEMs. Overall, AI models performed comparably to, or slightly better than, CEMs. However, these modest gains may not offset their lack of interpretability, high computational costs, and reliance on the specialized expertise required for implementation. We therefore conclude that AI models are best as a complement, rather than a replacement, to CEMs, which remain crucial for interpretability and informing decision-making.","rel_num_authors":4,"rel_authors":[{"author_name":"Benjamin Longaou Benteke","author_inst":"University of Guelph"},{"author_name":"Warsame Yusuf","author_inst":"Public Health Agency of Canada"},{"author_name":"Monica Gabriela Cojocaru","author_inst":"University of Guelph"},{"author_name":"David Champredon","author_inst":"Public Health Agency of Canada"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Changes in Resting-State Functional Network Specialization in Progressive Supranuclear Palsy","rel_doi":"10.64898\/2026.11.14.26367857","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26367857","rel_abs":"Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy characterized by heterogeneous clinical presentations and disruption of distributed neural networks. Resting-state functional MRI (rs-fMRI) provides a systems-level approach to examine intrinsic brain connectivity and may offer insights into disease-related network dysfunction. In this study, we compared rs-fMRI connectivity measures between individuals with PSP and healthy controls and explored differences across PSP clinical variants. 23 participants with probable or possible PSP and 23 age- and sex-matched healthy controls underwent structural and functional MRI. Graph theory metrics and functional connectivity measures across seven canonical resting-state networks were analyzed. Clinical severity was assessed using the PSP Rating Scale (PSPRS) and cognitive measures including the Montreal Cognitive Assessment (MoCA) and frontal assessment battery (FAB). Compared with controls, participants with PSP demonstrated significantly reduced global network modularity and segregation, indicating decreased functional network specialization. Functional connectivity was significantly reduced in multiple large-scale networks, including frontoparietal control, default mode, dorsal attention, somatomotor, and visual networks. No significant differences in graph theory metrics or network connectivity were observed between PSP clinical variants. These findings suggest that PSP is associated with widespread disruption of intrinsic functional networks, reflected by reduced modular organization and network segregation across several canonical resting-state systems while preserving local nodal clustering and global efficiency. Network-level alterations appear broadly similar across clinical variants, supporting the concept that PSP represents a distributed network disorder.","rel_num_authors":5,"rel_authors":[{"author_name":"Juan Vazquez","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Anja Soldan","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Marilyn Albert","author_inst":"Johns Hopkins University"},{"author_name":"Hanzhang Lu","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Alexander Pantelyat","author_inst":"Johns Hopkins University School of Medicine"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"White Matter Pathway-Specific Effects of Subthalamic Deep Brain Stimulation on Vergence Motor Strategy and Binocular Stability","rel_doi":"10.64898\/2026.11.14.26368127","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368127","rel_abs":"Objective: Clear vision across viewing distances requires the eyes to achieve binocular alignment and hold it steady. Alignment can be established through smooth dysconjugate eye movement, vergence, alone or in conjunction with rapid saccades. The circuits governing movement strategy and subsequent gaze holding remain less understood. Methods: We used subthalamic nucleus (STN) deep brain stimulation (DBS) to probe these components in 23 participants with Parkinson disease (PD), comparing binocular eye movements with stimulation on and off and relating behavioral changes to modeled stimulation anatomy. Results: Combined saccade vergence responses predominated in both stimulation states, but individual strategy changes were associated with stimulation location. Greater field of Forel coverage was associated with reduced saccade assisted divergence, and stimulation anatomy helped predict individual changes in this movement strategy. Greater right associative STN coverage correlated with shorter convergence latency. The clearest group effect emerged after movement ended; DBS reduced gaze-holding variance by 37.0% after convergence and 29.4% after divergence, an overall reduction of 33.3% (95% confidence interval, 13.7 to 49.3%; p=0.008). Participants with improved gaze holding had numerically greater modeled exposure to Forel and cerebellothalamic pathways. Conclusions: These findings suggest distinct contributions of associative STN to initiation, consistent with go\/no-go control, and Forel pathways to movement strategy. Improved gaze holding raises the novel possibility that stimulation engaging Forel and cerebellar outflow pathways enhances vergence neural integration. Significance: Binocular eye movements reveal how basal ganglia and cerebellar pathways establish movement strategy and sustain alignment, guiding targeted stimulation studies in PD.","rel_num_authors":5,"rel_authors":[{"author_name":"Ibrahim Quagraine","author_inst":"Case Western Reserve Univerity"},{"author_name":"Aratrik Guha","author_inst":"Case Western Reserve University University"},{"author_name":"Camilla Kilbane","author_inst":"Case Western Reserve University"},{"author_name":"Fatema F Ghasia","author_inst":"Cleveland Clinic"},{"author_name":"Aasef G Shaikh","author_inst":"Case Western Reserve University"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Sex and Gender Reporting and Female Participation Relative to Disease Burden in ClinicalTrials.gov","rel_doi":"10.64898\/2026.11.14.26368113","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368113","rel_abs":"Importance: Assessing representation by sex assigned at birth and gender identity requires reporting of both in trials. If disclosure of full gender and sex participation from clinicaltrials.gov is limited, it poses challenges in characterization and understanding of those participant experiences. Objective: To determine how often ClinicalTrials.gov trials published trials report sex and gender, which characteristics are associated with reporting, and how participants' female share compares with that of the general public. Design, Setting, and Participants: Cross-sectional study of interventional trials registered to ClinicalTrials.gov, with or without US sites, with primary completion on or after September 27, 2008, and results first posted from January 1, 2009, through April 30, 2026. Exposures: Funder type, phase, US sites, enrollment, primary completion year, number of countries, and therapeutic area. Main Outcomes and Measures: Reporting of sex and gender, and the female participation-to-prevalence ratio (PPR; trial female share divided by the number of people with the condition). Results: Among 58,007 trials (median enrollment, 72 [IQR, 31 to 206]; 42,644 [74%] with US sites), 553 (0.95%) reported gender and 57,683 (99.44%) reported sex. Gender reporting was more common with National Institutes of Health (NIH) funding (odds ratio [OR], 9.05; 95% CI, 6.65 to 12.6), US sites (OR, 4.21; 95% CI, 2.96 to 6.22), and larger enrollment. Across 10 conditions (15,552 mixed-sex trials), median PPR ranged from 0.68 (95% CI, 0.64 to 0.71) for chronic obstructive pulmonary disease to 1.05 (95% CI, 1.01 to 1.09) for obesity and had a relatively lower female share in 8. Among the 10 conditions most prevalent in our cohort, 6,917 of 16,097 trial condition combinations (43.0%) reached a PPR of at least 0.90; odds of reaching it were higher for NIH-funded (OR, 1.22; 95% CI, 1.11 to 1.34) and lower for government-funded trials (OR, 0.26; 95% CI, 0.20 to 0.33) as compared to industry-funded trials. Conclusions and Relevance: In ClinicalTrials.gov, sex reporting is nearly universal, whereas gender reporting is concentrated among NIH-funded, US-based, and larger trials. Female trial enrollment fell below the female share of people with the condition for most conditions, emphasizing the benefit of condition-specific benchmarks in clinical trials.","rel_num_authors":9,"rel_authors":[{"author_name":"Michael D. Green","author_inst":"Johns Hopkins Bloomberg School of Public Health"},{"author_name":"Maryam Aziz","author_inst":"Duke University School of Medicine"},{"author_name":"Rebecca D. Sullenger","author_inst":"Duke University School of Medicine"},{"author_name":"Brandon J. Yoo","author_inst":"Johns Hopkins Bloomberg School of Public Health"},{"author_name":"Emily C. O'Brien","author_inst":"Duke University School of Medicine"},{"author_name":"Ann Marie Navar","author_inst":"University of Texas Southwestern"},{"author_name":"Brenice Duroseau","author_inst":"Duke University School of Nursing"},{"author_name":"Roland J. Thorpe Jr.","author_inst":"Johns Hopkins Bloomberg School of Public Health"},{"author_name":"Carly L. Brantner","author_inst":"Duke University School of Medicine"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Molecular age of Barrett's esophagus indicates onset often occurs decades before diagnosis","rel_doi":"10.64898\/2026.11.13.26367463","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26367463","rel_abs":"Background Timely identification of Barrett's esophagus (BE) is crucial for early esophageal adenocarcinoma (EAC) detection. Screening is recommended from age 50 in individuals with additional risk factors, but biological BE onset age remains unknown. Objective Estimate biological BE onset age and duration before clinical diagnosis (dwell time). Design We applied a BE epigenetic clock to 61 samples from 41 patients in a population-representative Northern Ireland cohort and 164 samples from 140 patients in an independent UK cohort. BE dwell times were compared between patients with concurrent dysplasia\/EAC and age- and sex-matched non-dysplastic BE controls in these cross-sectional studies. In a longitudinal cohort, pre-progression biopsies from 31 future high-grade dysplasia (HGD)\/EAC progressors were compared with 35 non-progressors. Results Median estimated BE onset ages in the cross-sectional cohorts were 29.5 (IQR=22.5-45.8) and 29.3 (IQR=20.4-39.0) years, respectively. These estimates were further supported by independent epidemiologic modeling of age-specific BE prevalence data from more than 70,000 BE cases. Estimated dwell times were longer in patients with concurrent dysplasia (median difference 14.3 years; p=0.0042) or EAC (12.5 years; p=0.0002) than matched non-dysplastic BE controls. Dwell time exceeding 19.8 years was associated with higher odds of HGD\/EAC progression (OR=12.1, 95% CI 3.7-47.5; p=9.96 x 10-9;). Conclusion BE may arise decades before diagnosis. Although these findings do not justify lowering screening age, they suggest one-time screening from age 50 years may detect existing high-risk BE. Further modeling is warranted to evaluate implications for population-based screening, alongside prospective validation of epigenetic tissue age for progression risk stratification.","rel_num_authors":15,"rel_authors":[{"author_name":"Talita Oliveira","author_inst":"Queen's University Belfast"},{"author_name":"Samuel R. Reynolds","author_inst":"University of California, San Diego"},{"author_name":"Enya Scanlon","author_inst":"Queen's University Belfast"},{"author_name":"Victoria Child","author_inst":"Queen's University Belfast"},{"author_name":"Damian T. McManus","author_inst":"Queen's University Belfast"},{"author_name":"Brian Johnston","author_inst":"Belfast Health & Social Care Trust"},{"author_name":"Zhijian Hu","author_inst":"University of California, San Diego"},{"author_name":"Sarah Killcoyne","author_inst":"University of Cambridge"},{"author_name":"Barbara Nutzinger","author_inst":"University of Cambridge"},{"author_name":"Ginny Devonshire","author_inst":"University of Cambridge"},{"author_name":"Rebecca C. Fitzgerald","author_inst":"University of Cambridge"},{"author_name":"Richard C. Turkington","author_inst":"Queen's University Belfast"},{"author_name":"Amy Jayne McKnight","author_inst":"Queen's University Belfast"},{"author_name":"Helen G. Coleman","author_inst":"Queen's University Belfast"},{"author_name":"Kit Curtius","author_inst":"University of California, San Diego"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Efficacy of an early first dose of whole-cell pertussis vaccine in infants for the prevention of IgE-mediated food allergy: A randomised controlled trial","rel_doi":"10.64898\/2026.11.13.26367163","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26367163","rel_abs":"Background Evidence from mechanistic and observational studies suggests that replacing the first acellular pertussis (aP) vaccine dose in early infancy with a whole-cell pertussis (wP)-containing vaccine may reduce the risk of developing IgE-mediated food allergy during childhood. Objective We aimed to determine if a dose of wP at approximately 6 weeks old, in lieu of aP vaccine, could reduce the incidence of food allergy in infants. Methods In this multicentre, randomised, participant and outcome assessor-blinded, parallel, two-stage, Bayesian adaptive trial we assigned Australian infants to one of two pertussis vaccination schedules. These consisted of either a standard homologous priming with a hexavalent combination aP vaccine (diphtheria, tetanus, aP, hepatitis B, inactivated poliovirus types 1, 2, and 3, and Haemophilus influenzae type b; DTaP-HepB-IPV-Hib) at approximately 6 weeks, 4 months and 6 months old ( aP-only&rsquo schedule), or a first dose of a WHO-prequalified pentavalent wP combination vaccine (DTwP-HepB-Hib; Pentabio, PT Bio Farma Indonesia) at approximately 6 weeks old, followed by hexavalent aP combination vaccine at approximately 4 months and 6 months old ( mixed wP\/aP&rsquo schedule). The primary outcome was physician-confirmed food allergy by age 12 months requiring both evidence of sensitisation and compatible symptoms in response to either incidental or medically supervised oral food challenge. The initial target sample size was 3,000 enrolments to provide approximately 85% power to detect a policy-relevant 3 percentage point reduction in the risk of the primary outcome. Results A total of 972 infants were enrolled, 486 in each study arm. Of these, 26 of 486 (5.3%) assigned to the aP-only group and 31 of 486 (6.4%) assigned to the mixed wP\/aP schedule met the primary endpoint definition. The posterior median difference (95% credible interval) in food allergy among recipients of the mixed wP\/aP schedule compared to recipients of the aP-only schedule was 0.01 (-0.02, 0.04; probability [<0] 0.25). There were six serious adverse events (SAEs) among children receiving the aP-only group versus 12 among children receiving the mixed wP\/aP schedule; one SAE (hospitalisation for irritability; length of stay < 48 hours) was deemed related to wP vaccine. The trial was stopped early owing to operational reasons. Conclusions There is a low probability of a policy-relevant reduction in food allergy in infants receiving mixed wP\/aP versus aP-only pertussis vaccine schedules. Funded by the National Health and Medical Research Council of Australia; ANZCTR number, ACTRN12617000065392p. Clinical implications An early first dose of wP is unlikely to afford a policy-relevant reduction in the probability of developing food allergy, eczema or atopic sensitisation in infants. Capsule summary An early first dose of a 5-in-1 wP combination vaccine is reasonably tolerated but would not be expected to have a material impact on the prevalence of food allergy in infants. Key words Diphtheria-Tetanus-Pertussis Vaccine. Diphtheria-Tetanus-acellular Pertussis Vaccines. Food Hypersensitivity. Infant. Australia.","rel_num_authors":24,"rel_authors":[{"author_name":"Gladymar Perez Chacon","author_inst":"Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia"},{"author_name":"James Totterdell","author_inst":"Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia."},{"author_name":"Marie J. Estcourt","author_inst":"Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia."},{"author_name":"Kirsten P. Perrett","author_inst":"Department of Allergy and Immunology, Royal Children's Hospital, Parkville, Victoria, Australia."},{"author_name":"Dianne E. Campbell","author_inst":"Discipline of Child and Adolescent Health, The University of Sydney, Sydney, New South Wales, Australia."},{"author_name":"Julie A. Marsh","author_inst":"Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia."},{"author_name":"Nicholas Wood","author_inst":"Discipline of Child and Adolescent Health, The University of Sydney, Sydney, New South Wales, Australia."},{"author_name":"Adam W. Bartlett","author_inst":"Department of Infectious Diseases, Sydney Children's Hospital, Randwick, Sydney, New South Wales, Australia."},{"author_name":"Phoebe C.M. Williams","author_inst":"Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia."},{"author_name":"Michael D. O'Sullivan","author_inst":"Department of Immunology, Perth Children's Hospital , Nedlands, Western Australia, Australia."},{"author_name":"Claire S. Waddington","author_inst":"Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom."},{"author_name":"Nicole L. Messina","author_inst":"Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia."},{"author_name":"Brynn Wainstein","author_inst":"Department of Immunology, Sydney Children's Hospital, Randwick, Sydney, New South Wales, Australia."},{"author_name":"Peter Hsu","author_inst":"The Children's Hospital at Westmead, Westmead, Australia."},{"author_name":"Sonia McAlister","author_inst":"Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia."},{"author_name":"Mark A. Jones","author_inst":"Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia."},{"author_name":"Catherine Hughes","author_inst":"Immunisation Foundation of Australia, Australia."},{"author_name":"Ushma Wadia","author_inst":"Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia."},{"author_name":"Peter B. McIntyre","author_inst":"Dunedin School of Medicine, University of Otago, Dunedin, New Zealand."},{"author_name":"Nigel Curtis","author_inst":"Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia."},{"author_name":"Michael Gold","author_inst":"Discipline of Paediatrics, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia."},{"author_name":"Patrick G. Holt","author_inst":"Wal-yan Respiratory Research Centre, The Kids Research Institute Australia, Nedlands, Western Australia, Australia."},{"author_name":"Peter C. Richmond","author_inst":"Division of Paediatrics, School of Medicine, The University of Western Australia, Perth, Western Australia, Australia."},{"author_name":"Tom Snelling","author_inst":"Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia."}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Exome-wide rare-variant associations vary across disease trajectories","rel_doi":"10.64898\/2026.11.14.26368035","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368035","rel_abs":"Genetic studies of chronic disease typically collapse longitudinal clinical histories into binary case-control outcomes, obscuring disease timing and differences in genetic association patterns across disease transitions. Time-to-event analysis can preserve this information, but rare-variant analysis of post-diagnosis progression is challenged by sparse carrier-events and extensive censoring. We developed GATE-GENE, a scalable gene-based framework that maintains calibration under these conditions. Across 300 onset phenotypes in UK Biobank (UKB), GATE-GENE identified 107 exome-wide significant germline associations involving 89 genes and 67 diseases. Across 95 multi-state trajectories comprising baseline (T0), an upstream disease state (T1) and a downstream disease state (T2), disease onset (T0[-&gt;]T1) and subsequent progression (T1[-&gt;]T2) showed limited detectable sharing of rare-variant association signals. Progression showed greater concordance of gene-level association signals with downstream phenotypes (T0[-&gt;]T2) when the analyses shared T2 events occurring after T1. Removing overlapping downstream events reduced the median correlation between gene-level association signals from 0.063 to 0.001, after accounting for background correlation. Null simulations reproduced the relationship between event overlap and concordance without genetic effects, whereas additional simulations showed that near-zero concordance could persist despite extensive underlying causal-gene sharing. This attenuation was reproduced across three ancestry groups in All of Us. Cross-biobank meta-analysis identified 12 additional exome-wide significant progression associations beyond three UKB discoveries, although clinical sensitivity analyses suggested that the strongest PKD1 signals largely reflected underlying cystic kidney disease. Together, these findings establish GATE-GENE for investigating rare-variant associations with disease timing and progression, while demonstrating how overlapping clinical events and limited carrier-event information complicate inference about genetic sharing across disease transitions.","rel_num_authors":15,"rel_authors":[{"author_name":"Ying Wang","author_inst":"Massachusetts General Hospital; Broad Institute of MIT and Harvard; Ohio State University"},{"author_name":"Weijun Luo","author_inst":"College of Computing, Georgia Institute of Technology"},{"author_name":"Linfeng Hu","author_inst":"Massachusetts General Hospital; Broad Institute or MIT and Harvard"},{"author_name":"Tony Chen","author_inst":"Massachusetts General Hospital; Broad Institute or MIT and Harvard"},{"author_name":"Wenhan Lu","author_inst":"Massachusetts General Hospital; Broad Institute or MIT and Harvard"},{"author_name":"Connor Dowd","author_inst":"Broad Institute or MIT and Harvard"},{"author_name":"Cindy Wen","author_inst":"Massachusetts General Hospital; Broad Institute or MIT and Harvard"},{"author_name":"Wenjian Bi","author_inst":"University of Michigan School of Public Health"},{"author_name":"Satoshi Koyama","author_inst":"Massachusetts General Hospital; Broad Institute or MIT and Harvard"},{"author_name":"Ida Surakka","author_inst":"University of Michigan"},{"author_name":"Benjamin M Neale","author_inst":"Massachusetts General Hospital; Broad Institute or MIT and Harvard"},{"author_name":"Mark Daly","author_inst":"Massachusetts General Hospital; Broad Institute or MIT and Harvard"},{"author_name":"Pradeep Nataranjan","author_inst":"Amgen"},{"author_name":"Alicia Martin","author_inst":"Massachusetts General Hospital; Broad Institute or MIT and Harvard"},{"author_name":"Wei Zhou","author_inst":"Massachusetts General Hospital; Broad Institute or MIT and Harvard"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Circulating Apolipoprotein Profiles and Their Associations with Mild Cognitive and Behavioral Impairment in Older Adults: A Cross-Sectional Study","rel_doi":"10.64898\/2026.11.14.26368084","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368084","rel_abs":"Background Mild cognitive impairment (MCI) and mild behavioral impairment (MBI) are overlapping prodromal states associated with dementia risk. Circulating apolipoproteins (Apos) may be linked to cognitive and behavioral changes, but their relationships remain unclear. Objective Examine plasma concentrations of multiple Apos in prodromal dementia. Methods This cross-sectional study included 148 Thai participants aged 60-75 years: 56 cognitively normal controls, 47 with MCI without MBI, and 45 with MBI with or without MCI. We measured ApoA1, ApoA2, ApoB, ApoC1, ApoC3, ApoD, ApoE, ApoH, and ApoJ, five lipids, and APOE genotype, and computed an atherogenic Apo composite (ApoB-ApoC1-ApoC3). Primary analyses used multivariable linear regression of quantitative cognitive and behavioral outcomes. Group comparisons were secondary and served to contextualize the dimensional regression findings. Results Across Montreal Cognitive Assessment (MoCA) models, 20.7-28.2% of variance was explained by combinations of ApoH, ApoC3, APOE {varepsilon}4 carrier status, age, and male sex (inverse associations), and free cholesterol and education (positive associations). The atherogenic composite was inversely associated with MoCA total, memory index, and delayed recall scores, and with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) verbal fluency and word list recall. No significant predictors emerged for Neuropsychiatric Inventory (NPI) scores or NPI caregiver distress. All nine Apos differed significantly between groups, with levels highest in MCI, intermediate in MBI, and lowest in controls. Conclusions Circulating Apo profiles differed across controls, MCI, and MBI groups and were more consistently associated with cognitive than behavioral outcomes. ApoH and the atherogenic Apo composite warrant further investigation as candidate biomarkers of early cognitive dysfunction.","rel_num_authors":6,"rel_authors":[{"author_name":"Arisara Amrapala","author_inst":"Chulalongkorn University"},{"author_name":"Solaphat Hemrungrojn","author_inst":"Chulalongkorn University"},{"author_name":"Natawut Nupairoj","author_inst":"Chulalongkorn University"},{"author_name":"Marco Solmi","author_inst":"University of Ottawa"},{"author_name":"Chavit Tunvirachaisakul","author_inst":"Faculty of Medicine, Chulalongkorn University"},{"author_name":"Michael Maes","author_inst":"University of Electronic Science and Technology of China"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Circulating Apolipoprotein Profiles and Their Associations with Mild Cognitive and Behavioral Impairment in Older Adults: A Cross-Sectional Study","rel_doi":"10.64898\/2026.11.14.26368084","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368084","rel_abs":"Background Mild cognitive impairment (MCI) and mild behavioral impairment (MBI) are overlapping prodromal states associated with dementia risk. Circulating apolipoproteins (Apos) may be linked to cognitive and behavioral changes, but their relationships remain unclear. Objective Examine plasma concentrations of multiple Apos in prodromal dementia. Methods This cross-sectional study included 148 Thai participants aged 60-75 years: 56 cognitively normal controls, 47 with MCI without MBI, and 45 with MBI with or without MCI. We measured ApoA1, ApoA2, ApoB, ApoC1, ApoC3, ApoD, ApoE, ApoH, and ApoJ, five lipids, and APOE genotype, and computed an atherogenic Apo composite (ApoB-ApoC1-ApoC3). Primary analyses used multivariable linear regression of quantitative cognitive and behavioral outcomes. Group comparisons were secondary and served to contextualize the dimensional regression findings. Results Across Montreal Cognitive Assessment (MoCA) models, 20.7-28.2% of variance was explained by combinations of ApoH, ApoC3, APOE {varepsilon}4 carrier status, age, and male sex (inverse associations), and free cholesterol and education (positive associations). The atherogenic composite was inversely associated with MoCA total, memory index, and delayed recall scores, and with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) verbal fluency and word list recall. No significant predictors emerged for Neuropsychiatric Inventory (NPI) scores or NPI caregiver distress. All nine Apos differed significantly between groups, with levels highest in MCI, intermediate in MBI, and lowest in controls. Conclusions Circulating Apo profiles differed across controls, MCI, and MBI groups and were more consistently associated with cognitive than behavioral outcomes. ApoH and the atherogenic Apo composite warrant further investigation as candidate biomarkers of early cognitive dysfunction.","rel_num_authors":6,"rel_authors":[{"author_name":"Arisara Amrapala","author_inst":"Chulalongkorn University"},{"author_name":"Solaphat Hemrungrojn","author_inst":"Chulalongkorn University"},{"author_name":"Natawut Nupairoj","author_inst":"Chulalongkorn University"},{"author_name":"Marco Solmi","author_inst":"University of Ottawa"},{"author_name":"Chavit Tunvirachaisakul","author_inst":"Faculty of Medicine, Chulalongkorn University"},{"author_name":"Michael Maes","author_inst":"University of Electronic Science and Technology of China"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Barriers and facilitators to cervical precancer treatment adherence among women in Harare, Zimbabwe: A qualitative study","rel_doi":"10.64898\/2026.11.13.26368072","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26368072","rel_abs":"Adherence to recommended treatment after a positive cervical screening result remains suboptimal in Zimbabwe. This study explored how women interpreted a cervical precancer diagnosis and how emotional, interpersonal, economic, and health-system factors shaped treatment decisions. We conducted semi-structured in-depth interviews with 25 purposively selected women aged 25-50 years who had screened positive by visual inspection with acetic acid and were recommended for ablative or excisional treatment at two high-volume clinics in Harare. The qualitative component drew on the Health Belief Model and a phenomenological orientation to lived experience. Data were examined using combined deductive and inductive thematic analysis. Three interrelated themes were identified. First, women initially interpreted precancer through fear, shock, and uncertainty; misconceptions that precancer meant invasive cancer, infertility, or imminent death could delay action, whereas clear counselling reframed the diagnosis as treatable. Second, multilevel conditions shaped adherence. Supportive health workers, partner or family encouragement, prior awareness, and connection to HIV services facilitated treatment, while indirect costs, transport, fragmented referral pathways, scheduled excisional services, inconsistent communication, partner opposition, and sexual coercion impeded care. Third, Health Belief Model constructs operated in both directions: perceived severity motivated action when paired with credible benefits and self-efficacy, but produced avoidance when amplified by misinformation and weak support. Improving treatment completion will require standardised counselling, reliable navigation and follow-up, more accessible excisional services, and interventions that address partner dynamics and indirect costs. Screening scale-up should be matched by timely treatment capacity so that women with positive results complete the prevention pathway.","rel_num_authors":5,"rel_authors":[{"author_name":"Belinda Mutibura","author_inst":"University Of Zimbabwe"},{"author_name":"Grant Murewanhema","author_inst":"University of Zimbabwe Faculty of Medicine"},{"author_name":"Zvavahera  Michael Chirenje","author_inst":"University of Zimbabwe Faculty of Medicine"},{"author_name":"Nathan Mhungu","author_inst":"University of Zimbabwe Faculty of Medicine"},{"author_name":"Bothwell  Takaingofa Guzha","author_inst":"University of Zimbabwe Faculty of Medicine"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Wastewater metagenomic sequencing quantitatively tracks transmission dynamics for human pathogenic viruses","rel_doi":"10.64898\/2026.11.13.26368067","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26368067","rel_abs":"Wastewater metagenomic sequencing theoretically characterizes all nucleic acids in a sample, but whether sequencing reads reflect transmission dynamics of circulating viruses in the contributing community is unknown. We evaluated if wastewater metagenomic sequencing data can be used to reconstruct transmission dynamics of endemic, routinely circulating viruses. Using deep, untargeted wastewater metagenomic sequencing data from four locations in the United States, we generated quantitative estimates of transmission dynamics (time-varying growth rate and effective reproduction number) within a Bayesian framework for widely monitored viruses. Across locations and viruses, estimates were statistically concordant with those derived from clinical surveillance and polymerase chain reaction (PCR)-based wastewater monitoring data. Furthermore, we estimated growth rate from wastewater metagenomic sequencing data for numerous viruses not otherwise widely monitored, demonstrating the data expands the targets that can feasibly be monitored in parallel. Wastewater metagenomic sequencing can support both novel pathogen detection and routine surveillance of endemic pathogens.","rel_num_authors":7,"rel_authors":[{"author_name":"Elana M G Chan","author_inst":"Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA"},{"author_name":"Lennart Justen","author_inst":"Broad Institute of MIT and Harvard, Cambridge, MA, USA"},{"author_name":"Alessandro Zulli","author_inst":"SecureBio, Cambridge, MA, USA"},{"author_name":"Michael R McLaren","author_inst":"SecureBio, Cambridge, MA, USA"},{"author_name":"Rebecca Y Linfield","author_inst":"Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Leon S Moskatel","author_inst":"Department of Neurology, Stanford University, Palo Alto, CA, USA"},{"author_name":"Charles Whittaker","author_inst":"Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Multi-omics models for hypertension prediction using blood pressure PRS and omics scores","rel_doi":"10.64898\/2026.11.13.26368055","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26368055","rel_abs":"Background: Hypertension is a major modifiable risk factor for cardiovascular disease, yet the relative contributions of proteomic (ProtS), metabolomic (MetS), and polygenic risk scores (PRS) to incident hypertension risk remain incompletely characterized. Methods: We developed ProtS and MetS for systolic (SBP) and diastolic blood pressure (DBP), and hypertension using Elastic Net regression in the Multi-Ethnic Study of Atherosclerosis (MESA). We incorporated these scores with previously developed BP PRSs into 5 incremental XGBoost models, with external validation in the Jackson Heart Study (JHS). We further applied transfer learning to adapt the MESA-derived models to JHS. Elastic Net selected proteins were prioritized using Mendelian randomization, colocalization, and functional analyses. Results: In MESA, model discrimination improved with the addition of omics scores, with the combined model achieving an area under the curve (AUC) of 0.72 compared with 0.63 for the clinical baseline model. In JHS, ProtS showed the highest AUC of 0.68 and the smallest cross-cohort performance decline, compared to MetS and PRS. Incorporating measured SBP and DBP substantially improved discrimination, with the PRS+BP model achieving an AUC of 0.80 in MESA and the baseline+BP model achieving an AUC of 0.74 in JHS. Among JHS participants with normal baseline BP, ProtS provided the strongest discrimination among models without measured BP (AUC = 0.62), while PRS+BP model achieved an AUC of 0.69. Leaf-weight refreshing consistently improved calibration in JHS while preserving discrimination. Mendelian randomization identified 77 proteins associated with BP traits or hypertension, involved in vascular, inflammatory, renal, and natriuretic pathways. Conclusions: ProtS demonstrated superior predictive performance and cross-cohort transferability among the omics modalities evaluated, while measured BP remained the strongest predictors of incident hypertension. Proteomic and genetic information may provide complementary biological signals for identifying individuals at elevated hypertension risk, particularly before clinically elevated BP is detectable.","rel_num_authors":13,"rel_authors":[{"author_name":"Ziqing Wang","author_inst":"BIDMC"},{"author_name":"Yana Hrytsenko","author_inst":"Beth Israel Deaconess Medical Center"},{"author_name":"Sivan Almogy","author_inst":"Yale University"},{"author_name":"Brian W Spitzer","author_inst":"Beth Israel Deaconess Medical Center"},{"author_name":"Yogesh Purushotham","author_inst":"Beth Israel Deaconess Medical Center"},{"author_name":"Kent Taylor","author_inst":"The Lundquist Institute"},{"author_name":"Henry J. J. Lin","author_inst":"The Lundquist Institute"},{"author_name":"Usman A. Tahir","author_inst":"Beth Israel Deaconess Medical Center"},{"author_name":"Laura M. Raffield","author_inst":"University of North Carolina"},{"author_name":"Steve Rich","author_inst":"Virginia"},{"author_name":"Jerome Rotter","author_inst":"The Lundquist Institute"},{"author_name":"Zsu Zsu Chen","author_inst":"BIDMC"},{"author_name":"Tamar Sofer","author_inst":"Beth Israel Deaconess Medical Center"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Bipolar Disorder and Education: Deciphering a Complex Relationship using Genetic and Sibling Differences in a Multi-cohort Study","rel_doi":"10.64898\/2026.11.13.26368023","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26368023","rel_abs":"Background. While bipolar disorder has a positive genetic correlation (r~0.3) with educational attainment (EA), individuals with bipolar disorder diagnoses have lower EA in adulthood. To clarify this paradox, we hypothesise that bipolar disorder and educational outcomes share a positive genetic association, reflected in high academic performance earlier in life, but that emerging bipolar disorder symptoms disrupt academic trajectories, leading to the observed poor long-term educational outcomes. Methods. We employed a sibling comparison design across four population-based cohorts (Ntotal = 1,145,795 siblings). First, we tested the association between bipolar disorder polygenic scores (PGS) and educational outcomes (EA and academic performance) in the Norwegian Mother, Father and Child Cohort Study (MoBa) and UK Biobank (UKB). Second, we examined associations between academic performance at ages 10, 12, 13, and 14 and subsequent bipolar disorder diagnosis using registry data from Statistics Netherlands and Statistics Norway (with the Norwegian Control and Payment of Health Reimbursements Databases). Findings. Siblings with higher bipolar disorder PGS had significantly higher EA ({beta}W = 0.03, 95% CI [0.01, 0.05], N=16,746) as well as higher academic performance at age 10 (0.03 [0.01, 0.05], N=17,677) in MoBa. Secondly, individuals with bipolar disorder had better overall academic performance than their unaffected sibling at ages 10 (HRW = 1.12 [1.02, 1.22], N=343,898) and 12 (1.59 [1.16, 2.19], N=619,796). However, individuals with bipolar disorder experienced a decline in academic performance at ages 13 (0.84 [0.73, 0.96], N=320,342) and 14 (0.72 [0.61, 0.85], N=299,039). Interpretation. Bipolar disorder shares a positive genetic association with educational outcomes, reflected in early academic advantage. This is followed by an academic decline in mid-adolescence, highlighting the period of educational disruption associated with bipolar disorder. Funding. The Dutch Ministry of Education, Culture and Sciences, European Research Council, the Research Council of Norway, the Swedish Research Council","rel_num_authors":8,"rel_authors":[{"author_name":"Vaishnavi K Madhavan","author_inst":"Vrije Universiteit Amsterdam"},{"author_name":"Perline A Demange","author_inst":"University of Oslo"},{"author_name":"Ziada Ayorech","author_inst":"University of Oslo"},{"author_name":"Jouke Jan Hottenga","author_inst":"Hamad Bin Khalifa University"},{"author_name":"Meike Bartels","author_inst":"Vrije Universiteit Amsterdam"},{"author_name":"Eivind Ystrom","author_inst":"University of Oslo"},{"author_name":"Michel G Nivard","author_inst":"University of Bristol"},{"author_name":"Wonuola A Akingbuwa","author_inst":"Vrije Universiteit Amsterdam"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Nirsevimab effectiveness against RSV hospitalizations in children 8-23 months at risk of severe RSV","rel_doi":"10.64898\/2026.11.13.26368017","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26368017","rel_abs":"Importance: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in high-risk young children during their second RSV season. Nirsevimab, a long-acting monoclonal antibody against RSV, is recommended for some children who are at increased risk for severe RSV and entering their second RSV season to prevent severe RSV disease. Because of limited eligibility criteria for second season nirsevimab, estimating its effectiveness is challenging. Objective: We evaluated nirsevimab effectiveness against RSV-associated hospitalizations among young children eligible to receive nirsevimab during their second RSV season. Design: This retrospective case control study with a test-negative design was conducted during the 2024-2025 and 2025-2026 RSV seasons. Setting: Enrollment was in 26 hospitals across 24 U.S. states. Participants: Children eligible for nirsevimab during their second RSV season (as recommended in August 2023) were included. Nirsevimab-eligible children 8-23 months old hospitalized with respiratory symptoms were enrolled. Case-patients tested positive for RSV; control-patients tested negative for RSV. Exposures: Receipt of nirsevimab before or during the second RSV season and at least 7 days before symptom onset. Outcomes and measures: RSV-associated hospitalization. We estimated nirsevimab effectiveness using multivariable logistic regression adjusted for age, month and year of hospitalization, census region, and sex comparing the odds of second season nirsevimab receipt among case- and control-patients. Results: One hundred six case-patients and 125 control-patients were analyzed. Distributions of age, sex, race and ethnicity, and region were similar in case- and control-patients. Most case- and control-patients were eligible for nirsevimab because of chronic lung disease of prematurity (84.0% and 69.6%, respectively). Overall, 21 (19.8%) of case-patients and 53 (42.4%) of control-patients received nirsevimab. Adjusted nirsevimab effectiveness against RSV-associated hospitalizations was 78.1% (95% CI, 55.2%-89.3%); the median interval from nirsevimab receipt to symptom onset was 66.5 days (IQR = 30-96 days). Effectiveness was estimated to be higher if nirsevimab was received 8-59 days before symptom onset (88.5%, 95% CI, 63.4%-96.4%). Conclusions: This analysis provides real-world estimates of substantial nirsevimab effectiveness against RSV-associated hospitalizations for high-risk U.S. children in their second RSV season These data support recommendations for nirsevimab as a preventive strategy in this population.","rel_num_authors":33,"rel_authors":[{"author_name":"Regina M Simeone","author_inst":"CDC"},{"author_name":"Margaret M Newhams","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Amanda B Payne","author_inst":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, "},{"author_name":"Amber O Orzel-Lockwood","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Jemima Calixte","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Natasha Halasa","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee"},{"author_name":"Satoshi Kamidani","author_inst":"The Center for Childhood Infections and Vaccines of Childrens Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine, Atlan"},{"author_name":"Hillary Crandall","author_inst":"Division of Pediatric Critical Care, Department of Pediatrics, University of Utah and Primary Childrens Hospital, Salt Lake City, Utah"},{"author_name":"Katherine Irby","author_inst":"Section of Pediatric Critical Care, Department of Pediatrics, Arkansas Childrens Hospital, Little Rock, Arkansas"},{"author_name":"Aline B Maddux","author_inst":"Department of Pediatrics, Section of Critical Care Medicine, University of Colorado School of Medicine and Childrens Hospital Colorado, Aurora, Colorado"},{"author_name":"Danielle Zerr","author_inst":"Division of Infectious Diseases, Department of Pediatrics, University of Washington, Seattle, Washington; Seattle Children's Research Institute, Seattle, Washin"},{"author_name":"Judith Guzman-Cottrill","author_inst":"Department of Pediatrics, Oregon Health and Sciences University, Portland, Oregon"},{"author_name":"Jennifer Schuster","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Childrens Mercy; University of Missouri Kansas City, Kansas City, Missouri"},{"author_name":"Kathleen Chiotos","author_inst":"Division of Critical Care Medicine, Department of Anesthesiology and Critical Care, Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"author_name":"Michele Kong","author_inst":"Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama"},{"author_name":"Mary Allen Staat","author_inst":"Department of Pediatrics, Division of Infectious Diseases, Cincinnati Childrens Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnat"},{"author_name":"Janet Hume","author_inst":"Division of Pediatric Critical Care, University of Minnesota Masonic Childrens Hospital, Minneapolis, Minnesota"},{"author_name":"Melissa  S. Stockwell","author_inst":"Division of Child and Adolescent Health, Columbia University Vagelos College of Physicians and Surgeons and Department of Population and Family Health, Columbia"},{"author_name":"Melissa Cameron","author_inst":"Division of Pediatric Hospital Medicine, UC San Diego-Rady Childrens Hospital, San Diego, California"},{"author_name":"Alexander H Hogan","author_inst":"Division of Hospital Medicine, Connecticut Childrens Medical Center, Hartford, Connecticut"},{"author_name":"Jigar Chauhan","author_inst":"Division of Critical Care, Nemours Childrens Hospital, Wilmington, Delaware"},{"author_name":"Austin Biggs","author_inst":"Department of Pediatric Critical Care, Medical University of South Carolina and Shawn Jenkins Childrens Hospital, Charleston, South Carolina"},{"author_name":"Emily R Levy","author_inst":"Divisions of Pediatric Infectious Diseases and Pediatric Critical Care Medicine, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnes"},{"author_name":"Samina Bhumbra","author_inst":"Ryan White Center for Pediatric Infectious Disease and Global Health, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana"},{"author_name":"Tracie C Walker","author_inst":"Department of Pediatrics, University of North Carolina at Chapel Hill Childrens Hospital, Chapel Hill, North Carolina"},{"author_name":"Neelima K Marupudi","author_inst":"Department of Child Health, University of Arizona, Banner Childrens Hospital at Desert, Division of Pediatric Critical Care, Mesa, Arizona"},{"author_name":"Mary K Prahl","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, University of California, San Francisco, California"},{"author_name":"Kelly N Michelson","author_inst":"Division of Pediatric Critical Care Medicine, Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois"},{"author_name":"Lora Martin","author_inst":"Department of Pediatrics, University of Mississippi Medical Center, Jackson, Mississippi"},{"author_name":"Tamara Brandford","author_inst":"Division of Cardiology, Department of Pediatrics, Louisiana State University Health Sciences Center, Louisiana; Childrens Hospital of New Orleans, New Orleans, "},{"author_name":"Adrienne Randolph","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts; Departments of Anesthesia and Pediatrics, Harv"},{"author_name":"Angela P Campbell","author_inst":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, "},{"author_name":"- Overcoming RSV Network investigators","author_inst":""}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Nirsevimab effectiveness against RSV hospitalizations in children 8-23 months at risk of severe RSV","rel_doi":"10.64898\/2026.11.13.26368017","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26368017","rel_abs":"Importance: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in high-risk young children during their second RSV season. Nirsevimab, a long-acting monoclonal antibody against RSV, is recommended for some children who are at increased risk for severe RSV and entering their second RSV season to prevent severe RSV disease. Because of limited eligibility criteria for second season nirsevimab, estimating its effectiveness is challenging. Objective: We evaluated nirsevimab effectiveness against RSV-associated hospitalizations among young children eligible to receive nirsevimab during their second RSV season. Design: This retrospective case control study with a test-negative design was conducted during the 2024-2025 and 2025-2026 RSV seasons. Setting: Enrollment was in 26 hospitals across 24 U.S. states. Participants: Children eligible for nirsevimab during their second RSV season (as recommended in August 2023) were included. Nirsevimab-eligible children 8-23 months old hospitalized with respiratory symptoms were enrolled. Case-patients tested positive for RSV; control-patients tested negative for RSV. Exposures: Receipt of nirsevimab before or during the second RSV season and at least 7 days before symptom onset. Outcomes and measures: RSV-associated hospitalization. We estimated nirsevimab effectiveness using multivariable logistic regression adjusted for age, month and year of hospitalization, census region, and sex comparing the odds of second season nirsevimab receipt among case- and control-patients. Results: One hundred six case-patients and 125 control-patients were analyzed. Distributions of age, sex, race and ethnicity, and region were similar in case- and control-patients. Most case- and control-patients were eligible for nirsevimab because of chronic lung disease of prematurity (84.0% and 69.6%, respectively). Overall, 21 (19.8%) of case-patients and 53 (42.4%) of control-patients received nirsevimab. Adjusted nirsevimab effectiveness against RSV-associated hospitalizations was 78.1% (95% CI, 55.2%-89.3%); the median interval from nirsevimab receipt to symptom onset was 66.5 days (IQR = 30-96 days). Effectiveness was estimated to be higher if nirsevimab was received 8-59 days before symptom onset (88.5%, 95% CI, 63.4%-96.4%). Conclusions: This analysis provides real-world estimates of substantial nirsevimab effectiveness against RSV-associated hospitalizations for high-risk U.S. children in their second RSV season These data support recommendations for nirsevimab as a preventive strategy in this population.","rel_num_authors":33,"rel_authors":[{"author_name":"Regina M Simeone","author_inst":"CDC"},{"author_name":"Margaret M Newhams","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Amanda B Payne","author_inst":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, "},{"author_name":"Amber O Orzel-Lockwood","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Jemima Calixte","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Natasha Halasa","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee"},{"author_name":"Satoshi Kamidani","author_inst":"The Center for Childhood Infections and Vaccines of Childrens Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine, Atlan"},{"author_name":"Hillary Crandall","author_inst":"Division of Pediatric Critical Care, Department of Pediatrics, University of Utah and Primary Childrens Hospital, Salt Lake City, Utah"},{"author_name":"Katherine Irby","author_inst":"Section of Pediatric Critical Care, Department of Pediatrics, Arkansas Childrens Hospital, Little Rock, Arkansas"},{"author_name":"Aline B Maddux","author_inst":"Department of Pediatrics, Section of Critical Care Medicine, University of Colorado School of Medicine and Childrens Hospital Colorado, Aurora, Colorado"},{"author_name":"Danielle Zerr","author_inst":"Division of Infectious Diseases, Department of Pediatrics, University of Washington, Seattle, Washington; Seattle Children's Research Institute, Seattle, Washin"},{"author_name":"Judith Guzman-Cottrill","author_inst":"Department of Pediatrics, Oregon Health and Sciences University, Portland, Oregon"},{"author_name":"Jennifer Schuster","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Childrens Mercy; University of Missouri Kansas City, Kansas City, Missouri"},{"author_name":"Kathleen Chiotos","author_inst":"Division of Critical Care Medicine, Department of Anesthesiology and Critical Care, Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"author_name":"Michele Kong","author_inst":"Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama"},{"author_name":"Mary Allen Staat","author_inst":"Department of Pediatrics, Division of Infectious Diseases, Cincinnati Childrens Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnat"},{"author_name":"Janet Hume","author_inst":"Division of Pediatric Critical Care, University of Minnesota Masonic Childrens Hospital, Minneapolis, Minnesota"},{"author_name":"Melissa  S. Stockwell","author_inst":"Division of Child and Adolescent Health, Columbia University Vagelos College of Physicians and Surgeons and Department of Population and Family Health, Columbia"},{"author_name":"Melissa Cameron","author_inst":"Division of Pediatric Hospital Medicine, UC San Diego-Rady Childrens Hospital, San Diego, California"},{"author_name":"Alexander H Hogan","author_inst":"Division of Hospital Medicine, Connecticut Childrens Medical Center, Hartford, Connecticut"},{"author_name":"Jigar Chauhan","author_inst":"Division of Critical Care, Nemours Childrens Hospital, Wilmington, Delaware"},{"author_name":"Austin Biggs","author_inst":"Department of Pediatric Critical Care, Medical University of South Carolina and Shawn Jenkins Childrens Hospital, Charleston, South Carolina"},{"author_name":"Emily R Levy","author_inst":"Divisions of Pediatric Infectious Diseases and Pediatric Critical Care Medicine, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnes"},{"author_name":"Samina Bhumbra","author_inst":"Ryan White Center for Pediatric Infectious Disease and Global Health, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana"},{"author_name":"Tracie C Walker","author_inst":"Department of Pediatrics, University of North Carolina at Chapel Hill Childrens Hospital, Chapel Hill, North Carolina"},{"author_name":"Neelima K Marupudi","author_inst":"Department of Child Health, University of Arizona, Banner Childrens Hospital at Desert, Division of Pediatric Critical Care, Mesa, Arizona"},{"author_name":"Mary K Prahl","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, University of California, San Francisco, California"},{"author_name":"Kelly N Michelson","author_inst":"Division of Pediatric Critical Care Medicine, Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois"},{"author_name":"Lora Martin","author_inst":"Department of Pediatrics, University of Mississippi Medical Center, Jackson, Mississippi"},{"author_name":"Tamara Brandford","author_inst":"Division of Cardiology, Department of Pediatrics, Louisiana State University Health Sciences Center, Louisiana; Childrens Hospital of New Orleans, New Orleans, "},{"author_name":"Adrienne Randolph","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts; Departments of Anesthesia and Pediatrics, Harv"},{"author_name":"Angela P Campbell","author_inst":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, "},{"author_name":"- Overcoming RSV Network investigators","author_inst":""}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Nirsevimab effectiveness against RSV hospitalizations in children 8-23 months at risk of severe RSV","rel_doi":"10.64898\/2026.11.13.26368017","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26368017","rel_abs":"Importance: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in high-risk young children during their second RSV season. Nirsevimab, a long-acting monoclonal antibody against RSV, is recommended for some children who are at increased risk for severe RSV and entering their second RSV season to prevent severe RSV disease. Because of limited eligibility criteria for second season nirsevimab, estimating its effectiveness is challenging. Objective: We evaluated nirsevimab effectiveness against RSV-associated hospitalizations among young children eligible to receive nirsevimab during their second RSV season. Design: This retrospective case control study with a test-negative design was conducted during the 2024-2025 and 2025-2026 RSV seasons. Setting: Enrollment was in 26 hospitals across 24 U.S. states. Participants: Children eligible for nirsevimab during their second RSV season (as recommended in August 2023) were included. Nirsevimab-eligible children 8-23 months old hospitalized with respiratory symptoms were enrolled. Case-patients tested positive for RSV; control-patients tested negative for RSV. Exposures: Receipt of nirsevimab before or during the second RSV season and at least 7 days before symptom onset. Outcomes and measures: RSV-associated hospitalization. We estimated nirsevimab effectiveness using multivariable logistic regression adjusted for age, month and year of hospitalization, census region, and sex comparing the odds of second season nirsevimab receipt among case- and control-patients. Results: One hundred six case-patients and 125 control-patients were analyzed. Distributions of age, sex, race and ethnicity, and region were similar in case- and control-patients. Most case- and control-patients were eligible for nirsevimab because of chronic lung disease of prematurity (84.0% and 69.6%, respectively). Overall, 21 (19.8%) of case-patients and 53 (42.4%) of control-patients received nirsevimab. Adjusted nirsevimab effectiveness against RSV-associated hospitalizations was 78.1% (95% CI, 55.2%-89.3%); the median interval from nirsevimab receipt to symptom onset was 66.5 days (IQR = 30-96 days). Effectiveness was estimated to be higher if nirsevimab was received 8-59 days before symptom onset (88.5%, 95% CI, 63.4%-96.4%). Conclusions: This analysis provides real-world estimates of substantial nirsevimab effectiveness against RSV-associated hospitalizations for high-risk U.S. children in their second RSV season These data support recommendations for nirsevimab as a preventive strategy in this population.","rel_num_authors":33,"rel_authors":[{"author_name":"Regina M Simeone","author_inst":"CDC"},{"author_name":"Margaret M Newhams","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Amanda B Payne","author_inst":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, "},{"author_name":"Amber O Orzel-Lockwood","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Jemima Calixte","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Natasha Halasa","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee"},{"author_name":"Satoshi Kamidani","author_inst":"The Center for Childhood Infections and Vaccines of Childrens Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine, Atlan"},{"author_name":"Hillary Crandall","author_inst":"Division of Pediatric Critical Care, Department of Pediatrics, University of Utah and Primary Childrens Hospital, Salt Lake City, Utah"},{"author_name":"Katherine Irby","author_inst":"Section of Pediatric Critical Care, Department of Pediatrics, Arkansas Childrens Hospital, Little Rock, Arkansas"},{"author_name":"Aline B Maddux","author_inst":"Department of Pediatrics, Section of Critical Care Medicine, University of Colorado School of Medicine and Childrens Hospital Colorado, Aurora, Colorado"},{"author_name":"Danielle Zerr","author_inst":"Division of Infectious Diseases, Department of Pediatrics, University of Washington, Seattle, Washington; Seattle Children's Research Institute, Seattle, Washin"},{"author_name":"Judith Guzman-Cottrill","author_inst":"Department of Pediatrics, Oregon Health and Sciences University, Portland, Oregon"},{"author_name":"Jennifer Schuster","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Childrens Mercy; University of Missouri Kansas City, Kansas City, Missouri"},{"author_name":"Kathleen Chiotos","author_inst":"Division of Critical Care Medicine, Department of Anesthesiology and Critical Care, Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"author_name":"Michele Kong","author_inst":"Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama"},{"author_name":"Mary Allen Staat","author_inst":"Department of Pediatrics, Division of Infectious Diseases, Cincinnati Childrens Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnat"},{"author_name":"Janet Hume","author_inst":"Division of Pediatric Critical Care, University of Minnesota Masonic Childrens Hospital, Minneapolis, Minnesota"},{"author_name":"Melissa  S. Stockwell","author_inst":"Division of Child and Adolescent Health, Columbia University Vagelos College of Physicians and Surgeons and Department of Population and Family Health, Columbia"},{"author_name":"Melissa Cameron","author_inst":"Division of Pediatric Hospital Medicine, UC San Diego-Rady Childrens Hospital, San Diego, California"},{"author_name":"Alexander H Hogan","author_inst":"Division of Hospital Medicine, Connecticut Childrens Medical Center, Hartford, Connecticut"},{"author_name":"Jigar Chauhan","author_inst":"Division of Critical Care, Nemours Childrens Hospital, Wilmington, Delaware"},{"author_name":"Austin Biggs","author_inst":"Department of Pediatric Critical Care, Medical University of South Carolina and Shawn Jenkins Childrens Hospital, Charleston, South Carolina"},{"author_name":"Emily R Levy","author_inst":"Divisions of Pediatric Infectious Diseases and Pediatric Critical Care Medicine, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnes"},{"author_name":"Samina Bhumbra","author_inst":"Ryan White Center for Pediatric Infectious Disease and Global Health, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana"},{"author_name":"Tracie C Walker","author_inst":"Department of Pediatrics, University of North Carolina at Chapel Hill Childrens Hospital, Chapel Hill, North Carolina"},{"author_name":"Neelima K Marupudi","author_inst":"Department of Child Health, University of Arizona, Banner Childrens Hospital at Desert, Division of Pediatric Critical Care, Mesa, Arizona"},{"author_name":"Mary K Prahl","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, University of California, San Francisco, California"},{"author_name":"Kelly N Michelson","author_inst":"Division of Pediatric Critical Care Medicine, Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois"},{"author_name":"Lora Martin","author_inst":"Department of Pediatrics, University of Mississippi Medical Center, Jackson, Mississippi"},{"author_name":"Tamara Brandford","author_inst":"Division of Cardiology, Department of Pediatrics, Louisiana State University Health Sciences Center, Louisiana; Childrens Hospital of New Orleans, New Orleans, "},{"author_name":"Adrienne Randolph","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts; Departments of Anesthesia and Pediatrics, Harv"},{"author_name":"Angela P Campbell","author_inst":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, "},{"author_name":"- Overcoming RSV Network investigators","author_inst":""}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Nirsevimab effectiveness against RSV hospitalizations in children 8-23 months at risk of severe RSV","rel_doi":"10.64898\/2026.11.13.26368017","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26368017","rel_abs":"Importance: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in high-risk young children during their second RSV season. Nirsevimab, a long-acting monoclonal antibody against RSV, is recommended for some children who are at increased risk for severe RSV and entering their second RSV season to prevent severe RSV disease. Because of limited eligibility criteria for second season nirsevimab, estimating its effectiveness is challenging. Objective: We evaluated nirsevimab effectiveness against RSV-associated hospitalizations among young children eligible to receive nirsevimab during their second RSV season. Design: This retrospective case control study with a test-negative design was conducted during the 2024-2025 and 2025-2026 RSV seasons. Setting: Enrollment was in 26 hospitals across 24 U.S. states. Participants: Children eligible for nirsevimab during their second RSV season (as recommended in August 2023) were included. Nirsevimab-eligible children 8-23 months old hospitalized with respiratory symptoms were enrolled. Case-patients tested positive for RSV; control-patients tested negative for RSV. Exposures: Receipt of nirsevimab before or during the second RSV season and at least 7 days before symptom onset. Outcomes and measures: RSV-associated hospitalization. We estimated nirsevimab effectiveness using multivariable logistic regression adjusted for age, month and year of hospitalization, census region, and sex comparing the odds of second season nirsevimab receipt among case- and control-patients. Results: One hundred six case-patients and 125 control-patients were analyzed. Distributions of age, sex, race and ethnicity, and region were similar in case- and control-patients. Most case- and control-patients were eligible for nirsevimab because of chronic lung disease of prematurity (84.0% and 69.6%, respectively). Overall, 21 (19.8%) of case-patients and 53 (42.4%) of control-patients received nirsevimab. Adjusted nirsevimab effectiveness against RSV-associated hospitalizations was 78.1% (95% CI, 55.2%-89.3%); the median interval from nirsevimab receipt to symptom onset was 66.5 days (IQR = 30-96 days). Effectiveness was estimated to be higher if nirsevimab was received 8-59 days before symptom onset (88.5%, 95% CI, 63.4%-96.4%). Conclusions: This analysis provides real-world estimates of substantial nirsevimab effectiveness against RSV-associated hospitalizations for high-risk U.S. children in their second RSV season These data support recommendations for nirsevimab as a preventive strategy in this population.","rel_num_authors":33,"rel_authors":[{"author_name":"Regina M Simeone","author_inst":"CDC"},{"author_name":"Margaret M Newhams","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Amanda B Payne","author_inst":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, "},{"author_name":"Amber O Orzel-Lockwood","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Jemima Calixte","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Natasha Halasa","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee"},{"author_name":"Satoshi Kamidani","author_inst":"The Center for Childhood Infections and Vaccines of Childrens Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine, Atlan"},{"author_name":"Hillary Crandall","author_inst":"Division of Pediatric Critical Care, Department of Pediatrics, University of Utah and Primary Childrens Hospital, Salt Lake City, Utah"},{"author_name":"Katherine Irby","author_inst":"Section of Pediatric Critical Care, Department of Pediatrics, Arkansas Childrens Hospital, Little Rock, Arkansas"},{"author_name":"Aline B Maddux","author_inst":"Department of Pediatrics, Section of Critical Care Medicine, University of Colorado School of Medicine and Childrens Hospital Colorado, Aurora, Colorado"},{"author_name":"Danielle Zerr","author_inst":"Division of Infectious Diseases, Department of Pediatrics, University of Washington, Seattle, Washington; Seattle Children's Research Institute, Seattle, Washin"},{"author_name":"Judith Guzman-Cottrill","author_inst":"Department of Pediatrics, Oregon Health and Sciences University, Portland, Oregon"},{"author_name":"Jennifer Schuster","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Childrens Mercy; University of Missouri Kansas City, Kansas City, Missouri"},{"author_name":"Kathleen Chiotos","author_inst":"Division of Critical Care Medicine, Department of Anesthesiology and Critical Care, Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"author_name":"Michele Kong","author_inst":"Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama"},{"author_name":"Mary Allen Staat","author_inst":"Department of Pediatrics, Division of Infectious Diseases, Cincinnati Childrens Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnat"},{"author_name":"Janet Hume","author_inst":"Division of Pediatric Critical Care, University of Minnesota Masonic Childrens Hospital, Minneapolis, Minnesota"},{"author_name":"Melissa  S. Stockwell","author_inst":"Division of Child and Adolescent Health, Columbia University Vagelos College of Physicians and Surgeons and Department of Population and Family Health, Columbia"},{"author_name":"Melissa Cameron","author_inst":"Division of Pediatric Hospital Medicine, UC San Diego-Rady Childrens Hospital, San Diego, California"},{"author_name":"Alexander H Hogan","author_inst":"Division of Hospital Medicine, Connecticut Childrens Medical Center, Hartford, Connecticut"},{"author_name":"Jigar Chauhan","author_inst":"Division of Critical Care, Nemours Childrens Hospital, Wilmington, Delaware"},{"author_name":"Austin Biggs","author_inst":"Department of Pediatric Critical Care, Medical University of South Carolina and Shawn Jenkins Childrens Hospital, Charleston, South Carolina"},{"author_name":"Emily R Levy","author_inst":"Divisions of Pediatric Infectious Diseases and Pediatric Critical Care Medicine, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnes"},{"author_name":"Samina Bhumbra","author_inst":"Ryan White Center for Pediatric Infectious Disease and Global Health, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana"},{"author_name":"Tracie C Walker","author_inst":"Department of Pediatrics, University of North Carolina at Chapel Hill Childrens Hospital, Chapel Hill, North Carolina"},{"author_name":"Neelima K Marupudi","author_inst":"Department of Child Health, University of Arizona, Banner Childrens Hospital at Desert, Division of Pediatric Critical Care, Mesa, Arizona"},{"author_name":"Mary K Prahl","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, University of California, San Francisco, California"},{"author_name":"Kelly N Michelson","author_inst":"Division of Pediatric Critical Care Medicine, Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois"},{"author_name":"Lora Martin","author_inst":"Department of Pediatrics, University of Mississippi Medical Center, Jackson, Mississippi"},{"author_name":"Tamara Brandford","author_inst":"Division of Cardiology, Department of Pediatrics, Louisiana State University Health Sciences Center, Louisiana; Childrens Hospital of New Orleans, New Orleans, "},{"author_name":"Adrienne Randolph","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts; Departments of Anesthesia and Pediatrics, Harv"},{"author_name":"Angela P Campbell","author_inst":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, "},{"author_name":"- Overcoming RSV Network investigators","author_inst":""}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Fentanyl dabbing with cannabis retail equipment: an ethnographic and drug-checking study","rel_doi":"10.64898\/2026.11.13.26367858","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26367858","rel_abs":"Background: Fentanyl's entrenchment in U.S. West Coast drug markets brought a shift from injecting to smoking illicit opioids. We characterize the next transition: the rise of 'dabbing,' vaporizing fentanyl with equipment sold for cannabis concentrates. Methods: This mixed-methods study combined ethnographic interviewing and participant observation among people who use fentanyl in California and Oregon (2024-2026) with survey data from a Los Angeles drug checking program. After identifying dabbing ethnographically, we added an optional smoking-method item to the survey. Results: Of 108 participants who stated a route of administration, 104 (96%) reported smoking; of 93 who named a smoking method, 81 (87%) reported dabbing. All 11 who first named another method and returned later then reported dabbing. Dabbing was reported at 250 of 405 (62%) encounters with a stated route. We observed participants adapting cannabis equipment. They praised dabbing's discretion, reduced stigma, and convenience, and its capacity for more large hits, more quickly; the same speed led some to call it wasteful, because it went through their fentanyl faster than other methods. Participants described rapidly rising tolerance and frequent dabbing-related burns, which we also observed. Some who had injected said dabbing approximated its \"rush.\" Conclusions: Dabbing has become the dominant way to consume fentanyl among people using drug checking services in Los Angeles, and was observed in every other city where we did fieldwork. Clinicians and programs should ask people how they smoke fentanyl, not only whether they smoke or inject; dabbing may reduce some risks while increasing others.","rel_num_authors":15,"rel_authors":[{"author_name":"Morgan Godvin","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Levi Cecil","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Adam Koncsol","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Caitlin A. Molina","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Megan Grabill","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Ruby Romero","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Elham Jalayer","author_inst":"Bienestar Human Services, Los Angeles, CA, USA"},{"author_name":"Naomi Villanueva","author_inst":"Bienestar Human Services, Los Angeles, CA, USA"},{"author_name":"Oscar Arellano","author_inst":"Homeless Outreach Program Integrated Care System (HOPICS), Special Service for Groups, Los Angeles, CA, USA"},{"author_name":"Amanda Cowan","author_inst":"Community Health Project Los Angeles, Los Angeles, CA, USA"},{"author_name":"Russell G. Buhr","author_inst":"Division of Pulmonary, Critical Care, and Sleep Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Honora Englander","author_inst":"Section of Addiction Medicine, Division of General Internal Medicine & Geriatrics, Department of Medicine, Oregon Health & Science University, Portland, OR, USA"},{"author_name":"Joseph R. Friedman","author_inst":"Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA"},{"author_name":"Philippe Bourgois","author_inst":"Department of Anthropology and Center for Social Medicine and Humanities, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Chelsea L. Shover","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Fentanyl dabbing with cannabis retail equipment: an ethnographic and drug-checking study","rel_doi":"10.64898\/2026.11.13.26367858","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26367858","rel_abs":"Background: Fentanyl's entrenchment in U.S. West Coast drug markets brought a shift from injecting to smoking illicit opioids. We characterize the next transition: the rise of 'dabbing,' vaporizing fentanyl with equipment sold for cannabis concentrates. Methods: This mixed-methods study combined ethnographic interviewing and participant observation among people who use fentanyl in California and Oregon (2024-2026) with survey data from a Los Angeles drug checking program. After identifying dabbing ethnographically, we added an optional smoking-method item to the survey. Results: Of 108 participants who stated a route of administration, 104 (96%) reported smoking; of 93 who named a smoking method, 81 (87%) reported dabbing. All 11 who first named another method and returned later then reported dabbing. Dabbing was reported at 250 of 405 (62%) encounters with a stated route. We observed participants adapting cannabis equipment. They praised dabbing's discretion, reduced stigma, and convenience, and its capacity for more large hits, more quickly; the same speed led some to call it wasteful, because it went through their fentanyl faster than other methods. Participants described rapidly rising tolerance and frequent dabbing-related burns, which we also observed. Some who had injected said dabbing approximated its \"rush.\" Conclusions: Dabbing has become the dominant way to consume fentanyl among people using drug checking services in Los Angeles, and was observed in every other city where we did fieldwork. Clinicians and programs should ask people how they smoke fentanyl, not only whether they smoke or inject; dabbing may reduce some risks while increasing others.","rel_num_authors":15,"rel_authors":[{"author_name":"Morgan Godvin","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Levi Cecil","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Adam Koncsol","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Caitlin A. Molina","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Megan Grabill","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Ruby Romero","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Elham Jalayer","author_inst":"Bienestar Human Services, Los Angeles, CA, USA"},{"author_name":"Naomi Villanueva","author_inst":"Bienestar Human Services, Los Angeles, CA, USA"},{"author_name":"Oscar Arellano","author_inst":"Homeless Outreach Program Integrated Care System (HOPICS), Special Service for Groups, Los Angeles, CA, USA"},{"author_name":"Amanda Cowan","author_inst":"Community Health Project Los Angeles, Los Angeles, CA, USA"},{"author_name":"Russell G. Buhr","author_inst":"Division of Pulmonary, Critical Care, and Sleep Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Honora Englander","author_inst":"Section of Addiction Medicine, Division of General Internal Medicine & Geriatrics, Department of Medicine, Oregon Health & Science University, Portland, OR, USA"},{"author_name":"Joseph R. Friedman","author_inst":"Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA"},{"author_name":"Philippe Bourgois","author_inst":"Department of Anthropology and Center for Social Medicine and Humanities, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Chelsea L. Shover","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Inter-articulatory Timing of Vocalic Tongue Body and Jaw Movements across Talkers with Dysarthria due to Various Neurological Conditions","rel_doi":"10.64898\/2026.11.13.26368039","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26368039","rel_abs":"Purpose: This study compared inter-articulatory timing patterns of the tongue and jaw across talkers with Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), multiple sclerosis (MS), and neurotypical controls (CON) to identify disease-related differences. The study also explored if a talker's tongue body cycle duration, which serve as a proxy for a talker's habitual speech rate, or a talker's reliance on their jaw, as indicated by their jaw movement amplitude, could predict their inter-articulatory timing patterns. Method: Using three-dimensional electromagnetic articulography, the movements of the posterior tongue and jaw were examined in 24 talkers with PD, 19 talkers with ALS, 18 talkers with HD, 18 talkers with MS, and 34 CON during a sentence repetition task ('Buy Kaia a kite'). The tongue movement during the segment [kai] served as the reference signal (tongue body cycle) for which the phase angle of the jaw reaching the maximum opening position during [kai] was calculated. Tongue body cycle durations were measured as the time between the tongue body movement onset to the tongue body movement offset. The jaw opening amplitude was measured as the relative positional change from the jaw's maximum closing position associated with [k] to the jaw's maximal opening position at the onset of the diphthong [ai]. Results: A significant group effect was found for phase angles. Pairwise comparisons showed that talkers with ALS had significantly larger phase angles than talkers with PD, MS, HD, and CON, indicating a timing pattern where the tongue reached the target [a] earlier relative to the jaw. No significant differences were found for any other pairwise comparisons. Furthermore, no significant associations were found between tongue body cycle durations and phase angles. A significant association was found between jaw amplitudes and phase angles when considering all talkers [rS(110) = .253, p = .008] and when only considering talkers of the control group [r(34) = .361, p = .036]. Conclusions: Findings suggest that during the production of [kai], tongue-jaw timing patterns of talkers with ALS differ from those of talkers with PD, MS, HD, and CON with the tongue reaching the maximum opening position before the jaw while the opposite pattern was observed for talkers of the other groups. However, the variability in tongue body cycle duration did not significantly contribute to the variability in phase angles and the variability in jaw amplitudes only accounted for 6% of the variability in phase angles across all talkers. Future studies are needed to determine if the observed tongue-jaw timing pattern of talkers with ALS generalizes to other phonetic contexts and determine the underlying factors that contribute to the unique tongue-jaw timing patterns of talkers with ALS.","rel_num_authors":3,"rel_authors":[{"author_name":"Tabea Thies","author_inst":"Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany"},{"author_name":"Mary S Dietrich","author_inst":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA"},{"author_name":"Antje Mefferd","author_inst":"Department of Hearing and Speech Sciences, Vanderbilt University Medical Center, Nashville, TN, USA"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"The gut microbiome and incident atherosclerotic cardiovascular events: Prospective analyses in three Swedish cohorts","rel_doi":"10.64898\/2026.11.12.26367976","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.12.26367976","rel_abs":"Background: Variation in the gut microbiome composition has been associated with atherosclerotic cardiovascular disease (ASCVD) in case-control designs. We aimed to investigate associations with incident ASCVD events applying a prospective design to reduce the impact of reverse causality. Methods: We assessed associations between gut microbiome features measured by shotgun metagenomic sequencing and incident total ASCVD, ischemic heart disease (IHD) and ischemic stroke, including fatal and non-fatal events as defined by registry follow-up in 17,216 participants from three Swedish population-based cohorts (SCAPIS, SIMPLER, and MOS). Results from Cox proportional hazards regression models adjusted for demographic, and lifestyle factors, medication, and prevalent diabetes were combined across cohorts using a fixed-effect meta-analysis accounting for multiple testing. Associations were tested for replication in HUNT and FINRISK. Results: During a median of 6-8 y follow-up, 769 incident ASCVD events occurred. Species diversity was inversely associated with ASCVD and IHD, with a hazard ratio for IHD of 0.86 per SD increase in species richness (95% CI: 0.79-0.95). Sixty-eight common species (i.e., present in ?30% individuals) were associated with incident IHD after adjusting for sex and birth country, but only eight remained in fully adjusted models, including Ruminococcus_B gnavus. Among others, inverse associations were observed for SFEL01 sp004557245 and Fimadaptatus sp900553645 from Christensenellales, an order in which butyrate production has been reported. Streptococcus mutans and Limosilactobacillus fermentum, oral-associated species previously associated with coronary atherosclerosis, were associated with a higher risk of incident IHD, which remained after adjustment for dental health. Replication analysis in the HUNT study supported the finding for S. mutans. No associations were observed with ischemic stroke. Conclusions: Gut species diversity and specific species abundance were associated with incident IHD, providing evidence supporting a protective role of two Christensenellales species and an adverse role of oral species and R. gnavus in the development of IHD.","rel_num_authors":30,"rel_authors":[{"author_name":"Kamalita Pertiwi","author_inst":"Uppsala University"},{"author_name":"Ulf Hammar","author_inst":"Uppsala University"},{"author_name":"Koen Dekkers","author_inst":"Uppsala University"},{"author_name":"Eivind Coward","author_inst":"Norges teknisk-naturvitenskapelige universitet Institutt for samfunnsmedisin og sykepleie"},{"author_name":"Oleg Kambur","author_inst":"Ita-Suomen yliopisto Laaketieteen laitos"},{"author_name":"Gabriel Baldanzi","author_inst":"Uppsala University"},{"author_name":"Mario Delgado-Velandia","author_inst":"Uppsala Universitet"},{"author_name":"Sergi Sayols-Baixeras","author_inst":"Uppsala University"},{"author_name":"Shuai Yuan","author_inst":"Karolinska Institutet"},{"author_name":"Peter Persson","author_inst":"Lunds universitet Clinical Research Centre"},{"author_name":"David Gabrielsson","author_inst":"Institutet for Halso- och Sjukvardsekonomi"},{"author_name":"Mariam Miari","author_inst":"Lunds Universitet"},{"author_name":"Camila Gazolla Volpiano","author_inst":"University of Turku"},{"author_name":"Guillaume Meric","author_inst":"Baker Heart and Diabetes Institute"},{"author_name":"Daniel J\u00f6nsson","author_inst":"Department of Clinical Sciences Malm\u00f6,Lund University"},{"author_name":"Gunnar Engstr\u00f6m","author_inst":"Lund University"},{"author_name":"J. Gustav Smith","author_inst":"Goteborgs universitet"},{"author_name":"Karl Micha\u00eblsson","author_inst":"Uppsala Universitet"},{"author_name":"Olle Melander","author_inst":"Lunds Universitet"},{"author_name":"Johan \u00c4rnl\u00f6v","author_inst":"karolinska institutet"},{"author_name":"Rob Knight","author_inst":"University of California San Diego"},{"author_name":"Robin Hofmann","author_inst":"Karolinska Institutet"},{"author_name":"Teemu J. Niiranen","author_inst":"University of Turku"},{"author_name":"Aki S. Havulinna","author_inst":"Turun yliopiston Teknillinen tiedekunta"},{"author_name":"Veikko Salomaa","author_inst":"University of Turku, Department of Internal Medicine"},{"author_name":"Kristian Hveem","author_inst":"Norwegian University of Science and Technology"},{"author_name":"Claes Ohlsson","author_inst":"University of Gothenburg"},{"author_name":"Marju Orho-Melander","author_inst":"Lund University"},{"author_name":"Susanna C. Larsson","author_inst":"Karolinska Institutet"},{"author_name":"Tove Fall","author_inst":"Uppsala Universitet"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Investigating Differential Changes in Cardiovascular Mortality by Documented diabetes in the United States Before and During the COVID-19 Pandemic: A Comparative Time-Series Analysis","rel_doi":"10.64898\/2026.11.12.26367977","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.12.26367977","rel_abs":"BackgroundWhether diabetes modified pandemic-related changes in cardiovascular disease (CVD) mortality remains uncertain. We examined differential changes in US CVD mortality among deaths with versus without diabetes documented on the death certificate.\n\nMethodsWe analyzed CDC WONDER Multiple Cause of Death data from 2005 to 2024, identifying deaths with CVD as the underlying cause among adults aged [&ge;]25 years. Cohorts were CVD deaths with diabetes documented as a contributing cause (CVD+DM) and CVD deaths without documented diabetes. Because pre-2020 trajectories differed, the primary comparison of age-adjusted rates used a comparative interrupted time-series model allowing cohort-specific pre-2020 trends. Difference-in-differences estimates (2015-2019 vs 2020-2024) were descriptive.\n\nResultsCVD+DM mortality declined from 43.1 per 100,000 in 2005 to 34.3 in 2019 and was 38.4 in 2024; mortality without documented diabetes declined from 398.7 to 296.6 and was 289.8. In the primary analysis, CVD+DM mortality showed a 13.1% greater relative level increase at 2020 (95% CI, 10.4%-15.9%), with no significant differential change in slope thereafter. Descriptively, the ratio of rate ratios was 1.16, and the absolute difference-in-differences was 5.0 per 100,000.\n\nConclusionsAfter accounting for cohort-specific pre-2020 trends, CVD mortality with documented diabetes showed a greater relative increase at the 2020 transition. These findings describe differential mortality patterns rather than a causal effect of diabetes or the pandemic.\n\nWHAT IS NEW?O_LICardiovascular disease mortality with documented diabetes showed a 13% greater relative level increase at the 2020 transition than cardiovascular disease mortality without documented diabetes, after accounting for pre-2020 trends.\nC_LIO_LIThe difference was concentrated in the level change around 2020, with no significant differential change in slope thereafter.\nC_LIO_LIFindings were directionally consistent across analyses using alternative baseline periods, breakpoints, and restriction to type 2 diabetes.\nC_LI\n\nWHAT ARE THE CLINICAL IMPLICATIONS?O_LIThe findings suggest that people with coexisting cardiovascular disease and diabetes may warrant particular attention during periods of major health system disruption, including efforts to maintain continuity of cardiometabolic care.\nC_LIO_LIBecause the analysis is based on death-certificate documentation, the findings should be interpreted as a population-level mortality signal rather than evidence that diabetes caused the observed mortality difference.\nC_LI","rel_num_authors":7,"rel_authors":[{"author_name":"Muhammad Usman Ghani","author_inst":"Central Michigan University"},{"author_name":"Haeyoon Chang","author_inst":"Albert Einstein College of Medicine"},{"author_name":"Shofikur Shuhag","author_inst":"Henry Ford St John Hospital"},{"author_name":"Sharat Kamath","author_inst":"Corewell Health Grand Rapids Hospitals - Butterworth"},{"author_name":"Shahzaib Chughtai","author_inst":"Covenant HealthCare College of Medicine at Central Michigan University"},{"author_name":"Mohammad Alfrad Nobel Bhuiyan","author_inst":"Louisiana State University Health Sciences Center at Shreveport"},{"author_name":"Carlos Jose Rodriguez","author_inst":"Albert Einstein College of Medicine and Montefiore Medical Center"}],"rel_date":"2026-11-15","rel_site":"medrxiv"},{"rel_title":"Investigating Differential Changes in Cardiovascular Mortality by Documented diabetes in the United States Before and During the COVID-19 Pandemic: A Comparative Time-Series Analysis","rel_doi":"10.64898\/2026.11.12.26367977","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.12.26367977","rel_abs":"BackgroundWhether diabetes modified pandemic-related changes in cardiovascular disease (CVD) mortality remains uncertain. We examined differential changes in US CVD mortality among deaths with versus without diabetes documented on the death certificate.\n\nMethodsWe analyzed CDC WONDER Multiple Cause of Death data from 2005 to 2024, identifying deaths with CVD as the underlying cause among adults aged [&ge;]25 years. Cohorts were CVD deaths with diabetes documented as a contributing cause (CVD+DM) and CVD deaths without documented diabetes. Because pre-2020 trajectories differed, the primary comparison of age-adjusted rates used a comparative interrupted time-series model allowing cohort-specific pre-2020 trends. Difference-in-differences estimates (2015-2019 vs 2020-2024) were descriptive.\n\nResultsCVD+DM mortality declined from 43.1 per 100,000 in 2005 to 34.3 in 2019 and was 38.4 in 2024; mortality without documented diabetes declined from 398.7 to 296.6 and was 289.8. In the primary analysis, CVD+DM mortality showed a 13.1% greater relative level increase at 2020 (95% CI, 10.4%-15.9%), with no significant differential change in slope thereafter. Descriptively, the ratio of rate ratios was 1.16, and the absolute difference-in-differences was 5.0 per 100,000.\n\nConclusionsAfter accounting for cohort-specific pre-2020 trends, CVD mortality with documented diabetes showed a greater relative increase at the 2020 transition. These findings describe differential mortality patterns rather than a causal effect of diabetes or the pandemic.\n\nWHAT IS NEW?O_LICardiovascular disease mortality with documented diabetes showed a 13% greater relative level increase at the 2020 transition than cardiovascular disease mortality without documented diabetes, after accounting for pre-2020 trends.\nC_LIO_LIThe difference was concentrated in the level change around 2020, with no significant differential change in slope thereafter.\nC_LIO_LIFindings were directionally consistent across analyses using alternative baseline periods, breakpoints, and restriction to type 2 diabetes.\nC_LI\n\nWHAT ARE THE CLINICAL IMPLICATIONS?O_LIThe findings suggest that people with coexisting cardiovascular disease and diabetes may warrant particular attention during periods of major health system disruption, including efforts to maintain continuity of cardiometabolic care.\nC_LIO_LIBecause the analysis is based on death-certificate documentation, the findings should be interpreted as a population-level mortality signal rather than evidence that diabetes caused the observed mortality difference.\nC_LI","rel_num_authors":7,"rel_authors":[{"author_name":"Muhammad Usman Ghani","author_inst":"Central Michigan University"},{"author_name":"Haeyoon Chang","author_inst":"Albert Einstein College of Medicine"},{"author_name":"Shofikur Shuhag","author_inst":"Henry Ford St John Hospital"},{"author_name":"Sharat Kamath","author_inst":"Corewell Health Grand Rapids Hospitals - Butterworth"},{"author_name":"Shahzaib Chughtai","author_inst":"Covenant HealthCare College of Medicine at Central Michigan University"},{"author_name":"Mohammad Alfrad Nobel Bhuiyan","author_inst":"Louisiana State University Health Sciences Center at Shreveport"},{"author_name":"Carlos Jose Rodriguez","author_inst":"Albert Einstein College of Medicine and Montefiore Medical Center"}],"rel_date":"2026-11-15","rel_site":"medrxiv"},{"rel_title":"Maternal and Neonatal Outcomes Associated with Prenatal Prescription Stimulant Treatment Among Pregnant Individuals with Opioid Use Disorder","rel_doi":"10.64898\/2026.11.12.26367944","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.12.26367944","rel_abs":"IntroductionClinicians and Medicaid programs must decide whether to continue prescription stimulants in pregnancies complicated by opioid use disorder (OUD), yet no safety evidence exists for this population and stimulant coverage is frequently restricted. We evaluated maternal and neonatal outcomes associated with prescription stimulant treatment during pregnancy among individuals with OUD, including those with co-occurring stimulant use disorder (StUD) and attention-deficit\/hyperactivity disorder (ADHD)\n\nMethodsWe conducted a retrospective cohort study of Medicaidinsured pregnant individuals in Tennessee (2010-2021) with OUD. Our exposure of interest was any prescription amphetamine or methylphenidateclass stimulant overlapping pregnancy. The primary maternal outcome was overdose from delivery through 1 year postpartum; secondary outcomes included death, severe maternal morbidity and cardiovascular complications in the first 6 weeks postpartum. The primary neonatal outcome was preterm birth; secondary outcomes included low birth weight, NICU admission, neonatal opioid withdrawal syndrome (NOWS), and death. We used overlap weighting to estimate adjusted odds ratios (aORs) and predicted probabilities and evaluated effect modification by buprenorphine.\n\nResultsAmong 12,327 pregnancies with OUD, 380 (3.1%) received prescription stimulants during pregnancy; stimulant treated individuals were slightly older and more likely to have mental health comorbidities. In adjusted analyses, stimulant treatment was not associated with postpartum overdose (aOR, 1.13; 95% CI, 0.61-2.08), preterm birth (aOR, 1.04; 95% CI, 0.74-1.46), cardiovascular complications, severe maternal morbidity, low birth weight, or NOWS. Odds of NICU admission were higher among stimulant exposed infants (aOR, 1.58; 95% CI, 1.17-2.14). Maternal and infant deaths were rare. In exploratory analyses, overdose odds were elevated among pregnancies receiving both stimulants and buprenorphine (P for interaction = .03) and the cardiovascular composite was elevated within the ADHD subgroup (aOR, 2.33; 95% CI, 1.13-4.82).\n\nConclusionsThese first OUD-specific estimates do not support routine discontinuation of clinically indicated stimulant therapy in pregnancy. Higher NICU admission among stimulant-exposed infants, unaccompanied by differences in preterm birth, low birth weight, gestational age, or NOWS, is more consistent with intensified surveillance than with neonatal harm. Two exploratory signals require replication before they can inform practice.","rel_num_authors":10,"rel_authors":[{"author_name":"Thomas Reese","author_inst":"Vanderbilt University Medical Center"},{"author_name":"Ashley A Leech","author_inst":"Vanderbilt University Medical Center"},{"author_name":"Julia C Phillippi","author_inst":"Vanderbilt University"},{"author_name":"Stephen Patrick","author_inst":"Emory University"},{"author_name":"Elizabeth McNeer","author_inst":"Vanderbilt University Medical Center"},{"author_name":"Sarah Loch","author_inst":"Emory University"},{"author_name":"Jessica Young","author_inst":"Vanderbilt University Medical Center"},{"author_name":"Amanda von Horn","author_inst":"Vanderbilt University Medical Center"},{"author_name":"Mauli V Shah","author_inst":"Vanderbilt University Medical Center"},{"author_name":"Andrew D Wiese","author_inst":"Vanderbilt University Medical Center"}],"rel_date":"2026-11-15","rel_site":"medrxiv"},{"rel_title":"Shifting source hubs and the factors associated with cross-country Zika virus transmission: a phylogeographic network analysis, 2012-2025","rel_doi":"10.64898\/2026.11.12.26367925","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.12.26367925","rel_abs":"BackgroundZika virus local transmission has been reported in at least 97 countries and territories, but the sources, routes, and determinants of cross-country spread remain incompletely understood. We reconstructed a phylogeographic network, characterized source activity across epidemic phases, and examined factors associated with identified cross-country transmission events.\n\nMethodology\/Principal FindingsWe analyzed a time-scaled Nextstrain phylogeny of 1,043 Zika virus genomes collected between February 2013 and March 2026. Parent-child branches assigned to different locations were screened and consolidated into 81 source- destination-year events involving 39 locations. Network analysis characterized temporal and geographic patterns, routes, hubs, and communities. For the analysis of associated factors, 68 events with complete covariate data were compared, using mixed-effects models, with eligible year-matched control records for which no event was identified, with all 68 events retained and a new control set drawn in each of 200 iterations. Asia contributed the earliest event, from Thailand in 2012. Most events occurred within the Americas (79.0%) and were concentrated during 2014-2016, with Brazil as the principal source hub. All six events from 2019 onward originated from Thailand or India and reached destinations in Asia, Europe, and Africa. Thailands source activity spanned 2012-2025. Event identification was positively associated with high source-country incidence (odds ratio [OR], 2.66; 95% confidence interval [CI], 1.39-9.69), greater air travel (OR, 2.52; 95% CI, 1.58-5.67), and higher destination-country GNI per capita (OR, 1.70; 95% CI, 1.20-4.50). It was negatively associated with greater geographic distance (OR, 0.11; 95% CI, 0.02-0.20) and higher source-country GNI per capita (OR, 0.64; 95% CI, 0.45-0.94). Fourteen source countries showed elevated residual source propensities, with Brazil and Thailand among the highest.\n\nConclusions\/SignificanceThe transmission network showed a shift in dominant source hubs, from early activity in Asia to the Americas during the 2014-2016 epidemic and back to Asia in recent years. High source-country incidence, greater air travel, and shorter distance can help identify country pairs requiring closer surveillance, alongside established routes in the Americas and persistent or emerging Asian sources, particularly as El Nino may increase vector-borne transmission potential in 2026-2027.\n\nAuthor SummaryZika virus can spread between countries without being recognized immediately through routine surveillance. We analyzed genetic sequences from 1,043 Zika virus samples and used their evolutionary relationships and geographic information to reconstruct cross-country transmission events. After screening and consolidating records, we identified 81 events involving 39 countries and territories. Source activity changed across epidemic phases. Thailand contributed the earliest event in 2012, while transmission during the 2014-2016 epidemic occurred predominantly within the Americas, with Brazil as the principal source hub. All events identified from 2019 onward originated from Thailand or India, showing the renewed prominence of Asian sources. Cross-country events were more likely to be identified when the source country had high reported Zika incidence, air travel between the countries was greater, and geographic distance was shorter. Several countries remained unusually prominent as sources after the measured factors were taken into account, including the major network hubs Brazil and Thailand. These findings can help health agencies use historical transmission patterns and current epidemiological conditions to identify routes requiring closer surveillance, especially as El Nino may increase the potential for mosquito-borne transmission in 2026-2027.","rel_num_authors":8,"rel_authors":[{"author_name":"Mingfan Pang","author_inst":"Chinese Center for Disease Control and Prevention"},{"author_name":"Xinyan Bu","author_inst":"Sun Yat-Sen University"},{"author_name":"Qiyong Liu","author_inst":"Chinese Center for Disease Control and Prevention"},{"author_name":"Chao Li","author_inst":"Chinese Center for Disease Control and Prevention"},{"author_name":"Nimyan Chan","author_inst":"University of Hong Kong"},{"author_name":"Hanran Ji","author_inst":"Chinese Center for Disease Control and Prevention"},{"author_name":"Xiaopeng Qi","author_inst":"Chinese Center for Disease Control and Prevention"},{"author_name":"Yangmu Huang","author_inst":"Peking University Health Science Centre"}],"rel_date":"2026-11-15","rel_site":"medrxiv"}]}